WO2004031189A1

WO2004031189A1 - Pyridino and pyrimidino pyrazinones for treatment of anxiety and depression

Info

Publication number: WO2004031189A1
Application number: PCT/US2003/030570
Authority: WO
Inventors: Thais Motria Sielecki-Dzurdz; Argyrios George Arvanitis; Carolyn Diane Dzierba
Original assignee: Bristol-Myers Squibb Pharma Company
Priority date: 2002-09-30
Filing date: 2003-09-29
Publication date: 2004-04-15
Also published as: US7067658B2; AU2003279025A1; TW200427686A; US20040082784A1

Abstract

The present invention provides compounds of Formula (I): wherein the variables A, B, Ar, R1, R2, and R3 are as defined herein. The compounds of Formula (I) can function as corticotropin releasing factor (CRF) receptor antagonists and can be useful, for example, in the treatment of disorders characterized by abnormal levels of CRF such as anxiety and depression.

Description

PYRIDINO AND PYRIMIDINO PYRAZINONES FOR TREATMENT OF ANXIETY AND DEPRESSION

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority of U.S. Provisional Application Serial No.

60/414,853, filed September 30, 2002, the disclosure of which is incoφorated herein by reference in its entirety for all puφoses.

FIELD OF THE INVENTION

[0002] The present invention provides pyridino and pyrimidino pyrazinone compounds useful as corticotropin releasing factor (CRF) receptor antagonists for the treatment of disorders characterized by physiologically abnormal levels of CRF.

BACKGROUND OF THE INVENTION

[0003] Corticotropin releasing factor (CRF), synonymous with corticotropin releasing hormone (CRH), is a 41 amino acid peptide that coordinates the overall response of the body to stress. As an agonist of CRF receptors (e.g., CRFi and CRF₂), CRF is well known as the primary physiological secretagogue controlling hypothalamic-pituitary-adrenal (HP A) axis activity which mediates the endocrine stress response. CRF also plays a central role in the autonomic and behavioral responses to stress. Variation in physiological levels of CRF has been correlated with various disorders including depression, anxiety, and irritable bowel syndrome.

[0004] Antagonists of CRF receptors have been shown to effectively ameliorate behavioral stress responses in animal models. It is well established that systemic administration of CRFi receptor antagonists leads to anxiolytic and antidepressant effects in rodents. Animal model evidence also shows that CRFi antagonists can help alleviate the symptoms of d g withdrawal, stress-induced seizures, and certain inflammations. A role for CRF has also been postulated in the etiology and pathophysiology of Alzheimer's disease, Parkinson's disease, Huntington's disease, progressive supranuclear palsy, and amyofrophic lateral sclerosis as they relate to the dysfunction of CRF neurons in the central nervous system. Eating disorders, such as anorexia nervosa, have also been linked to elevated levels of CRF.

[0005] Though widely dispersed throughout the central nervous system, CRF receptors are also found in peripheral systems including glandular, vascular, gastrointestinal, and immune system tissues. Accordingly, CRF antagonists are believed to have potential in treating numerous disorders of the peripheral systems. Some CRF-related disorders of peripheral systems include, for example, hypertension, tachycardia, congestive heart failure, stroke, irritable bowel syndrome, post-operative ileus, and colonic hypersensitivity. Studies have indicated that CRFi antagonists may also be useful as hair growth stimulators. [0006] Numerous articles have reported the physiological role of CRF and the potential therapeutic activity of non-peptidic CRF receptor antagonists. Some of these articles, detailing much of the above discussion, include, for example; Gilligan, et al., J. Medicinal Chem., 2000, 43, 1641, Newport, et al., Curr. Opin. Neurobiology, 2000, 10, 211; Mastorakos, et al., Ann. N.Y. Acad. Sci., 2000, 900, 95; Koob, et al, Ann. N.Y. Acad. Sci., 2000, 909, 170; Maillot, et al, Gastroenterology, 2000, 119, 1569; Chrousos, Int. J. Obesity, 2000, 24, Suppl. 2, S50; Owens, et al, Exp. Opin. Invest. Drugs, 1999, 8, 1849; McCarthy, et al., Current Pharmaceutical Design, 1999, 5, 289; Heinrichs, et al., Baillier's Clinical Endocrinology and Metabolism, 1999, 13, 541; Arborelius, et al., Journal of Endocrinology, 1999, 160, 1; Webster, et al, Ann. N.Y. Acad. Sci., 1998, 840, 21; and Chalmers, et al., TiPS, 1996, 17, 166; De Souza, Hosp. Practice, 1988, 23, 59; WO 02/19975; and U.S. Pat. No. 5,236,901, each of which is incoφorated herein by reference in its entirety. [0007] Separate from the compounds reported herein, some pyrimidino pyrazinone- based compounds have been reported in WO 01/62758 as kinase inhibitors and WO 01/19825 for the treatment of chemokine mediated diseases.

[0008] As evidenced by the numerous publications directed to the study of CRF and its connection with various disorders, there is a cunent need for new ways in which to reduce the effects of abnormal levels of CRF or CRF receptors. For example, treatment methods for alleviating or reducing the physiological and/or neurological symptoms associated with elevated levels of CRF are desirable. The compounds described herein help fulfill these and other needs. SUMMARY OF THE INVENTION

[0009] The present invention provides compounds of Formula (I):

(i) or pharmaceutically acceptable salt form thereof, or prodmg form thereof, or radiolabeled form thereof, wherein the variables A, B, Ar, R¹, R², and R³ are as defined herein below. The compounds of Formula (I) can have CRF- receptor antagonist activity and therefore can be useful in various methods including the treatment of disorders characterized by abnormal levels of CRF.

[0010] Accordingly, the present invention provides compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier.

[0011] The present invention further provides methods of reducing symptoms caused by elevated levels of corticotropin releasing factor in a mammal comprising administering to the mammal a therapeutically effective amount of a compound Formula (I).

[0012] The present invention further provides methods of treating stress-related symptoms in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula (I).

[0013] Further provided by the present invention are methods of treating disorders characterized by abnormal levels of corticotropin releasing factor in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula

(I)*

[0014] In yet further embodiments, methods are provided for the treatment of anxiety, depression, or irritable bowel syndrome in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula (I).

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[0015] In a first aspect, the present invention provides, inter alia, compounds of

Formula (I):

(I) or a pharmaceutically acceptable salt forms thereof, or prodrug form thereof, or radiolabeled form thereof, wherein:

A and B are independently CR^ or N, with the proviso that at least one of A and B is N;

Ar is aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted by one or more substituents independently selected from C1-C6 alkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, halogen, CN, NO₂, OR⁵, and SR⁵;

R¹ is H, CN, C1-C4 haloalkyl, NR^lcR^ld, NR^lcCOR^lb, COR^l , CONR^lcR^ld, OR^lc, SR^lc, C1-C4 alkyl substituted with 0 to 3 R^la, C2-C4 alkenyl substituted with 0 to 3 R^la, C2-C4 alkynyl substituted with 0 to 3 R^la, C3-C6 cycloalkyl substituted with 0 to 3 R^la, or C4-C8 cycloalkylalkyl substituted with 0 to 3 Rl^a, with the proviso that R¹ is not CH₂X, wherein X is halogen; each R! ^a is, independently at each occunence, halogen, CN, N₃, NO₂, C1-C2 haloalkyl, NRl^cRl^d, NRl^cCORlb COR^lb, OR^l , SR^lc, S(O)R8, or S(O)2R⁸; each Rib is, independently at each occunence, C1-C4 alkyl, C1-C4 haloalkyl, C3- C cycloalkyl, C2-C4 alkenyl, or C2-C4 alkynyl; each Rl° is, independently at each occunence, selected from H, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C2-C4 alkenyl, or C2-C4 alkynyl; each Rid is, independently at each occunence, selected from H, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C2-C4 alkenyl, or C2-C4 alkynyl;

R² is H, C1-C3 haloalkyl, CN, OH, COR²b SH, SR²b Sθ2NHR²c, SO2NR²CR2d_; CONHR2C_J C0NR2c_R2d_; 0C0R²b_; OR²b NR²CR2d_; C02R^2b, C1-C4 alkyl substituted with 0 to 3 R2a C2-C4 alkenyl substituted with 0 to 3 R^2a, C2-C4 alkynyl substituted with 0 to 3 R2 _or C3-C6 cycloalkyl substituted with 0 to 3 R2 ^* with the proviso that R² is not CH₂X, wherein X is halogen; each R2a is, independently at each occunence, halogen, CN, N₃, NO₂, CF3, OR ^c, NR2C, NR cR2d R²ccθ2R^2b, SR²c, SOR⁸, SO2R⁸, CO2R²b CONR²CR2d C0R² OCOR2b, NR2c_CONR2cR2d₅ NR²ccθ2R^2b, OCONR²CR2d _pi_peridinyl, pynolidinyl, piperazinyl, N-methylpiperazinyl, moφholinyl, or thiomoφholinyl; each R2b is, independently at each occunence, C1-C4 alkyl, C1-C4 haloalkyl, C3- C cycloalkyl, C4-C12 cycloalkylalkyl, aryl, heteroaryl, aryl-C--C₄ alkyl, or heteroaryl-d- C₄ alkyl; each R2^C is, independently at each occurrence, H, C1-C4 alkyl, C1-C4 haloalkyl, C3- Cβ cycloalkyl, C4-C12 cycloalkylalkyl aryl, heteroaryl, aryl-C₁-C₄ alkyl, or heteroaryl-C₁-C₄ alkyl; each R d is, independently at each occunence, H, C1-C4 alkyl, C1-C4 haloalkyl, C3- C cycloalkyl, C4-C12 cycloalkylalkyl aryl, heteroaryl, aryl-C₁-C alkyl, or heteroaryl-C₁-C₄ alkyl;

R3 is OR3c, NR3c_R3d HR³c, SR3c, S(O)R⁸, S(O)₂R⁸, Sθ2 HR³c, SO2NR3cR3d₅ cOR c, CONHR3C, CONR³c_R3d_j ^ substituted with 0 to 3 R^3a, heteroaryl substituted with 0 to 3 R^3a, heterocyclyl substituted with 0 to 3 R^3f, C1-C10 alkyl substituted with 0 to 3 R^3a, C3-C10 alkenyl substituted with 0 to 3 R^3a, C3-C10 alkynyl substituted with 0 to 3 R^3a, C3-C8 cycloalkyl substituted with 0 to 3 R^3a, C4-C12 cycloalkylalkyl substituted with 0 to 3 R^3a, C2-C10 alkoxyalkyl substituted with 0 to 3 R^3a, C2-C10 thioalkoxyalkyl substituted with 0 to 3 R³ , C5..C10 cycloalkenyl substituted with 0 to 3 R^3a, or C6-C10 cycloalkenylalkyl substituted with 0 to 3 R^3a, wherein one carbon in any cycloalkyl moiety is optionally replaced with O, S or NT5; each R^3a is, independently at each occurrence, Cl-Cio alkyl, C2-C10 alkenyl, C2-

C10 alkynyl, C3-C6 cycloalkyl, halogen, C1-C4 haloalkyl, CN, OR³c, SR^3c, S(O)_nR⁸,

COR^3b, NHR3csO2R^3b, OC(O)NR³CR3d _N3j 0C(0)0R b, CO2R^3c, OC(O)R³b,

NR3cC0R3b, N(COR³b)₂, NR3cC0NT3c_R3d NR3c_Cθ2R³ , NR³c_R3d C0NR3cR3d aryl, heteroaryl, or heterocyclyl; each R3 is, independently at each occunence, Ci-Cio alkyl substituted with 0 to 3 R^3e, C2-C10 alkenyl substituted with 0 to 3 R^3e, C2-C10 alkynyl substituted with 0 to 3 R^3e, C3-C8 cycloalkyl substituted with 0 to 3 R^3e, C4-C12 cycloalkylalkyl substituted with 0 to 3 R^3e, C2-C10 alkoxyalkyl substituted with 0 to 3 R^3e, C5-C10 cycloalkenyl substituted with 0 to 3 R^3e, or C6-C10 cycloalkenylalkyl substituted with 0 to 3 R^3e, wherein one carbon in any cycloalkyl moiety is optionally replaced with O, S or NT< ; each R3° is, independently at each occunence, H, C1-C10 alkyl substituted with 0 to 3 R^3e, C2-C10 alkenyl substituted with 0 to 3 R^3e, C2-C10 alkynyl substituted with 0 to 3 R^3e, C3-C8 cycloalkyl substituted with 0 to 3 R^3e, C4-C12 cycloalkylalkyl substituted with 0 to 3 R^3e, C2-C10 alkoxyalkyl substituted with 0 to 3 R^3e, C5.C10 cycloalkenyl substituted with 0 to 3 R^3e, or C6-C10 cycloalkenylalkyl substituted with 0 to 3 R^3e, wherein one carbon in any cycloalkyl moiety is optionally replaced with O, S or NR^; each R3d is, independently at each occunence, H, Cχ-Cio alkyl substituted with 0 to 3 R^3e, C2-C10 alkenyl substituted with 0 to 3 R^3e, C2-C10 alkynyl substituted with 0 to 3 R^3e, C3-C8 cycloalkyl substituted with 0 to 3 R^3e, C4-C12 cycloalkylalkyl substituted with 0 to 3 R^3e, C2-C10 alkoxyalkyl substituted with 0 to 3 R^3e, C5-C10 cycloalkenyl substituted with 0 to 3 R^3e, or Cβ-Cio cycloalkenylalkyl substituted with 0 to 3 R^3e, wherein one carbon in any cycloalkyl moiety is optionally replaced with O, S or NR^; each R^3e is, independently at each occurrence, Ci-Cβ alkyl, C2-C6 alkenyl,

C2-C10 alkynyl, C3-C6 cycloalkyl, halogen, C1-C4 haloalkyl, CN, OR^7a, SR^7a, S(O)_nR⁸, COR⁶, CO2R^7a, OC(O)R⁶, NR^7aCOR⁶, N(COR⁶)2, NR^7aCONR^7aR^7b, NR^7aCO2R⁶, NR^7aR^7b, NHR^7aSO2R⁶, OC(O)NR^7aR⁷ , N3, OC(O)OR⁶, CONR^7aR^7b, aryl, heteroaryl, or heterocyclyl; each R^3f is, independently at each occunence, oxo, sulfido, or R^3a;

R⁴ is H, halogen, CN, C1-C3 haloalkyl, COR ^b, OR ^c, SR^4c, SO2NHR ^c, SO2NR^4cR^4d, CONHR^4c, CONR^4cR^4d, OCOR^4b, NR^4cCONHR^4c, NR^4cCONR^4cR^4d, NR^4cCO2R^4b, OCONR^4cR^4d, NR^4cR^4d, CO2R^4b, C1-C4 alkyl substituted with 0 to 1 R^4a C2-C4 alkenyl substituted with 0 to 1 R^4a, C2-C4 alkynyl substituted with 0 to 1 R^4a, C3-C6 cycloalkyl substituted with 0 to 1 R^4a, piperidinyl, pyrrolidinyl, piperazinyl, N- methylpiperazinyl, moφholinyl, or thiomoφholinyl; each R^4a is, independently at each occunence, halogen, CN, CF3, OR^4c, NHR^4c, _NR4c_R4d_; NR^4cCO2R^4b SR ^c, SOR⁸, SO2R⁸, CO2R^4b, CONHR^4c, CONR^4cR^4d, COR^4b, OCOR^4b, NR^4cCONR^4cR^4d, NR^4cCO2R^4b, OCONR^4cR^4d, piperidinyl, pyrrolidinyl, piperazinyl, N-methylpiperazinyl, moφholinyl, or thiomoφholinyl; each R⁴b is, independently at each occunence, C1-C4 alkyl, C1-C4 haloalkyl, C3- Cβ cycloalkyl, C4-C12 cycloalkylalkyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl, or heteroaryl-C-- C₄ alkyl; each R^4c is, independently at each occunence, H, C1-C4 alkyl, C1-C4 haloalkyl, C3- Cβ cycloalkyl, C4-C12 cycloalkylalkyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl, or heteroaryl-Q- C₄ alkyl; each R^4d is, independently at each occunence, H, C1-C4 alkyl, C1-C4 haloalkyl, C3- Cβ cycloalkyl, C4-C12 cycloalkylalkyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl, or heteroaryl-Ci- C₄ alkyl;

R⁵ is H, C1-C4 alkyl, C1-C4 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, or C2-C6 alkoxyalkyl;

R⁶ is, independently at each occurrence, Ci-Cβ alkyl, C1-C6 haloalkyl C2- C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, C2-C8 alkoxyalkyl, Cs-C₁₂ bis(alkoxy)alkyl, aryl, aryl-C₁-C alkyl, heteroaryl, or heteroaryl- C C₄ alkyl; each R^7a is, independently at each occunence, H, Ci-Cβ alkyl, Cχ-C6 haloalkyl C2- C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, C2-C8 alkoxyalkyl, C₅-C₁₂ bis(alkoxy)alkyl, aryl, aryl-C₁-C₄ alkyl, heteroaryl, or heteroaryl- C--C₄ alkyl; each R^7b is, independently at each occunence, H, C1-C6 alkyl, Ci-Cβ haloalkyl C2- C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, C2-C8 alkoxyalkyl, C₅-C₁₂ bis(alkoxy)alkyl, aryl, aryl-C₁-C₄ alkyl, heteroaryl, or heteroaryl- -C₄ alkyl; and R⁸ is C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl, or heteroaryl-C₁-C₄ alkyl, or NR^7aR^7b.

[0016] According to some embodiments according to the first aspect, the present invention includes compounds of Formula (I) where A and B are both N. In other embodiments, the present invention includes compounds of Formula (I) wherein one of A and B is CR⁴. For example, the present invention includes compounds of Formula (la) and

(lb):

(la) (lb).

[0017] In some embodiments according to the first aspect, compounds of Formula (I) include those where Ar is aryl. Aryl can be, for example, phenyl substituted with 0 to 5 substituents or naphthyl substituted with 0 to 7 substituents. Example substituents include C1-C6 alkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C6 alkenyl, C2-C6 alkynyl, - C4 haloalkyl, C1-C4 haloalkoxy, halogen, CN, NO₂, OR⁵, and SR⁵.

[0018] In other embodiments according to the first aspect, the present invention includes compounds wherein Ar is heteroaryl, including for example, heteroaryl groups having six-membered or five-membered rings. Example heteroaryl groups include pyridyl or pyrimidinyl. In some embodiments, the heteroaryl group is substituted with 0 to 4 substituents such as, for example, Ci-C_f5 alkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, halogen, CN, NO₂, OR⁵, and SR⁵. Other example heteroaryl groups include oxazolyl, isoxazolyl, or thienyl. According to such embodiments, the heteroaryl group can be substituted with 0 to 4 substituents such as, for example, C1-C6 alkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, halogen, CN, NO₂, OR⁵, and SR⁵.

[0019] In some embodiments according to the first aspect, the present invention includes compounds of Formula (I) where R¹ is H, CN, OH, -C alkyl, or C--C₂ haloalkyl. In other embodiments, R¹ can be C₁-C₄. alkyl. [0020] In further embodiments according to the first aspect, the present invention includes compounds of Formula (I) where R² is H, CN, OH, SH, OR^2b, SR² , C1-C₃ haloalkyl, or d-C alkyl substituted with 0 to 3 R² . In other embodiments, R² can be H. [0021] In yet further embodiments according to the first aspect, the present invention includes compounds of Formula (I) where R³ is S(O)R⁸, S(O)₂R⁸ , COR c, CONHR3^C, CONR3cR3d, C1-C8 alkyl substituted with 0 to 3 R^3a, C3-C8 alkenyl substituted with 0 to 3 R^3a, C3-C8 alkynyl substituted with 0 to 3 R^3a, C3-C6 cycloalkyl substituted with 0 to 3 R^3a, or C4-C10 cycloalkylalkyl substituted with 0 to 3 R^3a. In some embodiments, one carbon in any cycloalkyl moiety can be optionally replaced with O, S or NR-\

[0022] According to some embodiments according to the first aspect, compounds of

Formula (I) can include those where R³ is Ci-Cβ alkyl substituted with 0 to 2 R3a. in yet further embodiments, R^3a can be, for example, methyl, ethyl, propyl, cyclopropyl, cyclobutyl,

F, CI, Br, CF₃, CN, d-C₁₀ alkyl, C₂-C₁₀ alkenyl, OR^3c, SR^3c, COR^3b, NHR^3cSO₂R^3b,

OC(O)NR^3cR^3d, N₃, OC(O)OR^3b, CO₂R^3c, OC(O)R^3b, NR^3cCOR^3b, N(COR^3b)₂,

NR^3cCONR^3cR^3d, NR^3cCO₂R^3b, NR^3cR^3d, or CONR^3cR^3d.

[0023] According to further embodiments, the present invention includes compounds of Formula (I) where R⁴ is H, CN, OH, C--C₄ alkyl, C C₃ haloalkyl, SR^4c, or OR^4c.

According to some embodiments, R⁴ can be H.

[0024] In a second aspect, the present invention includes compounds of Formula (I) wherein:

A is CR⁴ or N;

Ar is aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted by one or more substituents independently selected from C1-C alkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, halogen, CN, NO₂, OR⁵, and SR⁵;

R! is H, CN, OH, SH, C1-C4 haloalkyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, C1-C4 alkyl substituted with 0 to 3 Rl^a, C2-C4 alkenyl substituted with 0 to 3 R^la, or C2- C4 alkynyl substituted with 0 to 3 Rl^a;

R^la is F, CI, Br, CN, NO_2> OH, methyl, ethyl, OCH3, CF3, CHF2, or OCF3; R² is H, CN, OH, NR2c_R2d _Cl_ _{3 al yl} substituted with 0 to 3 R^2a, C--C₃ alkoxy, d-C₂ haloalkyl, or d-C₂ haloalkoxy;

R3 is SOR⁸, SO₂R⁸, SO2NR3cR3d₅ C0R C, CONHR3C, CONR³CR3d ^ substituted with 0 to 3 R^3a, heteroaryl substituted with 0 to 3 R^3a, heterocyclyl substituted with 0 to 3 R^3f, Ci-Cio alkyl substituted with 0 to 3 R^3a, C3-C10 alkenyl substituted with 0 to 3 R^3a, C3-C10 alkynyl substituted with 0 to 3 R^3a, C3-C8 cycloalkyl substituted with 0 to 3 R^3a, C4-C12 cycloalkylalkyl substituted with 0 to 3 R^3a, C2-C10 alkoxyalkyl substituted with 0 to 3 R^3a, C2-C10 thioalkoxyalkyl substituted with 0 to 3 R^3a, C5-C10 cycloalkenyl substituted with 0 to 3 R^3a, or C6-C10 cycloalkenylalkyl substituted with 0 to 3 R^3a, wherein one carbon in any cycloalkyl moiety is optionally replaced with O, S or NR*^;

R⁴ is H, halogen, CN, C1-C3 haloalkyl, OR^4<-\ SR⁴<-, NR⁴ R ^d, CO2R^4b, C1-C4 alkyl substituted with 0 to 1 R^4a, or C3-C6 cycloalkyl substituted with 0 tol R^4a; each R^4a is, independently at each occunence, halogen, CN, CF3, OR^4c, NHR^4c, _NR4c_R4d₅ NR^4cCO2R^4b, SR^4c, SOR⁸, SO2R⁸, CO2R^4b, CONHR^4c, CONR⁴ R , COR^4b, OCOR^4b, NR ^cCONR^4cR^4d, NR⁴ CO2R^4b, OCONR^4cR^4d; each R⁴b is, independently at each occunence, C1-C4 alkyl, C1-C4 haloalkyl, C3- Cβ cycloalkyl, C4-C12 cycloalkylalkyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl, or heteroaryl-d- C₄ alkyl; each R^4c is, independently at each occunence, H, C1-C4 alkyl, C1-C4 haloalkyl, C3- Cβ cycloalkyl, C4-C12 cycloalkylalkyl, aryl, heteroaryl, aryl-d-C₄ alkyl, or heteroaryl-d- C₄ alkyl; each R^4d is, independently at each occunence, H, C1-C4 alkyl, C1-C4 haloalkyl, C3- Cβ cycloalkyl, C4-C12 cycloalkylalkyl, aryl, heteroaryl, aryl-d-C₄ alkyl, or heteroaryl-d- C₄ alkyl;

R⁵ is H, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, or C2-C6 alkoxyalkyl; each R⁷ is, independently at each occunence, H, C1-C6 alkyl, C1-C6 haloalkyl, C3- C6 cycloalkyl, C4-C12 cycloalkylalkyl, or C2-C8 alkoxyalkyl; each R^7b is, independently at each occunence, H, C1-C6 alkyl, C1-C6 haloalkyl, C3- Cβ cycloalkyl, C4-C12 cycloalkylalkyl, or C2-C8 alkoxyalkyl; and R⁸ is C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, aryl, heteroaryl, aryl-d-C₄ alkyl, or heteroaryl-C₁-C₄ alkyl, or NR^7aR^7b. Remaining variables can be defined as described above in the first aspect of the invention.

[0025] In some embodiments according to the second and first aspects of the invention, A can be N or A can be CR⁴.

[0026] In further embodiments according to the second and first aspects of the invention, R¹ can be H, CN, OH, d-C₄ alkyl, or d-C₂ haloalkyl.

[0027] In yet further embodiments according to the second and first aspects of the invention, R² can be H, CN, OH, methyl, ethyl, methoxy, OCF₃, CF₃, CHF₂, CH₂CF₃, or CF₂CH₃. hi other embodiments, R² can be H.

[0028] In yet further embodiments according to the second and first aspects of the invention, R³ can be d-C₆ alkyl substituted with 0 to 2 R^3a.

[0029] In even further embodiments according to the second and first aspects of the invention, R⁴ can be H, CN, OH, d-C₄ alkyl, C C₃ haloalkyl, SR^4c, or OR^4c. In other embodiments, R⁴ can be H.

[0030] In still further embodiments according to the second and first aspects of the invention, Ar can be aryl. Aryl, can be, for example, phenyl substituted with 0 to 5 substituents or naphthyl substituted with 0 to 7 substituents. Example substituents can be independently selected from C1-C6 alkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, halogen, CN, NO₂, OR⁵, and SR⁵.

[0031] In other embodiments according to the second and first aspects of the mvention, Ar can be heteroaryl, such as for example a six-membered heteroaryl ring or a five-membered heteroaryl ring. Some example heteroaryl groups include pyridyl or pyrimidinyl. These groups can be substituted with 0 to 4 substituents such as, for example, C1-C6 alkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci- C4 haloalkyl, C1-C4 haloalkoxy, halogen, CN, NO₂, OR⁵, and SR⁵. Other example heteroaryl groups include oxazolyl, isoxazolyl, or thienyl. These groups can be substituted with 0 to 4 substituents such as , for example, C1-C6 alkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C6 alkenyl, Q2-C6 alkynyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, halogen, CN, NO₂, OR⁵, and SR⁵.

[0032] In a third aspect, the present invention includes compounds of Formula (I) wherein: A is N or CR⁴;

Ar is phenyl, pyridyl, pyrimidinyl, oxazolyl, isoxazolyl, or thienyl, wherein the phenyl is substituted with 0 to 5 R⁹ and the pyridyl, pyrimidinyl, oxazolyl, isoxazolyl, or thienyl is substituted with 0 to 4 R^9b;

R¹ is H, CN, methyl, ethyl, methoxy, OH, or C1-C2 haloalkyl;

R² is H, CN, OH, CH3, OCH3, CF3, CHF₂, or OCF3;

R³ is S(O)R⁸, S(O)₂R⁸ , COR3C, CONHR3c, CONR³CR3d, _Cl_ _g alkyl substituted with 0 to 3 R^3a, C3-C8 alkenyl substituted with 0 to 3 R^3a, C3-C8 alkynyl substituted with 0 to 3 R^3a, C3-C6 cycloalkyl substituted with 0 to 3 R^3a, or C4-C10 cycloalkylalkyl substituted with 0 to 3 R^3a, wherein one carbon in any cycloalkyl moiety is optionally replaced with O, S or NR⁵; each R3a is, independently at each occunence, methyl, ethyl, methoxy, ethoxy, thiomethoxy, thioethoxy, cyclopropyl, cyclobutyl, F, CI, CF3 CHF₂, CH₃, or OCF3;

R⁴ is H, CHF₂, CF₃, methyl, ethyl, CI, F, OH, SH, methoxy, thiomethoxy, CH₂CF₃, or CF₂CH₃; and each R⁹ and R^9b is, independently at each occunence, F, CI, Br, CN, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, isopropoxy, d-C₂ haloalkyl, or d-C₂ haloalkoxy. Remaining variables can be defined as recited above according to the second aspect of the invention.

[0033] In embodiments according to the first, second, and third aspects, compounds of Formula (I) include those where A is N or A is CR⁴.

[0034] In further embodiments according to the first, second, and third aspects, compounds of Formula (I) include those where R² is H.

[0035] In yet further embodiments according to the first, second, and third aspects, compounds of Formula (I) include those where R³ is butyl, pentyl, hexyl, heptyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, methoxyhexyl, thiomethoxyethyl, thiomethoxypropyl, thiomethoxybutyl, thiomethoxypentyl, thiomethoxyhexyl, 1-cyclopropylpropyl, 1-cyclopropylbutyl, 1-cyclopropylpentyl, 1- cyclobutylpropyl, 1-cyclobutylbutyl, 1-cyclobutylpentyl, 1 -cyclopropyl- l-(CF₃)-methyl, 1- cyclopropyl-l-(CF₃)-ethyl, 1 -cyclopropyl- l-(CF₃)-propyl, l-cyclobutyl-l-(CF₃)-methyl, 1- cyclobutyl-2-(CF₃)-ethyl, l-cyclobutyl-3-(CF₃)-propyl, or (cyclopropyl)₂CH. [0036] In yet further embodiments according to the first, second, and third aspects, compounds of Formula (I) include those wherein R⁴ is H.

[0037] In even further embodiments according to the first, second, and third aspects, compounds of Formula (I) include those wherein Ar is phenyl substituted with 0 to 5 R^9a.

Alternatively, Ar can be pyridyl substituted with 0 to 4 R^9b or pyrimidinyl substituted with 0 to 4 R^9b.

[0038] In a fourth aspect, the present invention includes compounds of Formula (I) wherein:

A is N or CR⁴;

Ar is phenyl substituted with 0 to 3 substituents each independently selected from F, CI, Br, CN, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, isopropoxy, CF , CHF₂, and OCF₃; or

Ar is pyridyl or pyrimidinyl substituted with 0 to 2 substituents each independently selected from F, CI, Br, CN, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, isopropoxy, CF₃, CHF₂, and OCF₃;

R¹ is H, CN, OH, methyl, ethyl, methoxy, or C1-C2 haloalkyl;

R² is H;

R is C1-C6 alkyl substituted with 0 to 2 R^3a ; and

R⁴ is H. Remaining variables can be defined as described above in the third aspect of the invention.

[0039] In embodiments according to the above first, second, third, and fourth aspects,

Ar can be phenyl substituted with 0 to 3 substituents each independently selected from F, CI, Br, CN, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, isopropoxy, CF₃, CHF₂, and OCF₃. [0040] In further embodiments according to the above first, second, third, and fourth aspects, Ar can be pyridyl or pyrimidinyl substituted with 0 to 2 substituents each independently selected from F, CI, Br, CN, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, isopropoxy, CF₃, CHF₂, and OCF₃. In some embodiments, pyridyl can be pyrid-3-yl. [0041] In yet further embodiments according to the above first, second, third, and fourth aspects, A can be N or A can be CR⁴.

[0042] In even further embodiments according to the above first, second, third, and fourth aspects, R can be butyl, pentyl, hexyl, heptyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, methoxyhexyl, thiomethoxyethyl, thiomethoxypropyl, thiomethoxybutyl, thiomethoxypentyl, thiomethoxyhexyl, 1-cyclopropylpropyl, 1- cyclopropylbutyl, 1-cyclopropylpentyl, 1-cyclobutylpropyl, 1-cyclobutylbutyl, 1- cyclobutylpentyl, 1 -cyclopropyl- l-(CF₃)-methyl, l-cyclopropyl-l-(CF₃)-ethyl, 1- cyclopropyl-l-(CF₃)-propyl, l-cyclobutyl-l-(CF₃)-methyl, l-cyclobutyl-2-(CF )-ethyl, 1- cyclobutyl-3-(CF₃)-propyl, or (cyclopropyl)₂CH.

[0043] In a fifth aspect, the present invention includes the compounds of Formula

(la):

selected from the group consisting of:

(i?)-8-(2,4-dichloro-phenyl)-4-isobutyl-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one;

(S)-8-(2,4-dichloro-phenyl)-4-isobutyl-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one;

(R)-8-(2,4-dichloro-phenyl)-2-methyl-4-(l-methyl-butyl)-4H-pyrido[2,3-b]pyrazin-3- one;

(S)-8-(2,4-dichloro-phenyl)-2-methyl-4-(l-methyl-butyl)-4H-pyrido[2,3-b]pyrazin-3- one;

(5)-4-(l-cyclopropyl-propyl)-8-(2,4-dichloro-phenyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one;

(R)-4-(l-cyclopropyl-propyl)-8-(2,4-dichloro-phenyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one;

(i?)-8-(2,4-dichloro-phenyl)-4-(l,2-dimethyl-propyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one;

(S)-8-(2,4-dichloro-phenyl)-4-(l,2-dimethyl-propyl)-2-methyl-4H-ρyrido[2,3- b]pyrazin-3-one;

(i?)-4-(l-cyclopropyl-butyl)-8-(2,4-dichloro-phenyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one;

(S)-4-(l-cyclopropyl-butyl)-8-(2,4-dichloro-phenyl)-2-methyl-4H-ρyrido[2,3- b]pyrazin-3-one;

(Λ)-8-(2,4-dichloro-pheny)-4-(2-methoxy-l-methyl-ethyl)-2-methyl-4H -pyrido[2,3- b]pyrazin-3-one;

(S)-8-(2,4-dichloro-pheny)-4-(2-methoxy- 1 -methyl-ethyl)-2-methyl-4H -pyrido [2,3- b]pyrazin-3-one; (S)-8-(2,4-dichloro-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one;

(R)-8-(2,4-dichloro-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one;

(R,S)-8-(2-chloro-4-methoxy-phenyl)-2-methyl-4-(l-propyl-butyl)-4H-pyrido[2,3- b]pyrazin-3-one;

(S)-8-(2-chloro-4-methoxy-phenyl)-4-(l-cyclopropyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(i?)-8-(2-chloro-4-methoxy-phenyl)-4-(l-cyclopropyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(i?)-8-(2-chloro-4-methoxy-phenyl)-4-( 1 -cyclobutyl-propyl)-2-methyl-4H-pyrido [2,3- b]pyrazin-3-one;

(S)-8-(2-chloro-4-methoxy-phenyl)-4-(l-cyclobutyl-propyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one;

(S)-8-(2-chloro-4-methoxy-phenyl)-4-(2-methoxy-l-methyl-ethyl)-2-methyl-4H- pyrido [2,3-b]pyrazin-3 -one ;

(i?)-8-(2-chloro-4-methoxy-phenyl)-4-(2-methoxy-l-methyl-ethyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(S)-8-(2-chloro-4-methoxy-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(R)-4-(l-cylcopropropyl-propyl)-8-(4-methoxy-2-methyl-phenyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(i?)-4-(l-cyclopropyl-butyl)-8-(4-methoxy-2-methyl-phenyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(S)-4-(l-cyclopropyl-butyl)-8-(4-methoxy-2-methyl-phenyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one;

(i?)-4-(2-methoxy-l-methyl-ethyl)-8-(4-methoxy-2-methyl-phenyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(R)-4-(l-ethyl-ρentyl)-8-(6-methoxy-2-methyl-pyridin-3-yl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(S)-4-(l-ethyl-pentyl)-8-(6-methoxy-2-methyl-pyridin-3-yl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(i?)-4-(l-cyclopropyl-propyl)-8-(6-methoxy-2-methyl-pyridin-3-yl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one; (i?)-4-(l-cyclopropyl-butyl)-8-(6-methoxy-2-methyl-pyridin-3-yl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(S)-4-(l-cyclopropyl-butyl)-8-(6-methoxy-2-methyl-pyridin-3-yl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(_Jrv)-4-(2-methoxy-l-methyl-ethyl)-8-(6-methoxy-2-methyl-pyridyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(R)-4-sec-butyl-8-(2-chloro-4-difluoromethoxy-phenyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(S)-8-(2-chloro-4-difluoromethoxy-phenyl)-4-(l-cyclopropyl-propyl)2-methyl-4H- pyrido [2,3 -b]pyrazin-3 -one ;

(i?)-8-(2-chloro-4-difluoromethoxy-phenyl)-4-(l-cyclopropyl-propyl)2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(R)-8-(2-chloro-4-difluoromethoxy-phenyl)-4-(l-cyclopropyl-butyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(S)-8- (2-chloro-4-difluoromethoxy-phenyl)-4- ( 1 -cyclopropyl-butyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(2?)-8-(2-chloro-4-difluoromethoxy-phenyl)-4-(2-methoxy-l-methyl-ethyl)-2-methyl- 4H-pyrido[2,3-b]pyrazin-3-one;

(i?)-8-(2-chloro-4-difluoromethoxy-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl- 4H-pyrido[2,3-b]pyrazin-3-one;

(S)-8-(2-chloro-4-difluoromethoxy-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl- 4H-pyrido[2,3-b]pyrazin-3-one;

(S)-8-(2-chloro-4-trifluoromethyl-phenyl)-4-(l-cyclopropyl-propyl)-2-methyl-4Η- pyrido[2,3-b]pyrazin-3-one;

(R)-8-(2-chloro-4-trifluoromethyl-phenyl)-4-(2-methoxy-l-methyl-ethyl)-2-methyl- 4H-pyrido[2,3-b]pyrazin-3-one;

(R)-8-(2-chloro-4-trifluoromethyl-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(R)-3-chloro-4-(4-(l-methoxymethylpropyl)-2-methyl-3-oxo-3,4-dihydro-pyrido[2,3- b]pyrazin-8-yl]-benzonitrile;

(_Jrv)-8-sec-butyl-4-(2,4-dichloro-phenyl)-6-methyl-8H-pteridin-7-one; and

(S)-8-sec-butyl-4-(2,4-dichloro-phenyl)-6-methyl-8H-pteridin-7-one. [0044] In a sixth aspect of the invention, there are provided compounds of Formula

(lb):

(lb) selected from the group consisting of:

(R)-5-(2,4-Dichloro-phenyl)-l-isobutyl-3-methyl-lH-pyrido[3,4-b]pyrazin-2-one;

(S)-5-(2,4-Dichloro-phenyl)-l-isobutyl-3-methyl-lH-pyrido[3,4-b]pyrazin-2-one;

(2?)-l-(l-Cyclopropyl-propyl)-5-(2,4-dichloro-phenyl)-3-methyl-lH-pyrido[3,4- b]pyrazin-2-one;

(S)-l-(l-Cyclopropyl-propyl)-5-(2,4-dichloro-phenyl)-3-methyl-lH-pyrido[3,4- b]pyrazin-2-one;

(i?)-5-(2,4-Dichloro-phenyl)-l-(l-methoxymethyl-propyl)-3-methyl-lH-pyrido[3,4- b]pyrazin-2-one;

(S)-5-(2,4-Dichloro-phenyl)-l-(l-methoxymethyl-propyl)-3-methyl-lH-pyrido[3,4- b]pyrazin-2-one;

(7?)-5-(2,4-Dichloro-phenyl)-l-(2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrido[3,4- b]pyrazin-2-one;

(S)-5-(2,4-Dichloro-phenyl)-l-(2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrido[3,4- b]pyrazin-2-one;

(R)-l-(l-Cyclopropyl-2-methoxy-ethyl)-5-(2,4-dichloro-phenyl)-3-methyl-lH- pyrido[3 ,4-b]pyrazin-2-one;

(S)-l-(l-Cyclopropyl-2-methoxy-ethyl)-5-(2,4-dichloro-phenyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(i?)-l-(l-Cyclobutyl-ethyl)-5-(2,4-dichloro-phenyl)-3-methyl-lH-pyrido[3,4- b]pyrazin-2-one;

(S)-l-(l-Cyclobutyl-ethyl)-5-(2,4-dichloro-phenyl)-3-methyl-lH-pyrido[3,4- b]pyrazin-2-one;

(i?)-l-(l-Cyclobutyl-propyl)-5-(2,4-dichloro-phenyl)-3-methyl-lH-pyrido[3,4- b]pyrazin-2-one; (S)-l-(l-Cyclobutyl-propyl)-5-(2,4-dichloro-phenyl)-3-methyl-lH-pyrido[3,4- b]pyrazin-2-one;

(R)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-cyclopropyl-ethyl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one ;

(S)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)- 1 -( 1 -cyclopropyl-ethyl)-3-methyl- 1H- pyrido[3,4-b]pyrazin-2-one;

(R)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-cyclopropyl-propyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-cyclopropyl-propyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(R)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(2-methoxy-l-methyl-ethyl)-3- methyl- 1 H-pyrido [3 ,4-b]pyrazin-2-one ;

(S)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)- 1 -(2-methoxy- 1 -methyl-ethyl)-3- methyl- 1 H-pyrido [3 ,4-b]pyrazin-2-one ;

(i?)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-methoxymethyl-propyl)-3-methyl- lH-pyrido [3 ,4-b]pyrazin-2-one;

(S)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-methoxymethyl-propyl)-3-methyl- lH-pyrido [3 ,4-b]pyrazin-2-one ;

(R)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-cyclopropyl-2-methoxy-ethyl)-3- methyl- lH-pyrido [3 ,4-b]pyrazin-2-one;

(S)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-cyclopropyl-2-methoxy-ethyl)-3- methyl-lH-pyrido[3,4-b]pyrazin-2-one;

(i?)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-cyclobutyl-ethyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-cyclobutyl-ethyl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one;

(R)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-cyclobutyl-propyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-cyclobutyl-propyl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one;

(i?)-l-(l-Cyclopropyl-ethyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-l-(l-Cyclopropyl-ethyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one ; (R)- 1 - ( 1 -Cyclopropyl-propyl)-5 -(6-methoxy-2-methyl-pyridin-3 -yl)-3-methyl- 1 H- pyrido [3 ,4-b]pyrazin-2-one ;

(S)-l-(l-Cyclopropyl-propyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(i?)-l-(2-Methoxy-l-methyl-ethyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3-methyl- lH-pyrido[3,4-b]pyrazin-2-one;

(S)-l-(2-Methoxy-l-methyl-ethyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3-methyl- lH-pyrido[3,4-b]pyrazin-2-one;

(R)- 1 -( 1 -Methoxymethyl-propyl)-5- (6-methoxy-2-methyl-pyridin-3 -yl)-3 -methyl- 1 H- pyrido [3 ,4-b]pyrazin-2-one;

(S)- 1 -( 1 -Methoxymethyl-propyl)-5 -(6-methoxy-2-methyl-pyridin-3 -yl)-3 -methyl- 1 H- pyrido[3,4-b]pyrazin-2-one;

(i?)-l-(l-Cyclopropyl-2-methoxy-ethyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3- methyl-lH-pyrido[3,4-b]pyrazin-2-one;

(S)-l-(l-Cyclopropyl-2-methoxy-ethyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3- methyl-lH-pyrido[3,4-b]pyrazin-2-one;

(_JR)-l-(l-Cyclobutyl-ethyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one ;

(S)-l-(l-Cyclobutyl-ethyl)-5-(6-methoxy-2-mefhyl-pyridin-3-yl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one ;

(R)-l-(l-Cyclobutyl-propyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one ;

(S)-l-(l-Cyclobutyl-propyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one;

(R)-l-(l-Cyclopropyl-ethyl)-5-(6-methoxy-2,5-dimethyl-pyridin-3-yl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one;

(S)-l-(l-Cyclopropyl-ethyl)-5-(6-methoxy-2,5-dimethyl-pyridin-3-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(i?)-l-(l-Cyclopropyl-piOpyl)-5-(6-methoxy-2,5-dimethyl-pyridin-3-yl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one;

(5)-l-(l-Cyclopropyl-propyl)-5-(6-methoxy-2,5-dimethyl-pyridin-3-yl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one;

(i?)-5-(6-Methoxy-2,5-dimethyl-pyridin-3-yl)-l-(2-methoxy-l-methyl-ethyl)-3- methyl-lH-pyrido[3,4-b]pyrazin-2-one; (5)-5-(6-Methoxy-2,5-dimethyl-pyridin-3 -yl)- l-(2-methoxy- 1 -methyl-ethyl)-3 - methyl- 1 H-pyrido [3 ,4-b]pyrazin-2-one;

(i?)-5-(6-Methoxy-2,5-dimethyl-pyridin-3-yl)-l-(l-methoxymethyl-propyl)-3-methyl- lH-pyrido [3 ,4-b]pyrazin-2-one;

(5)-5-(6-Methoxy-2,5-dimethyl-pyridin-3-yl)-l-(l-methoxymethyl-propyl)-3-methyl- 1 H-pyrido [3 ,4-b]pyrazin-2-one ;

(i?)-l-(l-Cyclopropyl-2-methoxy-ethyl)-5-(6-methoxy-2,5-dimethyl-pyridin-3-yl)-3- methyl-lH-pyrido[3,4-b]pyrazin-2-one;

(S)-l-(l-Cyclopropyl-2-methoxy-ethyl)-5-(6-methoxy-2,5-dimethyl-pyridin-3-yl)-3- methyl-lH-pyrido[3,4-b]pyrazin-2-one;

(i?)-l-(l-Cyclobutyl-ethyl)-5-(6-methoxy-2,5-dimethyl-pyridin-3-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(5)-l-(l-Cyclobutyl-ethyl)-5-(6-methoxy-2,5-dimethyl-pyridin-3-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(i?)-l-(l-Cyclobutyl-propyl)-5-(6-methoxy-2,5-dimethyl-pyridin-3-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(5)-l-(l-Cyclobutyl-propyl)-5-(6-methoxy-2,5-dimethyl-pyridin-3-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(Λ)-l-(l-Cyclopropyl-ethyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(5)-l-(l-Cyclopropyl-ethyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one ;

(i?)-l-(l-Cyclopropyl-propyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-l-(l-Cyclopropyl-propyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one ;

(i?)-5-(4-Methoxy-2,5-dimethyl-phenyl)-l-(2-methoxy-l-methyl-ethyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-5-(4-Methoxy-2,5-dimethyl-phenyl)-l-(2-methoxy-l-methyl-ethyl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one ;

(i?)-5-(4-Methoxy-2,5-dimethyl -phenyl)- 1 -( 1 -methoxymethyl-propyl)-3-methyl- 1 H- pyrido[3,4-b]pyrazin-2-one;

(5)-5-(4-Methoxy-2,5-dimethyl-phenyl)-l-(l-methoxymethyl-propyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one; (_Jrv)-l-(l-Cyclopropyl-2-methoxy-ethyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3- methyl-lH-pyrido[3,4-b]pyrazin-2-one;

(S)-l-(l-Cyclopropyl-2-methoxy-ethyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3- methyl-lH-pyrido[3,4-b]pyrazin-2-one;

(i?)-l-(l-Cyclobutyl-ethyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-l-(l-Cyclobutyl-ethyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(i?)-l-(l-Cyclobutyl-propyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one;

(S)-l-(l-Cyclobutyl-propyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(_JR)-l-(l-Cyclopropyl-ethyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one ;

(S)-l-(l-Cyclopropyl-ethyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(_Jrv)-l-(l-Cyclopropyl-propyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-l-(l-Cyclopropyl-propyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(i?)-5-(2,4-Dimethoxy-pyrimidin-5-yl)-l-(2-methoxy-l-methyl-ethyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-5-(2,4-Dimethoxy-pyrimidin-5-yl)-l-(2-methoxy-l-methyl-ethyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(i?)-5-(2,4-Dimethoxy-pyrimidin-5-yl)-l-(l-methoxymethyl-propyl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one;

(S)-5-(2,4-Dimethoxy-pyrimidin-5-yl)-l-(l-methoxymethyl-piOpyl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one ;

(i?)-l-(l-Cyclopropyl-2-methoxy-ethyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl- 1 H-pyrido [3 ,4-b]pyrazin-2-one ;

(S)-l-(l-Cyclopropyl-2-methoxy-ethyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl- lH-pyrido[3 ,4-b]pyrazin-2-one;

(i?)-l-(l-Cyclobutyl-ethyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one; (5)-l-(l-Cyclobutyl-ethyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl-lH- pyrido[3 ,4-b]pyrazin-2-one;

(i?)-l-(l-Cyclobutyl-propyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl-lH- pyrido[3 ,4-b]pyrazin-2-one;

(S)-l-(l-Cyclobutyl-propyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl-lH- pyrido[3 ,4-b]pyrazin-2-one.

[0045] Compounds of this invention can have one or more asymmetric centers.

Unless otherwise indicated, all chiral (enantiomeric and diastereomeric) and racemic forms of compounds of Formula (I) are included in the present invention. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds, and all such stable isomers are contemplated in the present invention. Accordingly, the present compounds can be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. All chiral, (enantiomeric and diastereomeric) and racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomer form is specifically indicated.

[0046] The term "alkyl" as used herein is meant to refer to a saturated hydrocarbon group which is straight-chained, branched or cyclized ("cycloalkyl"). Alkyl groups can be unsubstituted or substituted so that one or more of its hydrogens are replaced by another chemical group. Example alkyl groups include methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, t-butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl), cyclopentyl, cyclohexyl, norbomyl, and the like. "Alkenyl" refers to alkyl groups having one or more double carbon-carbon bonds. Example alkenyl groups include ethenyl, propenyl, cyclohexenyl, and the like. "Alkynyl" refers to alkyl groups having one or more triple carbon-carbon bonds. Example alkynyl groups include ethynyl, propynyl, and the like. "Haloalkyl" refers to branched, straight-chained, and cyclyl alkyl groups having one or more halogen substituents. Example haloalkyl groups include CF₃, C₂F₅, CHF , CC1₃, CHC1₂, C₂C1₅, and the like. The term "alkoxy" refers to an -O-alkyl group. Example alkoxy groups include, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy, and the like. The term "cycloalkyl" refers to cyclized alkyl groups, including mono-, bi- or poly-cyclic ring systems. Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and so forth. "Halo" or "halogen" includes fluoro, chloro, bromo, and iodo. [0047] "Aryl" groups refer to monocyclic or polycyclic aromatic hydrocarbons, including, for example, phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and the like. Aryl moieties are well known and described, for example, in Hawley's Condensed Chemical Dictionary (13 ed.), R J. Lewis, ed., J. Wiley & Sons, Inc., New York (1997). Aryl groups can be substituted or unsubstituted.

[0048] "Heteroaryl" groups are monocyclic and polycyclic aromatic hydrocarbons that include at least one heteroatom ring member such as sulfur, oxygen, or nitrogen. Heteroaryl groups include, without limitation, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pynyl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, 2,3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, benzoxazolin-2-on-yl, indolinyl, benzodioxolanyl, benzodioxane, and the like. Heteroaryl groups can be substituted or unsubstituted. [0049] "Heterocyclyl" groups can be saturated (i.e., containing no double or triple bonds) or unsaturated (i.e., containing one or more double or triple bonds) carbocyclyl groups wherein one or more of the ring-forming carbon atoms of the carbocyclyl group is replaced by a heteroatom such as O, S, or N. Heterocyclyl groups can be substituted or unsubstituted. Examples of heterocyclyl groups include moφholino, thiomoφholino, piperazinyl, tetrahydrof uranyl, tetrahydrothienyl, piperidinyl, pynolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, and the like. Some example heterocyclyl substituents can include d-C₆ alkyl, C₃-C₆ cycloalkyl, C -C₆ alkenyl, C₂-C₆ alkynyl, halogen, d-C₄ haloalkyl, CN, OR⁷, SH, NO₂, OCF₃, S(O)_nR⁷, COR⁷, CO₂R⁷, OC(O)R⁷, NR⁷COR⁸, N(COR⁷)₂, NR⁷CONR⁷R⁸, NR⁷CO₂R⁸, NR⁷R⁸, or CONR⁷R⁸, wherein R and R are as defined above according to the first aspect of the invention. Heterocyclyl groups can be substituted with any number of substituents such as, for example, 0 to 7, 0 to 6, 0 to 5, 0 to 4, 0 to 3, 0 to 2, or 0 to 1 substituents.

[0050] As refened to herein, the term "substituted" means that one or more hydrogen atoms is replaced with a non-hydrogen group, provided that normal valencies are maintained and that the substitution results in a stable compound.

[0051] The term "pharmaceutically acceptable salt" refers to acid or base salts of the compounds described herein. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. Pharmaceutically acceptable salts of the compounds of the invention can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are prefened. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incoφorated by reference in its entirety. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. Pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. Such conventional non- toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2- acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

[0052] "Prodrugs" refer to inactive compounds that can be converted upon absoφtion by a mammalian subject to an active compound of Formula (I). Prodrugs of the compounds of Formula (I) can be prepared by modifying functional groups present in the compounds of Formula (I) in such a way that the modifications are cleaved in vivo to produce the parent compounds. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of Formula (I). Preparation of prodrugs is well known in the art and described in, for example, Medicinal Chemistry: Principles and Practice, ed. F. D. King, The Royal Society of Chemistry, Cambridge, UK, 1994, which is incoφorated herein by reference in its entirety. [0053] Radiolabelled compounds of Formula I, i.e., wherein one or more of the atoms described are replaced by a radioactive isotope of that atom (e.g., C replaced by 1⁴C or by ^πC, and H replaced by H or F), are also provided herein. Such compounds have a variety of potential uses, e.g., as standards and reagents in determining the ability of a potential pharmaceutical to bind to target proteins or receptors, or for imaging compounds of this invention bound to biological receptors in vivo or in vitro.

[0054] The present invention further includes compositions comprising one or more compounds of Formula (I) and a pharmaceutically acceptable carrier. [0055] A "pharmaceutically acceptable carrier" refers to media generally accepted in the art for the delivery of biologically active agents to animals, in particular, mammals. Pharmaceutically acceptable carriers are formulated according to a number of factors well within the purview of those of ordinary skill in the art. These include, without limitation: the type and nature of the active agent being formulated; the subject to which the agent- containing composition is to be administered; the intended route of administration of the composition; and, the therapeutic indication being targeted. Pharmaceutically acceptable carriers include both aqueous and non-aqueous liquid media, as well as a variety of solid and semi-solid dosage forms. Such carriers can include a number of different ingredients and additives in addition to the active agent, such additional ingredients being included in the formulation for a variety of reasons, e.g., stabilization of the active agent, binders, etc., well known to those of ordinary skill in the art. Descriptions of suitable pharmaceutically acceptable carriers, and factors involved in their selection, are found in a variety of readily available sources such as, for example, Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, which is incoφorated herein by reference in its entirety.

[0056] The present invention further includes methods of reducing symptoms caused by elevated levels of corticotropin releasing factor in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula (I). [0057] The present invention further includes methods of treating stress-related symptoms in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula (I).

[0058] The present invention also includes methods of treating a disorder characterized by abnormal levels of corticotropin releasing factor in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula (I). According to some embodiments, the disorder can be characterized by elevated levels of corticotropin releasing factor. In some embodiments, the disorder affects the central nervous system. Some example disorders that can be treated according to the methods described herein include anxiety or depression. In some embodiments, the treatable disorder is irritable bowel syndrome.

[0059] Some disorders characterized by abnormal levels of corticotropin releasing factor include the following disorders: mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, seasonal affective disorder, postpartum depression, dysthemia, bipolar disorders, and cyclothymia; anxiety disorders including panic, phobias, obsessive-compulsive disorder; post-traumatic stress disorder; and sleep disorders induced by stress; inflammation; pain; chronic fatigue syndrome; stress-induced headache; cancer; human immunodeficiency vims

(HIV) infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases such as ulcers, irritable bowel syndrome, Crohn's disease, spastic colon, diarrhea, and post operative ileus, and colonic hypersensitivity associated by psychopathological disturbances or stress; eating disorders such as anorexia and bulimia nervosa; supranuclear palsy; amyotrophic lateral sclerosis; immune suppression; hemonhagic stress; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidianhetic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage (e.g., cerebral ischemia such as cerebral hippocampal ischemia); excitotoxic neuronal damage; epilepsy; cardiovascular disorders including hypertension, tachycardia and congestive heart failure; stroke; immune dysfunctions including stress-induced immune dysfunctions (e.g., stress induced fevers, porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human-animal interaction related stress in dogs); muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; chemical dependencies and addictions (e.g., dependencies on alcohol, cocaine, heroin, benzodiazepines, or other drugs); drag and alcohol withdrawal symptoms; osteoporosis; psychosocial dwarfism; hypoglycemia; hair loss; abnormal circadian rhythm; and disorders related to abnormal circadian rhythm such as time zone change syndrome, seasonal affective disorder, inegular sleep-wake pattern, delayed sleep phase syndrome, advanced sleep phase syndrome, non-24 hour sleep wake disorder, light-induced clock resetting, REM sleep disorder, hypersomnia, parasomnia, narcolepsy, nocturnal enuresis, restless legs syndrome, sleep apnea, dysthymia, and abnormal circadian rhythm associated with chronic administration and withdrawal of antidepressant agents. Thus, the compounds provided herein, because of their antagonism of CRF receptors, are expected to be useful in treating these and other disorders.

[0060] The term "therapeutically effective amount" refers to an amount of compound effective to reduce or eliminate at least one symptom of a disorder that the compound was used to treat.

[0061] Compounds of this invention can be administered to treat the above disorders by any suitable means that allows the compound to contact the compound's site of action, such as a CRF receptor, in the body of a mammal. The compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals either as an individual therapeutic agent or in combination with other therapeutic agents. Compounds of the present invention can be administered alone, or in combination with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

[0062] The dosage of compound administered varies depending on several factors such as the pharmacodynamic character of the particular compound, and its mode and route of administration; the recipient's age, weight, and health; nature and extent of symptoms; kind of concunent treatment; frequency of treatment; and desired effect. For use in the treatment of the above diseases or conditions, the compounds of this invention can be orally administered daily at a dosage of the active ingredient (e.g., a compound of Formula I) of about 0.002 to about 200 mg/kg of body weight. For example, a dose of about 0.01 to about 10 mg/kg can be divided into smaller doses and administered one to four times a day. Alternatively, sustained release formulations can be effective in obtaining the desired pharmacological effect.

[0063] Dosage forms (compositions) suitable for administration can contain from about 1 mg to about 100 mg of active ingredient per dosage unit. In these pharmaceutical compositions, the active ingredient (e.g., a compound of Formula I) can be present in an amount of about 0.5 to 95% by weight based on the total weight of the composition. [0064] The active ingredient (e.g., a compound of Formula I) can be administered orally in solid dosage forms such as capsules, tablets and powders, or in liquid forms such as elixirs, syrups, and/or suspensions. The compounds of this invention can also be administered parenterally in sterile liquid dose formulations.

[0065] Gelatin capsules can be used to contain the active ingredient and a suitable carrier such as, but not limited to, lactose, starch, magnesium stearate, steric acid, or cellulose derivatives. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of time. Compressed tablets can be sugar-coated or film-coated to mask any unpleasant taste, or used to protect the active ingredients from the atmosphere, or to allow selective disintegration of the tablet in the gastrointestinal tract. [0066] Liquid dose forms for oral administration can also contain coloring or flavoring agents to increase patient acceptance. [0067] Typically, water, pharmaceutically acceptable oils, saline, aqueous dextrose, and related sugar solutions and glycols, such as propylene glycol or polyethylene glycol, are suitable carriers for parenteral solutions. Solutions for parenteral administration can contain, for example, a water soluble salt of the active ingredient and suitable stabilizing agents.

Antioxidizing agents, such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or in combination, can act as suitable stabilizing agents. Also suitable as stabilizing agents are citric acid and its salts, and EDTA. In addition, parenteral solutions can contain preservatives such as, for example, benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

[0068] The compounds of this invention may also be used as reagents or standards in the biochemical study of neurological function, dysfunction, and disease.

[0069] Compounds of Formula (I) can be prepared by the following synthetic routes and schemes. Where a detailed description is not provided, it is assumed that those skilled in the art of organic synthesis will readily understand the meaning.

[0070] Compounds of Formula (I) can be prepared according to the route shown in

Scheme 1.

Scheme 1

According to scheme 1, a compound of Formula JJ can be coupled to an aromatic compound of Formula III, with elimination of M-K. For compounds of Formula π, K can represent a halide, pseudohalide (such as, for example, mesylate, tosylate or triflate), or thiomethyl. For compounds of Formula III, M can represent groups such as lithium, bromomagnesium, chlorozinc, (dihydroxy)boron, (dialkoxy)boron, trialkylstannyl, and the like. The coupling reaction of scheme 1 can be performed in the presence of an appropriate catalyst, such as tetrakis(triphenylphosphine)palladium, bis(triphenylphosphine)palladium dichloride, [1,3- bis(diphenylphosphino)propane]nickel dichloride, etc. Example methods involve the coupling of chloroheterocycles with zn-sztw-prepared arylzinc reagents according to the method described in Negishi et al., J. Org. Chem. 1977, 42, 1821, which is incoφorated herein by reference in its entirety, and the coupling with arylboronic esters according to the method described in Suzuki et al., Chem. Letters 1989, 1405, which is incoφorated herein by reference in its entirety. Appropriate solvents for reactions of this type usually include, for example, tetrahydrofuran, diethyl ether, dimethylformamide, or dimethylsulfoxide. Typical temperatures can range, for example, from ambient up to the boiling point of the solvent. [0071] Preparation of compounds of Formula VI wherein A is a nitrogen atom can proceed according to the route of Scheme 2.

Scheme 2

A compound of Formula IV, such as, for example, when K is chloride, can be obtained from commercial sources. Compounds bearing pseudohalide K groups can be made from the conesponding dihydroxy compounds by treatment with an appropriate activating reagent, such as an organosulfonic anhydride or sulfonyl chloride. Compounds of Formula TV can be converted to compounds of Formula VI by, for example, (i) monoalkylation with a compound P-NH₂, followed by reduction of the nitro group, or (ii) reduction of the nitro group, to give an amine compound of Formula V, followed by monoalkylation with a compound R³-NH₂. Pyrimidine chemistry of this type is well represented in the literature, and is reviewed in Comprehensive Heterocyclic Chemistry, vol. 6, which is incoφorated herein by reference in its entirety. Alkylation of chloropyrimidines with amine compounds can be accomplished under either acidic (e.g., HCl or acetic) or basic (e.g., trialkylamines, potassium tert-butoxide, etc.) conditions. Nitro groups in compounds of this type can be reduced to amino groups using one of any number of conditions, including catalytic hydrogenation, tin dichloride, sodium dithionite, zinc metal, iron powder, etc.

[0072] Compounds of Formula VI can be cyclized with an appropriate ketoester by condensation followed by intramolecular cyclization in toluene, ethanol, methanol, butanol, or other appropriate solvent either alone or in the presence of acid such as a toluenesulfonic acid, acetic acid, hydrochloric acid, Lewis acid, etc. The reaction can be mn at any suitable temperature such as, for example, ambient temperature to the boiling point of any given solvent to give the compounds of Formula (I).

[0073] An example preparation of compounds of Formula V, wherein A is carbon and

B is nitrogen, is shown in Scheme 3.

Scheme 3

V (A=CR⁴) X (B=N)

An hydroxypyridone compound of Formula VII can be nitrated to give compounds of Formula VLII employing conditions such as, for example, concentrated or fuming nitric acid, optionally in the presence of concentrated sulfuric or acetic acid. Both the hydroxy and pyridone groups in compounds of Formula VHI can be activated at the same time, using stronger conditions such as phosphoms oxychloride and heat, or excess toluenesulfonic anhydride, to give compounds of Formula IX. Selective monoalkylation of compounds of Formula IX is also possible, but can give mixtures of regioisomeric products. The nitro group of compounds of Formula X can then be reduced as discussed above, to give compounds of Formula V wherein A is CR⁴. Cyclization as described above can yield compounds of Formula (I).

[0074] Another route (scheme 4) can convert compounds of Formula II to the metallated compounds of Formula XI for coupling to appropriate aryl halides as described above. Scheme 4

ii xι

[0075] The compound of Formula IT (A=N) can also be synthesized by direct halogenation of compounds of Formula XII (scheme 5). This can be achieved selectively by forming the N-oxide with meta-chloroperbenzoic acid, or other appropriate oxidizing agents followed by treatment with a halogenating agent such as phosphorous oxychloride as described in Tomczuk et al., J. Med. Chem., 1991, 34, 2993, which is incoφorated herein by reference in its entirety.

Scheme 5

R³ R³ γ_γ ^R _{R N}J N

XII

II (A=B=N)

[0076] Compounds of Formula V, which are typically commercially available, can be exposed to aryl coupling conditions (scheme 6) as described above to give compounds of Formula XLTI, which can be elaborated to give compounds of Formula XIV, which upon treatment with an appropriate keto-ester under conditions described can give rise to compounds of Formula (I) where A = N.

Scheme 6

I (A = N)

[0077] Compounds of Formula XV (scheme 7), which are typically commercially available, can be reacted with an appropriate amine to give compounds of Formula XVI. The nitro group can then be reduced as described above and compounds of Formula XVIII cyclized with the desired ketoester in a manner analogous to the cyclizations previously described. This cyclized material can then be halogenated to give the desired halide derivative which, in turn, can be subjected to aryl coupling conditions as previously described to give the desired analogs. Alternatively, compounds of Formula XVIII can be directly metallated and the organolithium subjected to aryl coupling conditions as described above. Compounds of Formula XVHI can also be used as a precursor to XIX following reaction conditions described earlier.

Scheme 7

XV XVI Y\/ll

[0078] Commercially available compounds of Formula VH can be nitrated employing conditions such as fuming nitric acid, optionally in the presence of concentrated sulfuric or acetic acid (scheme 8). The hydroxypyridone compounds of Formula VHI can be selectively protected. One method of protection, for example, involves the treatment of dicyclohexylamine salts of compounds of Formula VLtl. Conversion of compounds of Formula XXI, where K = CI, can be achieved by treatment with sulfonyl chloride, or if K is a pseudohalide, treatment with organicsulfonic anhydride. The coupling reaction can be ran as described above to give compounds of Formula XXII and the nitro group reduced using catalytic hydrogenation, tin dichloride, sodiumithionite, etc. Cyclization as described above can give compounds of Formula I, where A = CR⁴. Scheme 8

[0079] Methods of synthesis of compounds R³-OH, R³-I and R³-NH₂ are related, in that the alcohol can be used in the synthesis of the other two compounds, as is shown in Scheme 9.

Scheme 9 R³-OH _R3_j > R³-N₃ R³-NH₂

(Scheme 1)

(Scheme 2)

For example, the hydroxy group can be converted to the following J groups, using the indicated reagents (this route is not limited to these J groups): methanesulfonate, using methanesulfonyl chloride or anhydride and an appropriate base; toluenesulfonate, using toluenesulfonyl chloride or anhydride and an appropriate base; iodide; using iodine / triphenylphosphine; bromide, using phosphorus tribromide or carbon tetrabromide / triphenylphosphine; or trifluorornethanesulfonate, using trifluoromethane-sulfonic anhydride and an appropriate base. Both compounds R³-OH and R³-I are used in the methods portrayed in Scheme 1. Conversion of R -J to R -N₃ typically uses an azide source, such as sodium azide, and a solvent such as dimethylsulfoxide or dimethylformamide, or water and a phase- transfer catalyst (such as tetrabutylammonium hydrogen sulfate). Reduction of the azide compound R -N₃ to R -NH₂ can be accomplished using reagents such as, for example, sodium borohydride or triphenylphosphine, or hydrogen gas and a catalyst (such as palladium on carbon). The amine R³-NH can then be employed in the methods portrayed in Scheme 2. [0080] In the cases where the compound R³-OH could be represented by Formula

XXIV (Scheme 10), wherein R^a and R^b represent substructures which, taken together with the carbinol methine group, comprise the entire group R , this compound can be prepared by addition to a carbonyl compound.

Scheme 10

R^E

R^a-wr + π o OH XT' R^D-M' (XXIV)

R^D o

(XXV)

This route can be useful in the case where R^a or R represent a cycloalkyl group, such as cyclopropyl. An organometallic reagent (where M' represents a metallic group, such as Li, CuCN, Cul, MgCl, MgBr, Mgl, ZnCl, CrCl, etc.) can be allowed to react with an aldehyde reagent to prepare the alcohol compound of Formula XXTV. Alternatively, a ketone of Formula XXV can be treated with a reducing agent, such as, for example, sodium borohydride, lithium aluminum hydride, etc., which can also generate the alcohol of Formula XXIV. Standard methods of ketone synthesis can be used where appropriate in the preparation of compounds of Formula XXV, which are familiar to those skilled in the art of organic synthesis. [0081] An homologous approach can also be employed in the synthesis of alcohols

R -OH, involving the ring-opening reaction of cyclic ether compounds with organometallic reagents (Scheme 11). Scheme 11

-WI'

Here, an organometallic reagent R^a-M" is used, where M" represents metals such as Mg, Zn or Cu. An example method is described in Huynh, et al., Tetrahedron Letters 1979, 17, 1503- 1506, which is incoφorated herein by reference in its entirety, where organomagnesium reagents are reacted with cyclic ethers with catalysis provided by copper (I) iodide. Use of an epoxide compound of Formula XXVII in this manner can result in synthesis of an alcohol compound of Formula XXVIII, and use of an oxetane compound of Formula XXVI can generate an alcohol of Formula XXLX. Both compounds XXVIII and XXIX are variants of R³-OH.

[0082] Synthesis of compound R³-NH₂ with Formula XXX is portrayed in Scheme

12.

Scheme 12

xxv xxx

XXXI xxxii A simple reductive amination of ketones of Formula XXV can produce amines of Formula XXX. This reaction can be performed using anhydrous ammonia in the presence of hydrogen and a catalyst. Alternatively, addition of an organometallic reagent to a nitrile compound gives an imine, which can be treated in situ with a reducing agent (such as, for example, sodium cyanoborohydride) to give amines of Formula XXX. Further, a compound of Formula XXXII, wherein Q is an optionally-substituted oxygen atom (i.e., an oxime) or nitrogen atom (i.e., a hydrazone), can be allowed to react with an organometallic reagent R -M'". Here, metallic groups M'" such as MgBr, CuCl or CeCl₂ can be used in additions to oximes or hydrazones. The intermediate addition products of Formula XXXI can be subjected to reductive cleavage (using conditions such as sodium/liquid ammonia or catalytic hydrogenation), which can afford amines of Formula XXX.

[0083] Amino acids, either naturally-occurring or synthetic, are potential sources of useful starting materials for the synthesis of the compounds of this invention. Scheme 13 shows some possible applications of this approach.

Scheme 13

R^a^ .C0₂H R^a _\ 0₂H R^a

OH

NH₂ NH-Prot NH-Prot XXXIII XXXIV xxxv

R^a.

NH₂ NH-Prot NH-Prot

XXXVIII XXXVII XXXVI

Protected amino acids of Formula XXXIV can be prepared from the parent compounds of Formula XXXLIL Some example protecting groups ("Prot") include tert-butoxycarbonyl, benzyloxycarbonyl, and triphenylmethyl. Standard texts in peptide chemistry describe amino protecting groups. The carboxylic acid group can be reduced using reagents such as lithium borohydride, giving, for example, alcohols of Formula XXV. The hydroxy group can be converted to a leaving group "J" as described before. The compounds of Formula XXXVI can be treated with appropriate reagents to produce a wide variety of functional groups (e.g., compounds of Formula XXXVII). For example, displacement of I with cyanide (e.g., sodium cyanide in warm dimethylformamide) can give a nitrile. Displacement of I with a mercaptan (in the presence of a base, such as potassium carbonate) can give a disulfide. Further, displacement of J with a secondary amine can give a tertiary amine, etc. [0084] The compounds of Formula (I) with unsaturated R¹ groups can be a further source of compounds. Unsaturated (double and triple) bonds can take part in cycloaddition chemistry using appropriate reagents (Scheme 14). Cycloaddition of an alkyne compound of Formula XXXLX with 1,3-dienes to give six-membered ring compounds like that of Formula XL (commonly known as the Diels-Alder reaction), and cycloaddition with 3-atom dipolar reagents to give heterocyclic compounds of Formula XLI, are familiar to those skilled in the art of organic synthesis. An example of this approach is the synthesis of an isoxazole compound of Formula XLII from the alkyne XXXIX and a nitrile oxide reagent.

Scheme 14

XLII [0085] The synthetic procedure in Scheme 15 shown below can be used to prepare compounds of Formula (la).

Scheme 15

Reaction of 4-chloropyridone of Formula XLIII with an aryl halide, such as benzyl bromide in benzene and in the presence of Ag₂CO as described in Scheme 15 (Smith A. M. et al, J. Med. Chem., 1993, 36, 8, which is incoφorated herein by reference) and at temperature ranges of , for example, about 30 to about 80 °C can afford the conesponding 2- benzyloxypyridine of Formula XLIV. This compound can be coupled, for example, with an arylboronic acid, ArB(OH)₂, under palladium-catalyzed conditions to give compounds of Formula XLV. The benzyloxy group can be removed by treatment with a strong acid, such as trifluoroacetic acid, triflic acid, sulfuric acid, HCl, etc. to give pyridones of Formula XLVI. This compound can be converted to the 2-halopyridine derivative with the action of POX₃, PX₅, (X is halo) or the conesponding triflate, tosylate or mesylate, which can be displaced with a primary amine R NH₂ to give XLVII. The nitro group can be reduced under conditions described in scheme 15, and the aminopyridine can be cyclized to XLVLII under the conditions described in scheme 15.

[0086] The following examples are provided to describe the invention in further detail and are intended to illustrate and not to limit the invention. Potency of binding to CRFi receptor for select compounds are listed as IC₅₀ ranges where a= <1 nM; b= 1- lOnM; c= 10-lOOnM; d= lOOnM-lμM; e= >lμM.

EXAMPLES

Table 1

Table 2

Preparation 1 2-Chloro-5-fluoro-4-methoxyphenylboronic acid

PARTA

[0087] To a l-chloro-3,4-difluorobenzene (25 g, 0.17 mol) cooled to 0 °C was added fuming nitric acid (50 mL) dropwise over 30 min. The orange solution was warmed to room temperature and stined for 2 h. The solution was poured slowly over ice and the resultant mixture extracted with diethyl ether. The diethyl ether layers were washed with brine, dried (Na₂SO ), filtered and concentrated in vacuo to give 26 g (80%) of l-chloro-4,5-difluoro-2- nitro-benzene: Crude 1H NMR (400 MHz, CDC1₃): δ 7.88 (dd, 7=9.3, 7.6 Hz, 1H), 7.43 (dd, J=9.3, 7.1 Hz, 1H). The crude material was pure enough to cany on to the next step. PART B

[0088] To sodium methoxide (100 mL of a 0.5 M solution in methanol, 50.1 mmol) cooled to 0 °C was added a solution of l-chloro-4,5-difluoro-2-nitro-benzene (9.7 g, 50.1 mmol) in methanol (10 mL) dropwise over 15 min. The solution was warmed to room temperature and stirred for 2 h, then poured slowly over ice. The yellow precipitate was collected by filtration and washed with cold water. The crystals were air dried to give 8.2 g (79%) of l-chloro-4-fluoro-5-methoxy-2-nitro-benzene: Crude 1H NMR (400 MHz, CDC1₃): δ 7.85 (d, 7=10.5 Hz, IH), 7.06 (d, 7=7.3 Hz, IH), 3.98 (s, 3H). The crade material was pure enough to carry on to the next step.

PART C

[0089] l-Chloro-4-fluoro-5-methoxy-2-nitro-benzene (16.3 g, 79.3 mmol) and Sn granules (29.1 g, 246 mmol) were suspended in water (200 mL). Concentrated HCl (79 mL, 952 mmol) was added dropwise over 20 min. The resulting mixture was heated to 55 °C for 3h. The solution was cooled to room temperature and carefully quenched with 1 N NaOH. The thick mixture was filtered through celite eluting the ethyl acetate to give a clear solution which was extracted with ethyl acetate. The ethyl acetate layers were washed with brine, dried (Na₂SO₄), filtered and concentrated in vacuo to give 26 g (80%) of 2-chloro-5-fluoro-4- methoxyaniline: Crade 1H NMR (400 MHz, CDC1₃): δ 6.88 (d, 7=8.3 Hz, IH), 6.57 (d, 7=12.2 Hz, IH), 3.79 (s, 3H), 3.77 (br s, 2H). The crade material was pure enough to cany on to the next step. >

PARTD

[0090] 2-Chloro-5-fluoro-4-methoxyaniline (14.0 g, 79.7 mmol) was cooled to 0 °C and cone. HCl (40 mL) was added over 20 min. The suspension was heated to 55 °C until the aniline was completely dissolved, then cooled back to 0 °C. A solution of sodium nitrite (6.1 g, 87.7 mmol) in water (15 mL) was added dropwise over 15 min. After complete addition the mixture was stirred at 0 °C for 30 min. Hexanes (24 mL) and dichloromethane (24 mL) were added followed by a solution of potassium iodide (26.5 g, 159.4 mmol) in water (25 mL) which was added dropwise over 30 min. After stirring at 0 °C for 4 h dichloromethane (50 mL) was added and the reaction quenched with sat. aq. NaHSO . The solution was extracted with dichloromethane. The organic layers were washed with brine, dried (Na₂SO ), filtered and concentrated in vacuo to give 21 g (92%) of l-chloro-4-fluoro-2-iodo-5- methoxy-benzene: Crade 1H NMR (400 MHz, CDC1₃): δ 7.48 (d, 7=10.3 Hz, IH), 7.04 (d, 7=7.8 Hz, IH), 3.86 (s, 3H). The crude material was pure enough to cany on to the next step.

PARTE

[0091] To l-chloro-4-fluoro-2-iodo-5-methoxy-benzene (10.0 g, 34.9 mmol) in THF

(70 mL) was cooled to -78 °C was added triisopropylborate (8.9 mL, 38.4 mmol) followed by dropwise addition of n-butyl lithium (24 mL of a 1.6 M solution in hexanes, 38.4 mL). The solution was stined and allowed to warm to room temperature over night by dissipation of the dry ice/acetone bath. IN HCl (50 mLO and water (50 mL) were added and the solution stirred at room temperature for 1 h. The solution was extracted with ethyl acetate. The organic layers were washed with brine, dried (Na₂SO₄), filtered and concentrated in vacuo. The residue was triturated with 1:1 hexanes/diethyl ether and the solid collected by filtration to give 3.8 g (53%) of pure l-chloro-4-fluoro-2-iodo-5-methoxyphenyl boronic acid: 1H NMR (400 MHz, CDC1₃): δ 7.64 (d, 7=11.7 Hz, IH), 6.91 (d, 7=7.3 Hz, IH), 5.21 (br s, 2H), 3.90 (s, 3H).

Preparation 2

2-ChIoro-4-dimethylammo-5-fluorophenylboronic acid

PARTS A and B

[0092] A solution of l-chloro-4,5-difluoro-2-nitro-benzene (Preparation 1) (20.0 g,

103.3 mmol), K₂CO₃ (31.4 g, 227.3 mmol) and dimethyl amine«HCl (9.3 g, 113.6 mmol) in acetonitrile (200 mL) was heated to reflux for 2h. The solution cooled to room temperature, quenched with water and extracted with ethyl acetate. The ethyl acetate layers were washed with brine, dried (Na₂SO₄), filtered and concentrated in vacuo to give 22.1 g (98%) of 1- chloro-5-dimethylamino-4-fluoro -2-nitro-benzene: Crude 1H NMR (400 MHz, CDC1₃): δ 7.83 (d, 7=14.2 Hz, IH), 6.72 (d, 7=8.3 Hz, IH), 3.09 (d, 7=2.2 Hz, 6H), 3.77 (br s, 2H). The crade material was pure enough to cany on to the next step. PARTS C, D and E

[0093] l-Chloro-4-fluoro-2-iodo-5-methoxyphenyl boronic acid was prepared substantially as described in Preparation 1, Parts C, D and E: 1H NMR (400 MHz, CDC1₃): δ 7.52 (d, 7=14.4 Hz, IH), 6.71 (d, 7=7.8 Hz, IH), 5.18 (br s, 2H), 2.93 (d, 7=1.2 Hz, 6H).

Example 1 (R,5)-8-(2,4-dichloro-phenyl)-4-isobutyl-2-methyI-4H-pyrido[2,3-b]pyrazin-3-one

PARTS A, B, and C

[0094] 2-Chloro-4-(2,4-dichloro-phenyl)-3-nitro-pyridine was prepared substantially as described in Example 9 and isolated as a brown viscous oil: crade ^!H NMR (300 MHz, CDC1₃): δ 8.6 (d, IH), 7.5 (s, IH), 7.38 (s, IH), 7.34 (d, IH), 7.20 (d, IH).

PARTD

[0095] 2-Chloro-4-(2,4-dichloro-phenyl)-3-nitro-pyridine (0.20 g, 0.66 mmol) and isobutylamine (0.096 g, 1.32 mmol) were treated substantially as described in Part D of Example 9 to yield 0.24 g (100%) of cmde [4-(2.4-dichloro-phenyl)-2-nitro-pyridin-2-yl]- isobutyl-amine: MS (AP) m z 340.2 [(M+H)⁺, 98].

PARTE

[0096] [4-(2.4-Dichloro-phenyl)-2-nitro-pyridin-2-yl]-isobutyl-amine (0.24 g, 0.71 mmol) and Na₂S₂04 (0.99 g, 5.69 mmol) were treated substantially as described in Part E of Example 9 to yield 0.22 g of 4-(2,4-dichloro-phenyl)-4-(2,4-dichloro-phenyl)-N²-isobutyl- pyridine-2,3-diamine: MS (AP) m/z 310.23 [(M+H)⁺, 78]. Taken on to Part F PARTF

[0097] 4-(2,4-Dichloro-phenyl)-4-(2,4-dichloro-phenyl)-N²-isobutyl-pyridine-2,3- diamine (0.22 g, 0.71 mmol) was treated substantially as described in Part F of Example 9 to give 6.7 mg (2.0%) of 8-(2,4-dichloro-phenyl)-4-isobutyl-2-methyl-4H-pyrido[2,3-b]pyrazin- 3-one (Example 1): 1H NMR (300 MHz, CD₃OD): Dδ 8.6 (d, IH), 7.6 (s, IH), 7.45 (d, IH), 7.39 (d, IH), 7.25 (d, IH), 4.4 (d, 2H), 2.4 (s, 2H), 2.35 (m, IH), 1.25 (s, IH), 0.95 (d, 6H). MS (ESI) m z 362.3 [(M+H)⁺, 100].

Example 2

(R,5)-8-(2,4-dichIoro-phenyl)-2-methyl-4-(l-methyl-butyl)-4H- pyrido[2,3-b]pyrazin-3-one

PARTS A, B, and C

[0098] 2-Chloro-4-(2,4-dichloro-phenyl)-3-nitro-pyridine was prepared substantially as described in Example 9.

PARTD

[0099] 2-Chloro-4-(2,4-dichloro-phenyl)-3-nitro-pyridine (0.20 g, 0.66 mmol) and 1- methyl-butylamine (0.11 g, 1.32 mmol) were treated substantially as described in Part D of Example 9 to produce 0.20 g (87 %) of crude [4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2-yι]- (l-methyl-butyl)-amine: MS (AP) m/z 354.2 [(M+H)+, 100]. PARTE

[00100] [4-(2,4-Dichloro-phenyl)-3-nifro-pyridin-2-yl]-(l-methyl-butyl)-amine

(0.25 g, 0.71 mmol) and Na₂S₂O (1.00 g, 5.72 mmol) were treated substantially as described in Part E of Example 9 to yield 0.22 g (96 %) of crude 4-(2,4-dichloro-phenyl)-N²-(l-methyl- butyl)-pyridine-2,3-diamine: MS (AP) m z 324.3 [(M+H)+, 76].

PARTF

[00101] 4-(2,4-Dichloro-phenyl)-N²-(l-methyl-butyl)-pyridine-2,3-diamine (0.22 g,

0.68 mmol) was treated substantially as described in Part F of Example 9 to give 3.5 mg (1.0 %) of crade 8-(2,4-dichloro-phenyl)-2-methyl-4-(l-methyl-butyl)-4H-pyrido[2,3-b]pyrazin- 3-one (Example 2): 1H NMR (300 MHz, CD₃OD): δ 8.6 (d, IH), 7.6 (s, IH), 7.4 (d, IH), 7.39 (d, IH), 7.25 (d, IH), 2.4 (s, 3H), 1.90 (m, IH), 1.6 (s, 3H), 1.3 (s, 2H), 1.15 (m, 2H), 0.95 (t, 3H). MS (ESI) m/z 376.3 [(M+H)+, 100].

Example 3a

(5)-4-(l-cyclopropyI-propyl)-8-(2,4-dichloro-phenyI)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PARTS A, B, and C

[00102] 2-Chloro-4-(2,4-dichloro-phenyl)-3-nitro-pyridine was prepared substantially as described in Example 9.

PARTD

[00103] 2-Chloro-4-(2,4-dichloro-phenyl)-3-nitro-pyridine (0.26 g, 0.86 mmol) and 1- cyclopropyl-propylamine (0.23 g, 1.71 mmol) were substantially as described in Part D of Example 9 to produce 2.32 g (100 %) of crade (l-cyclopropyl-propyl)-[4-(2,4-dichloro- phenyl)-3-nitro-pyridin-2-yl]-amine: MS (AP) m/z 366.2 [(M+H)⁺, 96].

PARTE

[00104] (l-Cyclopropyl-propyl)-[4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2-yl]-amine

(0.26 g, 0.71 mmol) and Na₂S₂O₄ (1.00 g, 5.72 mmol) were treated substantially as described in Part E of Example 9 to yield 1.60 g (75 %) of crade N²-(l-cyclopropyl-propyl)-4-(2,4- dichloro-phenyl)-pyridine-2,3-diamine: MS (AP) m/z 336.3 [(M+H)⁺, 98].

PARTF

[00105] N²-(l-cyclopropyl-propyl)-4-(2,4-dichloro-phenyl)-pyridine-2,3-diamine (0.16 g, 0.48 mmol) was treated substantially as described in Part F of Example 9 to give 8.3 mg (4.0 %) of 4-(l-cyclopropyl-propyl)-8-(2,4-dichloro-phenyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one (Example 3a): 1H NMR (300 MHz, CD₃OD): δ 8.6 (d, IH), 7.6 (s, IH), 7.45 (d, IH), 7.39 (d, IH), 7.25 (d, IH), 5.10 (m, IH), 4.4 (m, IH), 2.4 (s, 3H), 1.25 (s, 2H), 0.85 (t, 3H), 0.75 (m, IH), 0.50-0.15 (m, 3H). MS (ESI) m/z 388.3 [(M+H)⁺, 100].

Example 3b (R)-4-(l-cyclopropyl-propyl)-8-(2,4-dichloro-phenyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PARTS A, B, and C

[00106] 2-Chloro-4-(2,4-dichloro-phenyl)-3-nitro-pyridine was prepared substantially as described in Example 9. PARTD

[00107] 2-Chloro-4-(2,4-dichloro-phenyl)-3-nitro-ρyridine (0.34 g, 1.12 mmol) and 1- cyclopropyl-propylamine (0.30 g, 2.24 mmol) were treated substantially as described in Part D of Example 9 to produce 0.26 g (83 %) of crude (l-cyclopropyl-propyl)-[4-(2,4-dichloro- phenyl)-3-nitro-pyridin-2-yl]-amine: MS (AP) m z 366.3 [(M+H)⁺, 100].

PARTE

[00108] (l-Cyclopropyl-propyl)-[4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2-yl]-amine

(0.46 g, 1.26 mmol) and Na₂S O₄ (1.76 g, 10.1 mmol) were treated substantially as described in Part E of Example 9 to yield 0.16 g (66 %) of crade N²-(l-cyclopropyl-propyl)-4-(2,4- dichloro-phenyl)-pyridine-2,3-diamine: MS (AP) m z 336.3 [(M+H)⁺, 100].

PARTF

[00109] N²-(l-cyclopropyl-propyl)-4-(2,4-dichloro-phenyl)-pyridine-2,3-diamine

(0.25g, 0.74 mmol) was treated substantially as described in Part F of Example 9 to give 6.1 mg (3 %) of 4-(l-cyclopropyl-propyl)-8-(2,4-dichloro-phenyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one (Example 3b) 1H NMR (300 MHz, CD₃OD): δ 8.5 (d, IH), 7.6 (s, IH), 7.4 (d, IH), 7.35 (d, IH), 7.25 (d, IH), 5.1 (q, IH), 4.4 (q, IH), 2.4 (s, 3H), 1.25 (s, 2H), 0.85 (t, 3H), 0.65 (m, IH), 0.50-0.10 (m, 3H). MS (ESI) m z 388.3 [(M+H)⁺, 100].

Example 4

(R,5)-8-(2,4-dichloro-phenyl)-4-(l,2-dimethyl-propyI)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PARTS A, B, and C

[00110] 2-Chloro-4-(2,4-dichloro-phenyl)-3-nitro-pyridine was prepared substantially as described in Example 9. PARTD

[00111] 2-Chloro-4-(2,4-dichloro-phenyl)-3-nitro-pyridine (0.20 g, 0.66 mmol) and

1,2-dimethyl-propylamine (0.11 g, 1.32 mmol) were treated substantially as described in Part D of Example 9 to produce 0.26 g (100 %) of [4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2-yl]- (l,2-dimethyl-propyl)-amine. MS (AP) m/z 354.2 [(M+H)⁺, 100].

PARTE

[00112] [4-(2,4-Dichloro-phenyl)-3-nitro-pyridin-2-yl]-(l,2-dimethyl-propyl)-amine

(0.26 g, 0.74 mmol) and Na₂S₂O₄ (1.03 g, 5.94 mmol) were treated substantially as described in Part E of Example 9 to yield 0.18 g (75 %) of crade 4-(2,4-dichloro-phenyl)-N²-(l,2- dimethyl-propyl)-pyridine-2,3-diamine: MS (AP) m z 324.3 [(M+H)⁺, 70].

PARTF

[00113] 4-(2,4-Dichloro-phenyl)-N²-(l ,2-dimethyl-propyl)-pyridine-2,3-diamine (0.18 g, 0.56 mmol) was treated substantially as described in Part F of Example 9 to give 4.0 mg (2 %) of 8-(2,4-dichloro-phenyl)-4-(l,2-dimethyl-propyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3- one (Example 4): 1H NMR (300 MHz, CD₃OD): δ 8.6 (d, IH), 7.6 (s, IH), 7.4 (d, IH), 7.35 (d, IH), 7.25 (d, IH), 2.2 (s, 3H), 1.6 (m, 2H), 1.3 (s, 2H), 1.15 (d, 3H), 0.95 (m, IH), 0.65 (bs, 3H). MS (ESI) m/z 376.3 [(M+H)⁺, 100].

Example 5 (R,5)-4-(l-cyclopropyl-butyI)-8-(2,4-dichloro-phenyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one PARTA

[00114] 2-Benzyloxy-4-chloro-3-nitro-pyridine (Wilde, et. al. WO 99/01454, which is incoφorated herein by reference in its entirety) (11 g, 41.6 mmol) and 2,4- dichlorophenylboronic acid (11.9 g, 62.3 mmol) were treated substantially as described in Part A of Example 19a to give 8.0 g (51%) of 2-benzyloxy-4-(2,4-dichloro-phenyl)-3-nitro- pyridine: MS (AP) m/z 375.2 [(M+H)⁺, 100].

PARTB

[00115] 2-Benzyloxy-4-(2,4-dichloro-phenyl)-3-nitro-pyridine (8.0 g, 21.3 mmol) was treated substantially as described in Part B of Example 19a to give 4-(2,4-dichloro-phenyl)-3- nitro-lH-pyridin-2-one (3.5 g, 58%): MS (AP) m/z 285.1 [(M+H)⁺, 98].

PART C

[00116] Trifluoro-methanesulfonic acid 4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2-yl- ester (1.0 g, 2.40 mmol), prepared substantially as described in Part C of Example 19a, and 1- cyclopropyl-butylamine HCl (1.0 g, 4.79 mmol) were treated substantially as described in Part C of Example 19a to produce 0.66 g (72%) of crude (l-cyclopropyl-butyl)-[4-(2,4- dichloro-phenyl)-3-nitro-ρyridin-2-yl]-amine: MS (AP) m z 380.3 [(M+H)⁺, 100].

PARTD

[00117] (l-Cyclopropyl-butyl)-[4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2-yl]-amine

(0.66 g, 1.74 mmol) and Na S₂O (2.45 g, 14.0 mmol) were treated substantially as described in Part E of Example 9 to yield 0.44g (72%) of N²-(l-cyclopropyl-butyl)-4-(2,4-dichloro- phenyl)-pyridine-2,3-diamine: MS (AP) m/z 350.3 [(M+H)⁺, 100].

PARTE

[00118] N²-(l-Cycloproρyl-butyl)-4-(2,4-dichloro-phenyl)-pyridine-2,3-diamine (0.44 g, 1.26 mmol) was treated substantially as described in Part F of Example 9 to give 7.8 mg (2%) of 4-(l-cyclopropyl-butyl)-8-(2,4-dichloro-phenyl)-2-methyl-4H-pyrido[2,3-b]pyrazin- 3-one (Example 5): 1H NMR (300 MHz, CDC1₃): δ 8.5 (d, IH), 7.5 (s, IH), 7.39 (d, IH), 7.30 (s, IH), 7.2 (d, IH), 5.10 (q, IH), 4.5 (q, IH), 2.5 (s, 3H), 2.4-2.0 (m, 3H), 1.2 (m, IH), 0.90 (t, 3H), 0.70 (m, IH), 0.50-0.20 (m, 3H). MS (AP) m z 402.33 [(M+H)+, 100].

Example 9 (R,S)-8-(2,4-dichloro-pheny)-4-(2-methoxy-l-methyl-ethyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PARTA

[00119] To a solution of 2-benzyloxy-4-chloro-3-nitro-pyridine (Wilde, et. al. WO

99/01454, which is incoφorated herein by reference)(5 g, 18.9 mmol) in DME/H₂O, was added 2,4-dichloroρhenylboronic acid (3.60 g, 18.9 mmol), Ba(OH)₂ .8H₂O (5.96 g, 18.9 mmol) , and Pd(PPh₃)₂Cl₂ (0.77 g, 1.09 mmol) and the mixture was heated at reflux for 5h. The reaction was cooled and poured into EtOAc and H O (500 mL). The EtOAc layer was washed with H₂O, brine, dried (Na₂SO₄), filtered and concentrated in vacuo. Purification using flash chromatography (10% EtOAc-Hexane) gave 5.79g (82 %) of 2-benzyloxy-4-(2,4- dichloro-phenyl)-3-nitro-pyridine as a viscous oil: crade MS (AP) m/z 375.2 [(M+H)⁺, 100].

PARTB

[00120] 2-Benzyloxy-4-(2,4-dichloro-phenyl)-3-nitro-pyridine (5.79 g, 15.4 mmol) was dissolved in TFA (20 mL) and stined at room temperature for 4h. The reaction mixture was concentrated and washed with 20% EtOAc/Hexane, and concentrated in vacuo to yield 1.0 g (23 %) of 4-(2,4-dichloro-phenyl)-3-nitro-lH-pyridin-2-one as a solid: crade MS (AP) m z 285.1 [(M+H)⁺, 100] .

PART C

[00121] To 10 mL of POCl₃ was added 4-(2,4-dichloro-phenyl)-3-nitro-lH-pyridin-2- one (1.0 g, 3.51 mmol), followed by the addition of DMF (1-2 mL) and the reaction refluxed for 5 h. The reaction mixture was cooled to room temperature and poured over ice-H₂O (200 mL). The solution was extracted with EtOAc, washed with H₂O, brine, dried (MgSO₄), filtered, and concentrated in vacuo to give 0.20 g (19 %) of 2-chloro-4-(2,4-dichloro-phenyl)- 3-nitro-pyridine as a brown viscous oil: crude 1H HNMR (300 MHz, CDC1₃): δ 8.6 (d, IH), 7.5 (s, IH), 7.38 (s, IH), 7.34 (d, IH), 7.20 (d, IH). PARTD

[00122] 2-Chloro-4-(2,4-dichloro-phenyl)-3-nitro-pyridine (0.20 g, 0.66 mmol) was dissolved in acetonitrile (20 mL) , followed by the addition of 2-methoxy-l-methyl- ethylamine (0.12 g, 1.32 mmol) and Hunig's base (0.037 g, 0.29 mmol). The reaction was stined at reflux for 64 h. The solution was cooled to room temperature and extracted with EtOAc/H O. The organic layer was washed with brine, dried (Na SO₄), filtered, and concentrated to yield 0.20 g (87 %) of [4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2-yl]-(2- methoxy-l-methyl-ethyl)-amine: MS (AP) m/z 356.2 [(M+H)⁺, 86].

PARTE

[00123] [4-(2,4-Dichloro-phenyl)-3-nitro-pyridin-2-yl]-(2-methoxy-l-methyl-ethyl)- amine (0.20 g, 0.56 mmol was dissolved in dioxane (8 mL) and H₂O (8 mL), followed by cone. NFL-OH (0.3 mL) and Na₂S₂O₄ (0.79 g, 4.53 mmol) and stined at room temperature for 4 h. The solution was extracted with EtOAc, washed with H₂O, brine, dried (Na₂SO ), filtered, and concentrated in vacuo to produce 0.13 g (72 %) of 4-(2,4-dichloro-phenyl)-N²- (2-methoxy-l-methyl-ethyl)-pyridine-2,3-diamine: MS (AP) m z 326.2 [(M+H)⁺, 90].

PARTF

[00124] 4-(2,4-Dichloro-phenyl)-N²-(2-methoxy-l-methyl-ethyl)-pyridine-2,3-diamine

(0.13 g, 0.40 mmol) was dissolved in toluene (20 mL), followed by methyl pyruvate (0.081 g, 0.80 mmol) and heated at reflux overnight. The reaction was concentrated in vacuo and purified by reverse phase prep HPLC to yield 3.2 mg (2 %) of 8-(2,4-dichloro-pheny)-4-(2- methoxy-l-methyl-ethyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 9): 'HNMR (300 MHz, CD₃OD): δ 8.6 (d, IH), 7.6 (s, IH), 7.4-7.25 (m, 3H), 4.4 (m, IH), 3.8 (m, IH), 3.3 (s, 3H), 2.4 (s, 3H), 1.6 (d, 2H), 1.25 (s, 2H). MS (AP) m/z 378.3 [(M+H)⁺, 100].

Example 10 (R,S)-8-(2,4-dichloro-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PARTS A, B, and C

[00125] 2-Chloro-4-(2,4-dichloro-phenyl)-3-nitro-pyridine was prepared substantially as described in Example 9.

PARTD

[00126] 2-Chloro-4-(2,4-dichloro-phenyl)-3-nitro-pyridine (0.20 g, 0.66 mmol) and 1- methoxymethyl-propylamine (0.14 g, 1.32mmol) were treated as in Part D of Example 9 to yield 0.21 g (88 %) of [4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2-yl]-(l-methoxymethyl- propyl)-amine: MS (AP) m/z 370.2 [(M+H)⁺, 97].

PARTE

[00127] 4-(2,4-Dichloro-phenyl)-3-nitro-pyridin-2-yl]-(l-methoxymethyl-propyl)- amine (0.21 g, 0.57 mmol) and Na S O (0.80 g, 4.58 mmol) were treated as in Part E of Example 9 to give 0.13g (68 %) crade 4-(2,4-dichloro-phenyl)-N²-(l-methoxymethyl- propyl)-pyridine-2,3-diamine: MS (AP) m/z 340.3 [(M+H)⁺, 100].

PARTF

[00128] 4-(2,4-Dichloro-phenyl)-N²-(l-methoxymethyl-propyl)-pyridine-2,3-diamine

(0.13 g, 0.38 mmol) was treated as in Part F of Example 9 to yield 3.0 mg (2 %) of 8-(2,4- dichloro-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one

(Example 10): 1H NMR (300 MHz, CD₃OD): δ 8.6 (bs, IH), 7.6 (s, IH), 7.45-7.25 (m, 3H), 3.3 (s, 3H), 2.43 (s, IH), 2.40 (s, 3H), 1.9 (m, IH), 1.5 (m, IH), 1.3 (s, 2H), 0.85 (t, 3H). MS (ESI) m/z 392.3 [(M+H)⁺, 100].

Example 10a (R)-8-(2,4-dichloro-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H- pyrido[2,3-&]pyrazin-3-one

PARTS A and B

[00129] 4-(2,4-Dichloro-phenyl)-3-nitro-lH-pyridin-2-one was prepared substantially as described in Example 19a.

PART C

[00130] Trifluoro-methanesulfonic acid 4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2-yl- ester (3.0 g, 7.19 mmol), prepared substantially as described in Part C of Example 19a, and 1- methoxymethyl-propylamine HCl (2.01 g, 14.4 mmol) were treated substantially as described in Part C of Example 19a to produce 2.11 g (79 %) of [4-(2,4-dichloro-phenyl)-3- nitro-pyridin-2-yl]-(l-methoxymethyl-proρyl)-amine: MS (AP) m/z 370.2 [(M+H)⁺, 100].

PARTD

[00131] [4-(2,4-Dichloro-phenyl)-3-nitro-pyridin-2-yl]-(l-methoxymethyl-propyl)- amine (2.11 g, 5.72 mmol) and Na₂S₂O (8.03 g, 46.1 mmol) were treated substantially as described in Part E of Example 9 to yield 1.14 g (59 %) of 4-(2,4-dichloro-phenyl)-N²-(l- methoxymethyl-propyl)-pyridine-2,3-diamine: MS (AP) m z 340.2 [(M+H)⁺, 100].

PARTE

[00132] N²-(l-cyclopropyl-butyl)-4-(2,4-dichloro-ρhenyl)-ρyridine-2,3-diamine (1.14 g, 3.35 mmol) was treated substantially as described in Part F of Example 9 to give 6.7 mg (0.5 %) of (R)-8-(2,4-dichloro-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one (Example 10a): 1H NMR (300 MHz, CDC1₃): δ 8.54 (bs, IH), 7.54 (s, IH), 7.40 (d, IH), 7.28 (s, IH), 7.20 (d, IH), 6.2 (m, IH), 4.3 (m, IH), 3.8 (m, IH), 3.3 (s, 3H), 2.47 (s, 3H), 2.0 (m, IH), 1.30 (s, IH), 0.90 (t, 3H). MS (AP) m/z 392.3 [(M+H)⁺, 100].

Example 10b (5)-8-(2,4-dichloro-phenyl)-2-methyl-4-(l-methoxymethyl-propyl)-2-methyl-4H- pyrido[2,3-6]pyrazin-3-one

PARTS A, B, and C

[00133] 2-Chloro-4-(2,4-dichloro-phenyl)-3-nitro-pyridine was prepared substantially as described in Example 9.

PARTD

[00134] 2-Chloro-4-(2,4-dichloro-phenyl)-3-nitro-pyridine (0.25 g, 0.82 mmol) and 1- methoxymethyl-propylamine (0.23 g, 1.65 mmol) were treated substantially as described in Part D of Example 9 to produce 0.25 g (83 %) of [4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2- yl]-(l-methoxymethyl-propyl)-amine: MS (AP) m/z 370.2 [(M+H)⁺, 98].

PARTE

[00135] [4-(2,4-Dichloro-phenyl)-3-nitro-pyridin-2-yl]-(l-methoxymethyl-propyl)- amine (0.25 g, 0.67 mmol) and Na₂S₂O₄ (0.95 g, 5.45 mmol) were treated substantially as described in Part E of Example 9 to yield 0.13 g (56 %) of 4-(2,4-dichloro-phenyl)-N²-(l- methoxymethyl-propyl)-pyridine-2,3-diamine: MS (AP) m z 340.3 [(M+H)⁺, 100]. PARTF

[00136] 4-(2,4-Dichloro-phenyl)-N²-(l-methoxymethyl-propyl)-pyridine-2,3-diamine

(0.13 g, 0.38 mmol) was treated substantially as described in Part F of Example 9 to give 5.1 mg (3 %) of (S)-8-(2,4-dichloro-phenyl)-2-methyl-4-(l-methoxymethyl-propyl)-2-methyl- 4H-pyrido[2,3-b]pyrazin-3-one (Example 10b): 1H NMR (300 MHz, CD₃OD): δ 8.5 (d, IH), 7.5 (s, IH), 7.4 (d, IH), 7.39 (d, IH), 7.25 (d, IH), 3.75 (m, 2H), 3.25 (s, 3H), 2.39 (s, 3H), 1.95 (m, IH), 1.25 (s, 2H), 0.80 (t, 3H). MS (ESI) m/z 392.29 [(M+H)⁺, 100].

Example 18 (R,S)-8-(2-chloro-4-methoxy-phenyl)-2-methyl-4-(l-propyl-butyl)-4H- pyrido[2,3-b]pyrazin-3-one

PARTS A and B

[00137] 4-(2,4-Dichloro-phenyl)-3-nitro-lH-pyridin-2-one was prepared substantially as described in Example 19a.

PART C

[00138] Trifluoro-methanesulfonic acid 4-(2-chloro-4-methoxy-phenyl)-3-nitro- pyridin-2-yl ester(0.50 g, 1.21 mmol), prepared substantially as described in Part C of Example 19a, and 1-propyl-butylamine (0.28 g, 2.42 mmol) were treated in the same manner as in Part C of Example 19a to produce 0.31 g (69 %) of [4-(2-chloro-4-methoxy-phenyl)-3- nitro-pyridin-2-yl]-(l-propyl-butyl)-amine: MS (AP) m/z 377.9 [(M+H)⁺, 100].

PARTD

[00139] [4-(2-Chloro-4-methoxy-phenyl)-3-nitro-pyridin-2-yl]-(l-propyl-butyl)-amine

(0.31 g, 0.82 mmol) and Na₂S O (1.15 g, 6.62 mmol) were treated substantially as described in Part E of Example 9 to give 0.49 g (100 %) 4-(2-chloro-4-methoxy-phenyl)-N²-(l-propyl- butyl)-pyridine-2,3-diamine: MS (AP) m/z 347.9 [(M+H)⁺, 100].

PARTE

[00140] 4-(2-Chloro-4-methoxy-phenyl)-N²-(l-propyl-butyl)-pyridine-2,3-diamine

(0.49 g, 1.41 mmol) was treated substantially as described in Part F of Example 9 to give 1.3 mg (0.23%) of 8-(2-chloro-4-methoxy-phenyl)-2-methyl-4-(l-propyl-butyl)-4H-pyrido[2,3- b]pyrazin-3-one (Example 18): 1H NMR (300, MHz, CDC1₃): δ 8.5 (d, IH), 7.20 (d, IH), 7.07 (s, IH), 6.98 (d, IH), 6.95 (d, IH), 3.88 (s, 3H), 2.45 (s, 3H), 2.35-1.80 (m, 8H), 1.3- 1.15 (m, 4H), 0.90 (t, 3H). MS (AP) m/z 399.9 [(M+H)⁺, 100].

Example 19a (S)-8-(2-chloro-4-methoxy-phenyl)-4-(l-cyclopropyl-propyl)-2-methyl-4H- pyrido[2,3-6]pyrazin-3-one

PARTA

[00141] To a solution of 2-benzyloxy-4-chloro-3-nitro-pyridine (Wilde, et al. WO

99/01454, which is incoφorated herein by reference) (3.0 g, 11.3 mmol) in ethanol (10 mL) and toluene (40 mL), was added Na₂CO₃ (14.17 mL, 2 M), 2-chloro-4- methoxyphenylboronic acid (3.17 g, 17.0 mmol), and Pd(PPh₃)₂Cl₂ (0.48 g, 0.68 mmol) and the mixture was heated at reflux for 5h. The reaction was cooled and poured into EtOAc and H₂O (500 mL). The EtOAc layer was washed with H₂O, brine, dried (Na₂SO ), filtered and concentrated in vacuo. Purification using flash chromatography (10% EtOAc-Hexane) gave 1.51 g (36 %) of 2-benzyloxy-4-(2-chloro-4-methoxy-phenyl)-3-nitro-pyridine as a viscous oil: MS (AP) m z 370.8 [(M+H)⁺, 100]. PART B

[00142] 2-Benzyloxy-4-(2-chloro-4-methoxy-phenyl)-3-nitro-pyridine (1.51 g, 4.07 mmol) was dissolved in TFA (20 mL) and stined at room temperature for 4h. The reaction mixture was concentrated, washed with toluene, and concentrated in vacuo to yield 1.19 g (100 %) of 4-(2-chloro-4-methoxy-phenyl)-3-nitro-lH-pyridin-2-one as a solid: MS (AP) m/z 280.7 [(M+H)⁺, 100].

PART C

[00143] To a solution of 4-(2-chloro-4-methoxy-phenyl)-3-nitro-lH-pyridin-2-one

(1.19 g, 4.24 mmol) in CH₂C1₂ (50 mL), was added Na₂CO₃ (1.10 g, 10.4 mmol). The reaction was cooled to -78 °C, and trifluoromethanesulfonic anhydride (3.55 g, 12.6 mmol) was added dropwise. After the addition, the reaction stined for 15 min at -78 °C, then warmed to 0 °C for lh to yield trifluoro-methanesulfonic acid 4-(2-chloro-4-methoxy- phenyl)-3-nitro-pyridin-2-yl ester. The reaction mixture was filtered and the collected solid was washed with CHC1₃. The filtrate was concentrated in vacuo and dissolved in toluene (20 mL), followed by Et N (0.20 mL, 1.45 mmol) and 1-cyclopropyl-propylamine HCl (0.16 g, 1.45 mmol), and heated at 130 °C overnight. The reaction was cooled and poured over an ice water bath. The mixture was extracted with CH₂C1 , washed with H₂O, brine, dried (MgSO₄), filtered, and concentrated in vacuo. Purification using flash chromatography (20% EtOAc/Hexane yielded 0.17 g (65 %) of [4-(2-chloro-4-methoxy-phenyl)-3-nitro-pyridin-2- yl]-(l-cyclopropyl-propyl)-amine: MS (AP) m z 361.8 [(M+H)⁺, 100].

PARTD

[00144] [4-(2-Chloro-4-methoxy-phenyl)-3-nitro-pyridin-2-yl]-(l-cyclopropyl-propyl)- amine (0.17 g, 0.47 mmol) and Na₂S₂O₄ (0.66 g, 3.79 mmol) were treated substantially as described in Part E of Example 9 to give 0.14 g (88 %) crade 4-(2-chloro-4-methoxy- phenyl)-N²-(l-cyclopropyl-propyl)-pyridine-2,3-diamine: MS (AP) m z 331.8 [(M+H)⁺,

100].

PARTE

[00145] 4-(2-Chloro-4-methoxy-phenyl)-N²-(l-cyclopropyl-propyl)-pyridine-2,3- diamine (0.14 g, 0.42 mmol) was treated substantially as described in Part F of Example 9 to give 4.2 mg (3%) of (R)-8-(2-chloro-4-methoxy-phenyl)-4-(l-cyclopropyl-propyl)-2-methyl- 4H-pyrido[2,3-b]pyrazin-3-one (Example 19a): 1H NMR (300 MHz, CDC1₃): δ D8.5 (d, IH), 7.30 (s, IH), 7.20 (s, IH), 7.07 (s, IH), 6.9 (d, IH), 5.0 (q, IH), 4.45 (q, IH), 3.88 (s, 3H), 2.5 (s, 3H), 2.4-2.0 (m, 3H), 0.90 (t, 3H), 0.75 (m, IH), 0.50-0.25 (m, 2H). MS (AP) m z 383.9 [(M+H)⁺, 100].

Example 19b (R)-8-(2-chloro-4-methoxy-phenyl)-4-(l-cycIopropyl-propyI)-2-methyl-4H- pyrido[2,3-6]pyrazin-3-one

PARTS A and B

[00146] 4-(2-Chloro-4-methoxy-phenyl)-3-nitro-lH-pyridin-2-one was prepared substantially as described in Example 19a.

PART C

[00147] Trifluoro-methanesulfonic acid 4-(2-chloro-4-methoxy-phenyl)-3-nitro- pyridin-2-yl ester (0.91 g, 2.20 mmol), prepared substantially as described in Part C of Example 19a, and l-cyclopropyl-propylamine HCl (0.56 g, 4.41 mmol) were treated substantially as described in Part C of Example 19a to produce 0.56 g (72 %) of [4-(2-chloro- 4-methoxy-phenyl)-3-nitro-pyridin-2-yl]-(l-cyclopropyl-propyl)-amine: MS (AP) m/z 361.8 [(M+H)⁺, 100].

PARTD

[00148] [4-(2-Chloro-4-methoxy-phenyl)-3-nitro-pyridin-2-yl]-(l-cyclopropyl-propyl)- amine (0.56 g, 1.55 mmol) and Na₂S₂O (2.17 g, 12.5 mmol) were treated substantially as described in Part E of Example 9 to give 0.49 g (96 %) of crade 4-(2-chloro-4-methoxy- phenyl)-N²-(l-cyclopropyl-propyl)-pyridine-2,3-diamine: MS (AP) m/z 331.8 [(M+H)⁺, 100]. PARTE

[00149] 4-(2-Chloro-4-methoxy-phenyl)-N²-(l-cyclopropyl-propyl)-pyridine-2,3- diamine (0.49 g, 1.48 mmol) was treated substantially as described in Part F of Example 9 to give 6.1 mg (1%) of 8-(2-chloro-4-methoxy-phenyl)-4-(l-cyclopropyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one (Example 19b). 1H NMR (300 MHz, CDC1₃): δ 8.43 (d, IH), 7.29 (s, IH), 7.20 (d, IH), 7.07 (d, IH), 6.94 (d, IH), 5.0 (q, IH), 4.5 (q, IH), 3.88 (s, 3H), 2.5 (s, 3H), 2.3-2.0 (m , 3H), 0.90 (t, 3H), 0.85 (m, IH), 0.50-0.30 (m, 2H). MS (AP) m/z 383.9 [(M+H)⁺, 100].

Example 23a 8-(2-chloro-4-methoxy-phenyl)-4-(l-cycIobutyl-propyl)-2-methyl-4H- pyrido[2,3-δ]pyrazin-3-one (Isomer A, R or S)

PARTS A and B

[00150] 4-(2-Chloro-4-methoxy-phenyl)-3-nitro-lH-pyridin-2-one was prepared substantially as described in Example 19a.

PART C

[00151] Trifluoro-methanesulfonic acid 4-(2-chloro-4-methoxy-phenyl)-3-nitro- pyridin-2-yl ester (0.50 g, 1.21 mmol), prepared substantially as described in Part C of Example 19a, and 1-cyclobutyl-propylamine HCl (0.36 g, 2.42 mmol) were treated substantially as described in Part C of Example 19a to produce 0.33 g (73 %) of [4-(2-chloro- 4-methoxy-phenyl)-3-nitro-pyridin-2-yl]-(l-cyclobutyl-propyl)-amine: MS (AP) m/z 375.9 [(M+H)⁺, 100]. PARTD

[00152] [4-(2-Chloro-4-methoxy-phenyl)-3-nitro-pyridin-2-yl]-(l-cyclobutyl-propyl)- amine (0.33 g, 0.88 mmol) and Na₂S₂O (1.33 g, 7.6 mmol) were treated substantially as described in Part E of Example 9 to give 0.33 g (100 %) 4-(2-chloro-4-methoxy-phenyl)-N²- (l-cyclobutyl-propyl)-pyridine-2,3-diamine: MS (AP) m/z 345.9 [(M+H)⁺, 100].

PARTE

[00153] 4-(2-Chloro-4-methoxy-phenyl)-N²-(l-cyclobutyl-propyl)-pyridine-2,3- diamine (0.33 g, 9.53 mmol) was treated substantially as described in Part F of Example 9 to give 1.3 mg (0.34%) of 8-(2-chloro-4-methoxy-phenyl)-4-(l-cyclobutyl-propyl)-2-methyl- 4H-pyrido[2,3-b]pyrazin-3-one (Example 23a): 1H NMR (300 MHz, CDC1₃): δ 8.5 (d, IH), 7.22 (d, IH), 7.20 (d, IH), 7.06 (s, IH), 6.90 (d, IH), 5.9 (m, IH), 3.88 (s, 3H), 2.45 (s, 3H), 2.2 (m, IH), 1.9-1.6 (m, 8H), 0.75 (t, 3H). MS (AP) m/z 397.9 [(M+H)⁺, 100].

Example 23b 8-(2-chloro-4-methoxy-phenyl)-4-(l-cyclobutyl-propyl)-2-methyI-4H- pyrido[2,3-b]pyrazin-3-one (Isomer B, R or S)

PARTS A and B

[00154] 4-(2-Chloro-4-methoxy-phenyl)-3-nitro-lH-pyridin-2-one was prepared substantially as described in Example 19a.

PART C

[00155] Trifluoro-methanesulfonic acid 4-(2-chloro-4-methoxy-phenyl)-3-nitro- pyridin-2-yl ester (0.50 g, 1.21 mmol), prepared substantially as described in Example 19a, and 1-cyclobutyl-propylamine HCl (0.36 g, 2.42 mmol) were treated substantially as described in Part C of Example 19a to produce 0.33 g (72 %) of [4-(2-chloro-4-methoxy- phenyl)-3-nitro-pyridin-2-yl]-(l-cyclobutyl-propyl)-amine: MS (AP) m/z 375.9 [(M+H)⁺, 25].

PARTD

[00156] [4-(2-Chloro-4-methoxy-phenyl)-3-nitro-pyridin-2-yl]-(l-cyclobutyl-propyl)- amine (0.33 g, 0.88 mmol) and Na₂S₂O₄ (1.33 g, 7.6 mmol) were treated substantially as described in Part E of Example 9 to give 0.46 g (100 %) 4-(2-chloro-4-methoxy-phenyl)-N²- (l-cyclobutyl-propyl)-pyridine-2,3-diamine: MS (AP) m/z 345.9 [(M+H)⁺, 100].

PARTE

[00157] 4-(2-chloro-4-methoxy-phenyl)-N²-(l-cyclobutyl-propyl)-pyridine-2,3- diamine (0.46 g, 1.33 mmol) was treated substantially as described in Part F of Example 9 to give 0.7 mg (0.13 %) of 8-(2-chloro-4-methoxy-phenyl)-4-(l-cyclobutyl-propyl)-2-methyl- 4H-pyrido[2,3-b]pyrazin-3-one (Example 23b): 1H NMR (300 MHz, CDC1₃): δ 8.5 (d, IH), 7.22 (d, IH), 7.20 (d, IH), 7.07 (s, IH), 6.9 (d, IH), 5.9 (m, IH), 3.88 (s, 3H), 2.5 (s, 3H), 2.3-1.8 (m, 9H), 0.80 (t, 3H). MS (AP) m/z 397.9 [(M+H)⁺, 100].

Example 25a (S)-8-(2-chloro-4-methoxy-phenyl)-4-(2-methoxy-l-methyl-ethyl)-2-methyl-4H^r- py rido [2,3-b]pyrazin-3-one

PARTS A and B

[00158] 4-(2-Chloro-4-methoxy-phenyl)-3-nitro-lH-pyridin-2-one was prepared substantially as described in Example 19a. PART C

[00159] Trifluoro-methanesulfonic acid 4-(2-chloro-4-methoxy-phenyl)-3-nitro- pyridin-2-yl ester (0.48 g, 1.16 mmol), prepared substantially as described in Part C of Example 19a, and 2-methoxy-l-methyl-ethylamine (0.21 g, 2.32 mmol) were treated substantially as described in Part C of Example 19a to produce 0.28 g (68 %) of [4-(2-chloro- 4-methoxy-phenyl)-3-nitro-pyridin-2-yl]-(2-methoxy-l-methyl-ethyl)-amine: MS (AP) m z 351.8 [(M+H)⁺, 90].

PARTD

[00160] [4-(2-chloro-4-methoxy-phenyl)-3-nitro-pyridin-2-yl]-(2-methoxy-l-methyl- ethyl)-amine (0.28 g, 0.80 mmol) and Na₂S₂O (1.12 g, 6.42 mmol) were treated substantially as described in Part E of Example 9 to give 0.22 g (84 %) 4-(2-chloro-4-methoxy-phenyl)- N²-(2-methoxy-l-methyl-ethyl)-pyridine-2,3-diamine: MS (AP) m/z 321.8 [(M+H)⁺, 72].

PARTE

[00161] 4-(2-chloro-4-methoxy-phenyl)-N²-(2-methoxy-l-methyl-ethyl)-pyridine-2,3- diamine (0.22 g, 0.68 mmol) was treated substantially as described in Part F of Example 9 to give 6.8 mg (3 %) of 8-(2-chloro-4-methoxy-phenyl)-4-(2-methoxy-l-methyl-ethyl)-2- methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 25a): 1H NMR (300 MHz, CDC1₃): δ 8.50 (d, IH), 7.23 (d, IH), 7.21 (d, IH), 7.07 (s, IH), 6.93 (d, IH), 4.4 (t, IH), 3.87 (s, 3H), 3.80 (q, IH), 3.34 (s, 3H), 2.48 (s, 3H), 1.62 (d, 3H) 1.25 (s, IH). MS (AP) m/z 373.8 [(M+H)⁺, 100].

Example 25b (R)-8-(2-chloro-4-methoxy-phenyl)-4-(2-methoxy-l-methyl-ethyl)-2-methyl-4H- pyrido [2,3-b]pyrazin-3-one PARTS A and B

[00162] 4-(2-Chloro-4-methoxy-phenyl)-3-nitro-lH-pyridin-2-one was prepared substantially as described in Example 19a.

PART C

[00163] Trifluoro-methanesulfonic acid 4-(2-chloro-4-methoxy-phenyl)-3-nitro- pyridin-2-yl ester (1.0 g, 2.42 mmol), prepared substantially as described in Part C of Example 19a, and 2-methoxy-l-methyl-ethylamine HCl (0.61 g, 4.85 mmol) were treated substantially as described in Part C of Example 19a to produce 0.29 g (34 %) of [4-(2- chloro-4-methoxy-phenyl)-3-nitro-pyridin-2-yl]-(2-methoxy-l-methyl-ethyl)-amine: MS

(AP) m z 351.8 [(M+H)⁺, 100].

PARTD

[00164] [4-(2-Chloro-4-methoxy-phenyl)-3-nitro-pyridin-2-yl]-(2-methoxy-l-methyl- ethyl)-amine (0.10 g, 0.27 mmol) and Na₂S₂O (0.38 g, 2.21 mmol) were treated substantially as described in Part E of Example 9 to give 0.21 g (81 %) 4-(2-chloro-4-methoxy-phenyl)- N²-(2-methoxy-l-methyl-ethyl)-pyridine-2,3-diamine: MS (AP) m/z 321.8 [(M+H)⁺, 100].

PARTE

[00165] 4-(2-Chloro-4-methoxy-phenyl)-N²-(2-methoxy-l-methyl-ethyl)-pyridine-2,3- diamine (0.21 g, 0.65 mmol) was treated substantially as described in Part F of Example 9 to give 7.3 mg (3 %) of (R)-8-(2-chloro-4-methoxy-phenyl)-4-(2-methoxy-l-methyl-ethyl)-2- methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 25b): 1H NMR (300 MHz, CDC1₃): δ 8.51 (d, IH), 7.26 (d, IH), 7.21 (s, IH), 7.07 (s, IH), 6.93 (d, 1H),4.4 (t, IH), 3.87 (s, 3H), 3.80 (m, 2H), 3.3 (s, 3H), 2.50 (s, 3H), 1.60 (d, 3H). MS (AP) m/z 373.8 [(M+H)⁺, 100].

Example 26a (5)-8-(2-chloro-4-methoxy-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H- pyrido[2,3-6]pyrazin-3-one

PARTS A and B

[00166] 4-(2-Chloro-4-methoxy-phenyl)-3-nitro-lH-pyridin-2-one was prepared substantially as described in Example 19a.

PART C

[00167] Trifluoro-methanesulfonic acid 4-(2-chloro-4-methoxy-phenyl)-3-nitro- pyridin-2-yl ester (0.40 g, 0.97 mmol), prepared substantially as described in Part C of Example 19a, and 1-methoxymethyl-propylamine HCl (0.27 g, 1.94 mmol) were treated substantially as described in Part C of Example 19a to produce 0.10 g (28 %) of [4-(2-chloro- 4-methoxy-phenyl)-3-nitro-pyridin-2-yl]-(l-methoxymethyl-propyl)-amine: MS (AP) m/z 365.8 [(M+H)⁺, 100].

PARTD

[00168] [4-(2-Chloro-4-methoxy-phenyl)-3-nitro-pyridin-2-yl]-(l-methoxymethyl- propyl)-amine (0.10 g, 0.27 mmol) and Na₂S₂O₄ (0.38 g, 2.21 mmol) were treated substantially as described in Part E of Example 9 to give 0.08 g (87 %) 4-(2-chloro-4- methoxy-phenyl)-N²-(l-methoxymethyl-propyl)-pyridine-2,3-diamine: MS (AP) m z 335.8 [(M+H)⁺, 100].

PARTE

[00169] 4-(2-Chloro-4-methoxy-phenyl)-N²-( 1 -methoxymethyl-propyl)-pyridine-2,3- diamine (0.080 g, 0.24 mmol) was treated substantially as described in Part F of Example 9 to give 2.7 mg (3%) of 8-(2-chloro-4-methoxy-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl- 4H-pyrido[2,3-b]pyrazin-3-one (Example 26a): 1H NMR (300 MHz, CDC1₃): δ 8.50 (bs, IH), 7.28 (s, IH), 7.22 (d, IH), 7.07 (s, IH), 6.91 (d, IH), 3.88 (s, 3H), 3.84 (m, IH), 3.38 (s, 3H), 2.50 (s, 3H), 1.25 (s, IH), 0.90 (t, 3H), 0.10 (s, 3H). MS (AP) m/z 387.9 [(M+H)⁺, 100].

Example 67a (R)-4-(l-cylcopropropyl-propyl)-8-(4-methoxy-2-methyl-phenyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PARTA

[00170] To a solution of 2-benzyloxy-4-chloro-3-nitro-pyridine (Wilde, et al. WO

99/01454, which is incoφorated herein by reference) (0.98 g, 3.7 mmol) in ethanol (lOmL) and toluene (40 mL), was added Na₂CO (4.6 mL, 2M), 4-methoxy-2-methylphenyl boronic acid (1.0 g, 5.6 mmol), and Pd(PPh₃)₂Cl₂ (0.156 g, 0.22 mmol) and the mixture was heated at reflux for 5h. The reaction was cooled and poured into EtOAc and H₂O (500 mL). The EtOAc layer was washed with H₂O, brine, dried Na₂SO , filtered and concentrated in vacuo. Purification using flash chromatography (10 % EtOAc/ hexane) gave 1.01 g (78%) of 2- benzyloxy-4-(4-methoxy-2-methyl-phenyl)-3-nitro-2,3-dihydro-pyridine as a viscous oil; MS(AP) m z 351.6 [(M+H)⁺, 100], 392.0 [(M+H+CH₃CN)⁺, 35]. The purified intermediate was used in the following step.

PART B

[00171] 2-Benzyloxy-4-(4-methoxy-2-methyl-phenyl)-3-nitro-2,3-dihydro-pyridine

(1.01 g, 2.9 mmol) was dissolved in TFA (25 mL) and stined at room temperature for 4h. The reaction mixture was concentrated in vacuo and the crude product 4-(4-methoxy-2- methyl-phenyl)-3-nitro-3H-pyridin-2-one: MS(AP) m/z 261.0 [(M+H)⁺, 87]. The crade intermediate was used in the next step.

PART C

[00172] To a solution of 4-(4-methoxy-2-methyl-phenyl)-3-nitro-3H-pyridin-2-one

(0.321 g, 1.23 mmol) CH₂C1₂ (13 mL), was added Na₂CO₃ (0.317 g, 3.02 mmol). The reaction was cooled to -78 °C, and trifluoromethanesulfonic anhydride (617 μL, 3.65 mmol) was added dropwise. After the addition, the reaction stined for 15 min at -78 °C, then warmed to 0 °C for lh. The reaction mixture was filtered and the collected solid was washed with CHC1₃. The filtrate was concentrated in vacuo and dissolved in toluene (20 mL) followed by Et₃N (343μL, 2.4 mmol) and 1-cyclopropyl propyl amine HCl (0.331 g, 2.4 mmol), and heated at 130 °C overnight. The reaction was cooled and poured onto ice/H₂O. The mixture was extracted with CH C1₂, washed with H O, brine, dried Na₂S0₄, filtered, and concentrated in vacuo. Purification using flash chromatography (10% EtOAc/Hexane) gave 0.220 g (54%) of (l-cyclopropyl-propyl)-[4-(4-methoxy-2-methyl-phenyl)-3-nitro-pyridin-2- yl]-amine: MS(AP) m/z 342.1 [(M+H)⁺, 100]. The purified intermediate was used in the following step.

PARTD

[00173] (l-Cyclopropyl-propyl)-[4-(4-methoxy-2-methyl-phenyl)-3-nitro-pyridin-2- yl]-amine (0.220, 0.64 mmol) was dissolved in dioxane (10 mL) and H₂O (10 mL), followed by cone. NH₄OH (0.4 mL) and Na₂S₂O₄ (0.906 g, 5.2 mmol) and stined at room temperature for 4h. The solution was extracted with EtOAc, washed with H₂O, brine, dried Na₂SO₄, filtered, and concentrated in vacuo to produce the crade intermediate N²-(l-cyclopropyl- propyl)-4-(4-methoxy-2-methyl-phenyl)-pyridine-2,3-diamine; MS(AP) m/z 312.2 [(M+H)⁺, 100]. The crude intermediate was used in the following step.

PARTE

[00174] N²-(l-cyclopropyl-propyl)-4-(4-methoxy-2-methyl-phenyl)-pyridine-2,3- diamine (0.183g, 0.59 mmol) was dissolved in toluene (10 mL), followed by methyl pyruvate (106μL, 1.2 mmol) and heated to 130 °C overnight. The reaction was concentrated in vacuo and purified by reverse phase reverse phase prep HPLC to yield 4-(l-cylcopropropyl-proρyl)- 8-(4-methoxy-2-methyl-phenyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 67a): 1H NMR (300 MHz, CDC1₃): δ 8.48-8.41 (2d, IH, =4.7 Hz), 7.26-7.10 (m, 2H), 6.87-6.83 (m, 2H), 5.09-5.02, 4.53-4.43 (2m, IH), 3.87 (s, 3H), 2.49 (s, 3H), 2.42-2.38 (m,lH), 2.12 (s, 3H), 2.09-2.02 (m, IH), 0.90-0.87 (t, 3H, 1=5.1 Hz), 0.80-0.77 (m, IH), 0.59-0.55 (m, IH), 0.41-0.29 (m, IH), 0.26-0.22 (m, IH). MS (AP) 364.1 [(M+H)⁺, 100].

Example 69 (R,5)-4-(l-cyclopropyl-butyl)-8-(4-methoxy-2-methyl-phenyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PARTA-B

[00175] 4-(4-Methoxy-2-methyl-phenyl)-3-nitro-3H-pyridin-2-one was prepared as substantially described in Example 67a.

PART C

[00176] Trifluoro-methanesulfonic acid 4-(4-methoxy-2-methyl-phenyl)-3-nitro- pyridin-2-yl-ester (0.764 g, 1.95 mmol), prepared substantially as described in Part C of

Example 67a, and 1-cylcopropyl-butyl amine HCl (0.580 g, 3.9 mmol) were treated substantially as described in Part C of Example 67a to produce 0.230 g (50%) of (1- cyclopropyl-butyl)-[4-(4-methoxy-2-methyl-phenyl)-3-nitro-pyridin-2-yl]amine.

PARTD

[00177] (l-Cyclopropyl-butyl)-[4-methoxy-2-methyl-phenyl)-3-nitro-pyridin-2- yl]amine (0.230 g, 0.65 mmol), and Na₂SO (0.910 g, 5.2 mmol), were treated substantially as described in Part D of Example 67a to give a crade yield of 0.226 g (107%) of N²-(l- cyclopropyl-butyl)-4-(4-methoxy-2-methyl-phenyl)-pyridine-2,3-diamine: MS(AP) m/z 326.3 [(M+H)⁺, 94]. PARTE

[00178] N²-(l-cylcopropyl-butyl)-4-(4-methoxy-2-methyl-phenyl)-pyridine-2,3- diamine (0.226 g, 0.69 mmol) and methyl pyruvate (126μL, 1.4 mmol) were treated substantially as described in Part E of Example 67a to give 4-(l-cyclopropyl-butyl)-8-(4- methoxy-2-methyl-phenyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 69): 1H NMR (300 MHz, CDC1₃): δ 8.47-8.39 (2d, IH, =4.7 Hz), 7.23-7.08 (m, 2H), 6.85-6.80 (m, 2H), 5.17-5.09, 4.57-4.49 (2m, IH), 3.84 (s, 3H), 2.47 (s,3H), 2.4-2.2 (m, 3H), 2.16 (s, 3H), 1.98-1.94 (m, 2H), 0.89-0.84 (t, 3H, =7.4 Hz), 0.69-0.67 (m, IH), 0.53-0.49 (m, IH), 0.46- 0.43 (m, IH), 0.22-0.19 (m, IH). MS (AP) 378.1 [(M+H)⁺, 100].

Example 73a (R)-4-(2-methoxy-l-methyl-ethyl)-8-(4-methoxy-2-methyl-phenyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PARTA-B

[00179] 4-(4-Methoxy-2-methyl-phenyl)-3-nitro-3H-pyridin-2-one was prepared substantially as described in Example 67a.

PART C

[00180] Trifluoro-methanesulfonic acid 4-(4-methoxy-2-methyl-phenyl)-3-nitro- pyridin-2-yl-ester (0.332 g, 0.74 mmol), prepared substantially as described in Part C of Example 67a, and 2-methoxy-l-methyl-ethylamine HCl (0.263 g, 67 mmol) were treated substantially as described in Part C of Example 67a to produce 0.120 g (54%) of (2-methoxy- l-methyl-ethyl)-[4-(4-methoxy-2-methyl-phenyl)-3-nitro-pyridin-2-yl]arήine; MS(AP) m/z 332.1 [(M+H)⁺, 94]. PARTD

[00181] 2-Methoxy-l-methyl-ethyl)-[4-(4-methoxy-2-methyl-phenyl)-3-nitro-pyridin-

2-yl]amine (0.120 g, 0.36 mmol), and Na₂SO (0.509 g, 2.9 mmol), were treated as in Part D of Example 67a to give a crude yield of 0.066 g (61%) of N²-(2-methoxy-l-methyl-ethyl)-4- (4-methoxy-2-methyl-phenyl)-pyridine-2,3-diamine; MS(AP) m/z 302.2 [(M+H)⁺, 100]. The cmde product was taken on to Part E.

PARTE

[00182] N²-(2-Methoxy-l-methyl-ethyl)-4-(4-methoxy-2-methyl-phenyl)-pyridine-2,3- diamine (0.066 g, 0.22 mmol) and methyl pyruvate (79μL, 0.88 mmol) were treated substantially as in Part E of Example 67a to give 4-(2-methoxy-l-methyl-ethyl)-8-(4- methoxy-2-methyl-phenyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 73a): 1H NMR (300MHz, CDC1₃): δ 8.49-8.47 (d, IH, =4.8 Hz), 7.16-7.12 (m, 2H), 6.86-6.82 (m, 2H), 4.41-4.36 (m, IH), 3.87 (s, 3H), 3.84-3.80 (m, 2H), 3.34 (s, 3H), 2.48 (s, 3H), 2.12 (s, 3H), 1.62-1.60 (d, 3H, =6.9 Hz). MS (AP) 354.2 [(M+H)⁺, 100].

Example 74a (R,5)- 8-(4-Methoxy-2-methyl-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PARTA-B

[00183] 4-(4-Methoxy-2-methyl-phenyl)-3-nitro-3H-pyridin-2-one was prepared substantially as described in Example 67a.

PART C

[00184] Trifluoro-methanesulfonic acid 4-(4-methoxy-2-methyl-phenyl)-3-nitro- pyridin-2-yl-ester (0.78 g, 1.98 mmol), prepared substantially as described in Part C of

Example 67a, and 1-methoxymethyl-propylamine (0.45g, 4.36 mmol) were treated substantially as described in Part C of Example 67a to produce 27 mg (40%) of [4-(4- methoxy-2-methyl-phenyl)-3-nitro-pyridin-2-yl]-(l-methoxymethyl-propyl)-amine; MS (El) m/z 346.33 [(M+H)⁺, 100].

PARTD

[00185] [4-(4-Methoxy-2-methyl-phenyl)-3-nitro-pyridin-2-yl]-(l-methoxymethyl- propyl)-amine (0.43 g, 0.36 mmol) and SnCl₂ (0.2 g, 1.08 mmol) in ethanol (2 mL) were heated to 70 °C for 4 h. The solution was cooled to room temperature and quenched with saturated aqueous NaHCO₃ then extracted with EtOAc, washed with H₂O, brine, dried (Na₂SO₄), filtered, and concentrated in vacuo to give a cmde yield of 0.40 g (99%) of 4-(4- methoxy-2-methyl-phenyl)-N²-(l-methoxymethyl-propyl)-pyridine-2,3-diamine; MS(EI) m z 316.28 [(M+H)⁺, 100]. The crade product was taken on to Part E.

PARTE

[00186] 4-(4-Methoxy-2-methyl-phenyl)-N²-(l-methoxymethyl-propyl)-pyridine-2,3- diamine (0.08 g, 0.25 mmol) and methyl pyruvate (33 μL, 0.38 mmol) were treated substantially as in Part E of Example 67a to give 3.0 mg of 8-(4-methoxy-2-methyl-phenyl)- 4-(l-methoxymethyl-propyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 74a): 1H NMR (400 MHz, CDC1₃) δ ppm 8.46 (d, 7=4.89 Hz, 1 H), 7.15 (d, 7=8.31 Hz, 1 H), 7.12 (d, 7=4.40 Hz, 1 H), 6.85 (d, 7=6.60 Hz, 1 H), 6.83 (d, 7=12.23 Hz, 1 H), 5.89 (m, 1 H), 4.38 (m, 1 H), 3.86 (s, 3 H), 3.77 (m, 1 H), 3.32 (s, 3 H), 2.46 (s, 3 H), 2.11 (s, 3 H), 1.77 (m, 2 H), 0.86 (t, 7=7.34 Hz, 2 H). MS (El) 368.30 [(M+H)⁺, 100]

Example 83a (R)-4-(l-Cyclopropyl-propyl)-8-(5-fluoro-4-methoxy-2-methyl-phenyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one PART A and B

[00187] 4-(5-Fluoro-4-methoxy-2-methyl-phenyl)-3-nitro- lH-pyridin-2-one was prepared substantially as described in Example 90a.

PART C

[00188] Trifluoro-methanesulfonic acid 4-(5-fluoro-4-methoxy-2-methyl-phenyl)-3- nitro-pyridin-2-yl ester (0.5 g, 1.22 mmol), prepared substantially as described in Part C of

Example 19a, and (R)- l-cyclopropyl-propylamine (0.33 g, 2.44 mmol) were treated substantially as described in Part C of Example 19a to produce 0.17 g (43%) of crude (R)-(l-

Cyclopropyl-propyl)-[4-(5-fluoro-4-methoxy-2-methyl-phenyl)-3-nitro-pyridin-2-yl]-amine.

PARTD

[00189] (R)-(l-Cyclopropyl-propyl)-[4-(5-fluoro-4-methoxy-2-methyl-phenyl)-3-nitro- pyridin-2-yl] -amine (0.17 g, 0.47 mmol) and Na₂S₂O (1.24 g, 7.10 mmol) were treated as in

Part E of Example 9 to give 0.15 g (98%) crude (R)-N²-(l-Cyclopropyl-propyl)-4-(5-fluoro-

4-methoxy-2-methyl-phenyl)-pyridine-2,3-dj amine.

PARTE

[00190] (R)-N²-(l-Cyclopropyl-propyl)-4-(5-fluoro-4-methoxy-2-methyl-phenyl)- pyridine-2,3-diamine (0.15 g, 0.46 mmol) was treated substantially as described in Part F of

Example 9 to give 4.5 mg (3 %) of (i?)-4-(l-Cyclopropyl-propyl)-8-(5-fluoro-4-methoxy-2- methyl-phenyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 83a). 1H NMR (300

MHz, CDC1₃) δ ppm 8.36 (d, 7=4.76 Hz, 1 H), 7.03 (d, 7=4.76 Hz, 1 H), 6.93 (d, 7=11.72 Hz,

1 H), 6.83 (d, 7=8.42 Hz, 1 H), 4.95 (m, 1 H), 3.89 (s, 3 H), 2.43 (s, 3 H), 2.20 (m, 2 H), 2.03

(s, 3 H), 0.80 (t, 7=7.51 Hz, 3 H), 0.53 (m, 2 H), 0.26 (m, 2 H), 0.10 (m, 1 H). MS (El) m/z

382.3 [(M+H)+, 100].

Example 90a (R)-8-(5-Fluoro-4-methoxy-2-methyl-phenyl)-4-(l-methoxymethyI-propyl)-2-methyI-4H- pyrido[2,3-b]pyrazin-3-one

PARTA

[00191] 2-Benzyloxy-4-chloro-3-nitro-pyridine (Wilde, et. al. WO 99/01454) (1.0 g,

3.78 mmol) and 5-fluoro-4-methoxy-2-methyl-phenylboronic acid (prepared substantially as described in Speicher, A.; Kolz, I.; Sambanje, R.P. Synthesis, 2002, 17, 2503, which is incoφorated herein by reference) (1.2 mg, 5.67 mmol) were treated substantially as described in Part A of Example 19a to give 1.15 g (83%) of 2-benzyloxy-4-(5-fluoro-4-methoxy-2- methyl-phenyl)-3-nitro-pyridine: MS (El) m/z 369.3 [(M+H)⁺, 100].

PART B

[00192] 2-Benzyloxy-4-(5-fluoro-4-methoxy-2-methyl-phenyl)-3-nitro-pyridine (1.5 g,

4.1 mmol) was treated substantially as described in Part B of Example 19a to give 4-(2- chloro-4-methoxy-5-methyl-phenyl)-3-nitro-lH-pyridin-2-one (1.1 g, 92%): MS (El) m/z 279.1 [(M+H)⁺, 100].

PART C

[00193] Trifluoro-methanesulfonic acid 4-(5-fluoro-4-methoxy-2-methyl-phenyl)-3- nitro-pyridin-2-yl ester (0.5 g, 1.2 mmol), prepared substantially as described in Part C of

Example 19a, and (i?)-l-methoxymethyl-propylamine*HCl (0.34 g, 2.4 mmol) were treated substantially as described in Part C of Example 19a to produce 0.16 g (37%) of crade (i?)-[4-

(5-fluoro-4-methoxy-2-methyl-phenyl)-3-nitro-pyridin-2-yl]-(l-methoxymethyl-propyl)- amine. PARTD

[00194] (R)-[4-(5-fluoro-4-methoxy-2-methyl-phenyl)-3-nitro-pyridin-2-yl]-(l- methoxymethyl-propyl)-amine (0.16 g, 0.44 mmol) and Na₂S₂O₄ (1.15 g, 6.6 mmol) were treated as in Part E of Example 9 to give 0.15 g (98%) crude (i?)-4-(5-Fluoro-4-methoxy-2- methyl-phenyl)-N²-(l-methoxymethyl-propyl)-pyridine-2,3-diamine. MS (AP) m/z 334.3

[(M+H)⁺, 100].

PARTE

[00195] (R)-4-(5-Fluoro-4-methoxy-2-methyl-phenyl)-N²-(l-methoxymethyl-propyl)- pyridine-2,3-diamine (0.15 g, 0.45 mmol) was treated substantially as described in Part F of

Example 9 to give 4.8 mg (3%) of (R)-8-(5-Fluoro-4-methoxy-2-methyl-phenyl)-4-(l- methoxymethyl-propyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 90a): 1H NMR

(300 MHz, CDC1₃) δ ppm 8.43 (d, J=5.13 Hz, 1 H), 7.04 (d, J=5.13 Hz, 1 H), 6.90 (d,

J=11.72 Hz, 1 H), 6.82 (d, =8.42 Hz, 1 H), 6.16 (m, 1 H), 4.30 (m, 1 H), 3.89 (s, 3 H), 3.72

(m, 1 H), 3.27 (s, 3 H), 2.41 (s, 3 H), 2.03 (m, 3 H), 1.64 (m, 2 H), 1.53 (d, J=6.96 Hz, 3 H).

MS (El) m z 386.3 [(M+H)+, 100].

Example 97 (R,S)-4-(l-ethyl-pentyl)-8-(6-methoxy-2-methyl-pyridin-3-yl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PARTS A and B

[00196] 6-Methoxy-2-methyl-3'-nitro-3-H[3,4']bipyridinyl-2'-one was prepared substantially as described in Example 99a.

PART C

[00197] Trifluoro-methanesulfonic acid 6-methoxy-2-methyl-3'-nitro-3'H-

[3,4']bipyridinyl ester (0.280 g, 0.71 mmol), prepared substantially as described in Part C of Example 99a, an 1-ethyl-pentyl amine (0.430 g, 2.8 mmol) were treated substantially as described in Part C of Example 99a to produce 0.200 g (51%) of (l-ethyl-pentyl)-6-methoxy- 2-methyl-3'-nitro-[3,4']bipyridinyl-2'-yl)amine.

PARTD

[00198] (l-Ethyl-pentyl)-6-methoxy-2-methyl-3'-nitro-[3,4']bipyridinyl-2'-yl)amine

(0.200 g, 0.56 mmol), and Na₂SO₄ (0.785 g, 4.5 mmol), were treated substantially as described in Part D of Example 99a to give a cmde yield of 0.066 g (36%) of 6-methoxy-N - (l-ethyl-pentyl)-2-methyl-[3,4']bipyridinyl-2',3'-diamine; MS (AP) m/z 329.2 [(M+H)⁺, 42].

PARTE

[00199] 6-Methoxy-N²-(l-ethyl-pentyl)-2-methyl-[3,4']bipyridinyl-2',3'-diamine

(0.066 g, 0.20 mmol) and methyl pyruvate (36μL, 0.40 mmol) were treated substantially as described in Part E of Example 99a to give 4-(l-ethyl-pentyl)-8-(6-methoxy-2-methyl- pyridin-3-yl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 97): 1H NMR (300 MHz, CDC1₃) δ 8.51-8.43 (m, IH), 7.50-7.47 (d, IH, =8.5 Hz), 7.16-7.11 (m, IH), 6.71-6.68 (d, IH, J=8.1 Hz), 4.01 (s, 3H), 2.48-2.46 (m, 3H), 2.29 (s, 3H), 0.88-0.79 (m, 9H), 0.57-0.49 (m, 4H). MS (AP) 381.1 [(M+H)⁺, 100].

Example 99a (R)-4-(l-cyclopropyl-propyl)-8-(6-methoxy-2-methyl-pyridin-3-yl)-2-methyl-4H- pyrido [2,3-b]pyrazin-3-one

PARTA

[00200] To a solution of 2-benzyloxy-4-chloro-3-nitro-pyridine (Wilde, et al. WO

99/01454, which is incoφorated herein by reference) (1.95 g, 7.4 mmol) in ethanol (lOmL) and toluene (40 mL), was added Na₂CO₃ (9.2 mL, 2M), 2-methoxy-6-methyl pyridine boronic acid (Wilde, et al. WO99/01454) (1.85 g, 11.1 mmol), and Pd(PPh₃)₂Cl₂ (0.31 g, 4.44 mmol) and the mixture was heated at reflux for 5h. The reaction was cooled and poured into EtOAc and H₂O (500 mL). The EtOAc layer was washed with H₂O, brine, dried Na₂SO₄, filtered and concentrated in vacuo. Purification using flash chromatography (10 % EtOAc/ hexane) gave 2.5 g (96%) of 2'-benzyl-6-methoxy-2-methyl-3'-nitro-2',3'-dihydro- [3,4']bipyridinyl as a viscous oil: MS (AP) m/z 352.5 [(M+H)⁺, 100], 392.9 [(M+H+CH₃CN)⁺, 65]. The purified intermediate was used in the following step.

PART B

[00201] 2'-Benzyl-6-methoxy-2-methyl-3'-nitro-2',3'-dihydro-[3,4']bipyridinyl (2.50 g, 7.1 mmol) was dissolved in TFA (25 mL) and stined at room temperature for 4h. The reaction mixture was concentrated in vacuo and the cmde product 6-methoxy-2-methyl-3'- nitro-3-H[3,4']bipyridinyl-2'-one; MS (AP) m/z 262.4 [(M+H)⁺, 100], 303.0 [(M+H+CH₃CN)⁺, 72]. The crade intermediate was used in the following step.

PART C

[00202] To a solution of 6-methoxy-2-methyl-3'-nitro-3-H[3,4']bipyridinyl-2'-one

(0.300 g, 1.1 mmol) CH₂C1₂ (20 mL), was added Na₂CO₃ (0.296 g, 2.7 mmol). The reaction was cooled to -78 °C, and trifluoromethanesulfonic anhydride (574μL, 3.4 mmol) was added dropwise. After the addition, the reaction stined for 15 min at -78 °C, then warmed to 0 °C for lh. The reaction mixture was filtered and the collected solid was washed with CHC1₃. The filtrate was concentrated in vacuo and dissolved in triethylamine (20 mL) followed by and 1-cyclopropyl propyl amine HCl (0.441 g, 3.3 mmol), and heated to reflux overnight. The reaction was cooled and poured onto ice/H₂O. The mixture was extracted with CH₂C1₂, washed with H₂O, brine, dried Na SO₄, filtered, and concentrated in vacuo. Purification using flash chromatography (10% EtOAc/Hexane) gave 0.138 g (49%) of (1-cyclopropyl- propyl)-(6-methoxy-2-methyl-3'-nitro-[3,4']bipyridinyl-2'-yl)-amine: MS (AP) m/z 343.1 [(M+H)⁺, 100]. The purified intermediate was used in the following step.

PARTD

[00203] (l-Cyclopropyl-propyl)-(6-methoxy-2-methyl-3'-nitro-[3,4']bipyridinyl-2'- yl)-amine (0.138, 0.40 mmol) was dissolved in dioxane (10 mL) and H O (10 mL), followed by cone. NH₄OH (0.4 mL) and Na S₂O₄ (0.57 g, 3.3 mmol) and stined at room temperature for 4h. The solution was extracted with EtOAc, washed with H₂O, brine, dried Na₂SO , filtered, and concentrated in vacuo to produce in crude yield 0.108 g (86%) of N²- (cyclopropyl-propyl)-6-methoxy-2-methyl-[3,4']bipyridinyl-2',3'-diamine: MS (AP) m/z 313.2 [(M+H)⁺, 47]. The crude intermediate was used in the following step.

PARTE

[00204] N²-(cyclopropyl-propyl)-6-methoxy-2-methyl- [3 ,4' ]bipyridinyl-2' ,3 ' -diamine

(0.053 g, 0.17 mmol) was dissolved in EtOH (10 mL), followed by methyl pyruvate (31μL, 0.34 mmol) and heated to reflux overnight. The reaction was concentrated in vacuo and purified by reverse phase prep HPLC to yield 4-(l-cyclopropyl-propyl)-8-(6-methoxy-2- methyl-pyridin-3-yl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 99a). 1H NMR (300 MHz, CDC1₃) δ 8.48-8.46 (2d, IH, J= 4.7), 7.66-7.63 (d, IH, J=8.8 Hz), 7.13-7.12 (d, IH, =4.7 Hz), 6.82-6.79 (d, IH, J=8.4 Hz), 5.11-4.91, 4.52-4.42 (2m, IH), 4.06 (s, 3H), 2.50 (s, 3H), 2.38 '(s, 3H), 2.37-2.18 (m, 2H), 2.09-1.9 (m, IH), 0.9-0.85 (t, 3H, =7.4 Hz), 0.80- 0.70 (m, IH), 0.51-0.42 (m, IH), 0.40-0.29 (m, IH), 0.22-0.17 (m, IH). MS (AP) m/z 365.4 [(M+H)⁺, 100].

Example 101 (R,S)-4-(l-cyclopropyl-butyl)-8-(6-methoxy-2-methyl-pyridin-3-yl)-2-methyl-4H- pyrido [2,3-b]pyrazin-3-one

PARTS A and B

[00205] 6-Methoxy-2-methyl-3'-nitro-3-H[3,4']biρyridinyl-2'-one was prepared substantially as described in Example 99a. PART C

[00206] Trifluoro-methanesulfonic acid 6-methoxy-2-methyl-3'-nitro-3'H-

[3,4']bipyridinyl ester (0.335 g, 1.3 mmol), prepared substantially as described in Part C of Example 99a, and 1-cyclopropyl-butylamine HCl (0.561 g, 5.2 mmol) were treated substantially as described in Part C of Example 99a to produce 0.075 g (15%) of (1- cyclopropyl-butyl)-6-methoxy-2-methyl-3'-nitro-[3,4']bipyridinyl-2'-yl)amine: MS (AP) m z 357.1 [(M+H)⁺, 100].

PARTD

[00207] (l-Cyclopropyl-butyl)-6-methoxy-2-methyl-3'-nitro-[3,4']bipyridinyl-2'- yl)amine (0.075 g, 0.21 mmol), and Na₂SO₄ (0.296 g, 1.7 mmol), were treated substantially as described in Part D of Example 99a to give a crade yield of 0.055 g (80%) of 6-methoxy- N²-(l-cyclopropyl-butyl)-2-methyl-[3,4']bipyridinyl-2',3'-di amine.

PARTE

[00208] 6-Methoxy-N²-(l-cyclopropyl-butyl)-2-methyl-[3,4']bipyridinyl-2',3'-diamine

(0.055 g, 0.20 mmol) and methyl pymvate (30μL, 0.40 mmol) were treated substantially as described in Part E of Example 99a to give 4-(l-cyclopropyl-butyl)-8-(6-methoxy-2-methyl- pyridin-3-yl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 101): 1H NMR (300 MHz, CDC1₃) δ 8.51-8.43 (2d, IH, 1=4.8 Hz), 7.48-7.46 (d, IH, J=8.4), 7.12-7.10 (m, IH), 6.70- 6.68 (d, IH, J=8.4 Hz), 5.17-5.09, 4.60-4.53 (2m, IH), 4.01 (s,3H), 3.17-3.13 (m, 2H), 2.50 (s, 3H), 2.31 (s, 3H), 2.22-2.15 (m, 3H), 0.92-0.87 (t, 3H, J=7.3 Hz), 0.79-0.73 (m, IH), 0.53- 0.43 (m, IH), 0.40-0.38 (m, IH), 0.21-0.17 (m, IH). MS (AP) 379.1 [(M+H)⁺, 100].

Example 105a (R)-4-(2-methoxy-l-methyl-ethyl)-8-(6-methoxy-2-methyl-pyridyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one PARTS A and B

[00209] 6-Methoxy-2-methyl-3'-nitro-3-H[3,4']bipyridinyl-2'-one was prepared substantially as described in Example 99a.

PART C

[00210] Trifluoro-methanesulfonic acid 6-methoxy-2-methyl-3'-nitro-3'H-

[3,4']bipyridinyl ester (0.280 g, 0.71 mmol), prepared as substantially described in Part C of Example 99a, and 2-methoxy-l-methyl-ethylamine HCl (0..358 g, 2.8 mmol) were treated substantially as described in Part C of Example 99a to produce 0.070 g (30%) of (2-methoxy- l-methyl-ethyl)-6-methoxy-2-methyl-3'-nitro-[3,4']bipyridinyl-2'-yl)amine: MS (AP) m/z 333.4 [(M+H)⁺, 100].

PARTD

[00211] (2-Methoxy-l-methyl-ethyl)-6-methoxy-2-methyl-3'-nitro-[3,4']bipyridinyl-

2'-yl)amine (0.070 g, 0.21 mmol), and Na₂SO₄ (0.296 g, 1.7 mmol), were treated substantially as described in Part D of Example 99a to give a crade yield of 0.054 g (85%) of 6-methoxy-N²-(2-methoxy- 1 -methyl-ethyl)-2-methyl-[3 ,4' ]bipyridinyl-2' ,3 ' -diamine: MS (AP) m/z 303.2 [(M+H)⁺, 100].

PARTE

[00212] 6-Methoxy-N²-(2-methoxy-l-methyl-ethyl)-2-methyl-[3,4']bipyridinyl-2',3'- diamine (0.054 g, 0.18 mmol) and methyl pyruvate (32μL, 0.36 mmol) were treated substantially as described in Part E of Example 99a to give 4-(2-methoxy-l-methyl-ethyl)-8- (6-methoxy-2-methyl-pyridyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 105a): 1H NMR (300 MHz, CDC1₃) δ 8.57-8.56 (d, IH, =4.7 Hz), 7.78-7.75 (d, IH, =8.5 Hz), 7.16-7.14 (d, IH, 1=5.1 Hz), 6.91-6.88 (d, IH, =8.7 Hz), 4.44-4.38 (t, IH, J=9.1 Hz), 4.11 (s, 3H), 3.79-3.74 (m, 2H), 3.34 (s, 3H), 2.48 (s, 3H), 2.42 (s, 3H), 1.62-1.59 (d, 3H, J=7.0 Hz). MS (AP) 355.6 [(M+H)⁺, 100].

Example 113 (R,5)-4-sec-butyl-8-(2-chloro-4-difluoromethoxy-phenyl)-2-methyl-4H- pyrido [2,3-b]pyrazin-3-one

PARTA

[00213] To a solution of 2-benzyloxy-4-chloro-3-nitro-pyridine (Wilde, et al. WO

99/01454, which is incoφorated herein by reference) (6.59 g, 24.9 mmol) in DME/H₂O, was added 2-chloro-4-difluoromethoxy-phenylboronic acid (Wilde, et al. WO 99/01454) (5.54 g, 24.9 mmol), Ba(OH)₂ 8H₂O (7.86 g, 24.9 mmol), and Pd(PPh₃)₂Cl₂ (1.01 g, 1.45 mmol) and the mixture was heated at reflux for 5h. The reaction was cooled and poured into EtOAc and H₂O (500 mL). The EtOAc layer was washed with H₂O, brine, dried Na SO₄, filtered and concentrated in vacuo to give 6.9 g (68%) of 2-benzyloxy-4-(2-chloro-4-difluoromethoxy- phenyl)-3-nitro-pyridine as a viscous oil; MS(AP) m z 408.9 [(M+H)⁺, 100].

PARTB

[00214] 2-Benzyloxy-4-(2-chloro-4-difluoromethoxy-phenyl)-3-nitro-pyridine(6.90g,

17.0 mmol) was dissolved in TFA (25 mL) and stined at room temperature for 4h. The reaction mixture was concentrated in vacuo. Purification using flash chromatography (15%

MeOH/ DCM) gave 1.00 g (19%) of 4-(2-chloro-4-difluoromethoxy-phenyl)-3-nitro-3H- pyridin-2-one as an orange solid: MS(AP) m/z 316.9 [(M+H)⁺, 98], 359.8 [(M+H+CH₃CN)⁺,

100].

PART C

[00215] To 10 mL of POCl₃ was added 4-(2-chloro-4-difluoromethoxy-phenyl)3-nitro-

3H-pyridin-2-one (0.20g, 0.63 mmol), followed by the addition of DMF (1-2 mL) and the reaction refluxed overnight. The reaction mixture was cooled to room temperature and poured over ice/H₂O (200 mL). The solution was extracted with EtOAc, washed H₂O, brine, dried Na₂SO₄, filtered, and concentrated in vacuo to give 0.176 g (96%) of 2-chloro-4-(2- chloro-4-difluoromethoxy-phenyl)-3-nitro-2,3-dihydro-pyridine as brown viscous oil.

PARTD

[00216] 2-Chloro-4-(2-chloro-4-difluoromethoxy-phenyl)-3-nitro-2,3-dihydro-pyridine

(0.176 g, 0.53 mmol) was dissolved in acetonitrile (20 mL), followed by the addition of sec butylamine (106 μL, 1.06 mmol) and Hunig's base (184 μL, 1.06 mmol). The reaction was stined at reflux for 64h. The solution was cooled to room temperature, extracted with EtOAc/H₂O, organic layer was then washed with IN HCl and made basic with IN NaOH. The organic layer was washed with brine, dried Na₂SO , filtered and concentrated to yield 0.163 g (83%) of sec-butyl-[4-(chloro-4-difluoromethoxy-phenyl)-3-nitro-2,3-dihydro- pyridin-2-yl]-amine as a yellow oil; MS (AP) 413.0 [(M+H+CH₃CN)⁺, 50].

PARTE

[00217] Sec-butyl-[4-(chloro-4-difluoromethoxy-phenyl)-3-nitro-2,3-dihydro-pyridin-

2-yl]-amine ( 0.163, 0.44 mmol) was dissolved in dioxane (10 mL) and H₂O (10 mL), followed by cone. NFL-OH (0.4 mL) and Na₂S O₄ (0.62 g, 3.55 mmol) and stirred at room temperature for 4h. The solution was extracted with EtOAc, washed with H₂O, brine, dried Na₂SO₄, filtered, and concentrated in vacuo to produce 0.145g (97%) of N²-sec-butyl-4-(2- chloro-4-difluoromethoxy-phenyl)-2,3-dihydro-pyridine-2,3-diamine as a yellow oil.

PARTF

[00218] Sec-butyl-[4-(chloro-4-difluoromethoxy-phenyl)-3-nitro-2,3-dihydro-pyridin-

2-yl]-amine (0.145 g, 0.43 mmol) was dissolved in toluene (20 mL), followed by methyl pyravate (77 μL, 0.86 mmol) and heated to reflux overnight. The reaction was concentrated in vacuo and purified by reverse phase prep HPLC giving 4-sec-butyl-8-(2-chloro-4- difluoromethoxy-phenyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 113): 1H NMR (300 MHz, CDC1₃) δ 8.53-8.52 (d, IH, J=4.8 Hz), 7.35-7.32 (m, 2H), 7.19-7.13 (m, 2H), 6.85-6.36 (t, IH, =73.2 Hz), 2.47 (s, 3H), 2.40-2.20 (m, IH), 2.10-2.07 (m,lH), 1.65- 1.63 (d, 3H, 1=6.9 Hz), 0.89-0.84 (t, 3H, 1=3.7). MS(AP) m/z 394.2 [(M+H)⁺, 100], 435.3 [(M+H+CH₃CN)⁺, 10].

Example 115a (5)-8-(2-Chloro-4-difluoromethoxy-phenyl)-4-(l-cyclopropyl-propyl)2-methyl-4H- pyrido [2,3-b]pyrazin-3-one

PARTS A and B

[00219] 4-(2-Chloro-4-difluoromethoxy-phenyl)-3-nitro-3H-pyridin-2-one was prepared substantially as described in Example 113.

PARTC

[00220] Trifluoro-methanesulfonic acid 4-(2-chloro-4-difluroromethoxy-phenyl)-3- nitro-pyridin-2-yl ester (0.269 g, 0.60 mmol), prepared substantially as described in Part C of Example 115b, and 1-cyclopropyl-proply amine HCl (0.162 g, 1.2 mmol) were treated in the same manner as in Part C of Example 115b with the exception that the crade product was purified using flash chromatography (10% EtOAc/Hexane) to produce 0.138 g (67%) of [4-2- chloro-4-difluoromethoxy-phenyl)-3-nitro-pyridin-2-yl]-(l-cyclopropyl-propyl) amine: MS (AP) m/z 398.0 [(M+H)⁺, 100).

PARTD

[00221] [4-(2-Chloro[4[difluoromethoxy-phenyl)-3-nitro-pyridin-2-yl]-(l-cyclopropyl- propyl)-amine (0.138 g, 0.40 mmol), and Na₂SO₄ (0.567 g, 8.07 mmol), were treated as in Part E of Example 113 to give in crude yield 0.170 g (116%) of 4-(2-chloro-4- difluoromethoxy-phenyl)- N -(l-cyclopropyl-propyl)-pyridine-2,3-diamine: MS (AP) m/z 368.1 [(M+H)⁺, 40]. PARTE

[00222] 4-(2-chloro-4-difluoromethoxy-phenyl)-N²-(l-cyclopropyl-propyl)-pyridine-

2,3-diamine (0.088 g, 0.24 mmol) and methyl pyravate (140μL, 1.54 mmol) were treated as in Part F of Example 113 with the exception that ethanol was used as the solvent, gave 8-(2- Chloro-4-difluoromethoxy-phenyl)-4-(l-cyclopropyl-propyl)2-methyl-4H-pyrido[2,3- b]pyrazin-3-one (Example 115a): 1H NMR (300 MHz, CDC1₃) δ 8.48-8.46 (2d, IH, J=4.7 Hz), 7.37-7.33 (m, 2H), 7.19-7.14 (m, 2H), 6.86-6.37 (t,lH, =73.3 Hz), 5.16-4.92, 4.90-4.41 (2m, IH), 2.57 (s, 3H), 2.49- 2.38 (m, IH), 2.29-2.19 (m, IH), 2.10-1.93 (m, IH), 0.90-0.85 (t, 3H, =7.3), 0.80-0.71 (m, IH), 0.59-0.50 (m, IH) 0.49-0.48 (m, IH), 0.23-0.18 (m, IH). MS (AP) m z 420.1 [(M+H)⁺, 100].

Example 115b (R)-8-(2-Chloro-4-difluoromethoxy-phenyl)-4-(l-cyclopropyl-propyl)2-methyl-4H- pyrido [2,3-b]pyrazin-3-one

PARTA

[00223] To a solution of 2-benzyloxy-4-chloro-3-nitro-pyridine (Wilde, et al. WO

99/01454, which is incoφorated herein by reference) (5.0g, 18.9 mmol) in DME/H₂O, was added 2-chloro-4-difluoromethoxy-phenylboronic acid (Wilde, et al. WO 99/01454, which is incoφorated by reference herein in its entirety) (4.20 g, 18.9 mmol), Ba(OH)₂ 8H₂O (5.96 g, 18.9 mmol), and Pd(PPh₃)₂Cl₂ (0.769 g, 1.10 mmol) were treated as in Part A of Example 113 to give 5.40 g (70%) of 2-benzyloxy-4-(2-chloro-4-difluoromethoxy-phenyl)-3-nitro- pyridine as a viscous oil. The crude intermediate was used in the following step. PART B

[00224] 2-Benzyloxy-4-(2-chloro-4-difluoromethoxy-phenyl)-3-nitro-pyridine (5.40 g,

13.3 mmol) and TFA (25 mL) were treated as in Part B of Example 113 with the exception that the cmde product was isolated as 3.90 g (93%) of 4-(2-chloro-4-difluoromethoxy- phenyl)-3-nitro-3H-pyridin-2-one: MS(AP) m/z 317.0 [(M+H)⁺, 90], 357.9 [(M+H+CH₃CN)⁺, 100].

PART C

[00225] To a solution of 2-benzyloxy-4-(2-chloro-4-difluoromethoxy-phenyl)-3-nitro- pyridin-2-one (0.364 g, 1.2 mmol) CH₂C1₂ (20 mL), was added Na₂CO₃ (0.299 g, 2.94 mmol). The reaction was cooled to -78 °C, and trifluoromethanesulfonic anhydride (576 μL, 3.6 mmol) was added dropwise. After the addition, the reaction stined for 15 min at -78 °C, then warmed to 0 °C for lh. The reaction mixture was filtered and the collected solid was washed with CHC1₃. The filtrate was concentrated in vacuo and dissolved in toluene (20 mL) followed by Et₃N( 231 μL, 1.7 mmol) and 1 -cyclopropyl propyl amine HCl (0.224 g, 1.7 mmol), and heated at 130 °C overnight. The reaction was cooled and poured onto ice/H₂O. The mixture was extracted with CH₂C1₂, washed with H₂O, brine, dried Na₂SO , filtered, and concentrated in vacuo to produce in crade yield 0.301 g, (91%) of [4-(2- chloro[4[difluoromethoxy-phenyl)-3-nitro-pyridin-2-yl]-(l-cyclopropyl-propyl)-amine. MS(AP) m/z 398.0 [(M+H)⁺, 100]. The crude intermediate was used in the following step.

PARTD

[00226] [4-(2-Chloro [4 [difluoromethoxy-phenyl)-3 -nitro-pyridin-2-yl] -( 1 -cyclopropyl- propyl)-amine (0.301 g, 0.76 mmol), and Na₂SO₄ (1.07 g, 6.12 mmol), were treated substantially as described in Part E of Example 113 to give 0.284 g (91%) of 4-(2-chloro-4- difluoromethoxy-phenyl)-N²-(l-cyclopropyl-propyl)-pyridine-2,3-diamine. The crade intermediate was used in the following step.

PARTE

[00227] 4-(2-Chloro-4-difluoromethoxy-phenyl)-N²-(l-cyclopropyl-propyl)-pyridine-

2,3-diamine (0.284 g, 0.77 mol) and methyl pyruvate (140 μL, 1.54 mmol) were treated substantially as described in Part F of Example 113 to give 8-(2-Chloro-4-difluoromethoxy- phenyl)-4-(l-cyclopropyl-propyl)2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 115b): 1H NMR (300 MHz, CDC1₃) δ 8.52-8.46 (2d, IH, J=4.8), 7.37-7.32 (m, 2H), 7.26-7.14 (m, 2H), 6.85-6.37(t,lH, 1=73.3 Hz), 5.09-4.95, 4.75-4.2 (2m, IH), 2.48 (s, 3H), 2.4-2.25 (m, IH), 2.23-2.16 (m, IH), 2.13-1.93 (m, IH), 0.90-0.85 (t, 3H, J=7.3 Hz), 0.80-0.67 (m, IH), 0.57-0.42 (m, IH), 0.40-0.29 (m, IH), 0.24-0.18 (m, IH). MS (AP) m/z 420.2 [(M+H)⁺, 100], 461.3 [(M+H+CH₃CN)⁺, 20].

Example 117 (R,5)-8-(2-Chloro-4-difluoromethoxy-phenyl)-4-(l-cyclopropyl-butyl)-2-methyl-4H- pyrido [2,3-b]pyrazin-3-one

PARTS A and B

[00228] 4-(2-Chloro-4-difluoromethoxy-phenyl)-3-nitro-3H-pyridin-2-one was prepared substantially as described in Example 113.

PART C

[00229] Trifluoro-methanesulfonic acid 4-(2-chloro-4-difluroromethoxy-phenyl)-3- nitro-pyridin-2-yl ester (0.369 g, 0.83 mmol), prepared substantially as described in Part C of Example 155b, and 1-cyclo-proply-butylamine HCl (0.246 g, 1.7 mmol) were treated substantially as described in Part C of Example 115b to produce in crade yield 0.380 g (111%) of [4-2-chloro-4-difluoromethoxy-phenyl)-3-nitro-pyridin-2-yl]-(l-cyclopropyl- butyl)-amine: MS (AP) m/z 412.0 [(M+H)⁺, 100].

PARTD

[00230] [4-2-Chloro-4-difluoromethoxy-phenyl)-3-nitro-pyridin-2-yl]-(l-cyclopropyl- butyl)-amine (0.380 g, 0.92 mmol), and Na₂SO₄ (1.30 g, 7.5 mmol), were treated substantially as described in Part E of Example 113 to give a cmde yield of 0.300g (86%) of 4-(2-chloro-4-difluoromethoxy-phenyl)- N²-(l-cyclopropyl-butyl)-pyridine-2,3-diamine.

PARTE

[00231] 4-(2-Chloro-4-difluoromethoxy-phenyl)-N²-(l-cyclopropyl-butyl)-pyridine-

2,3-diamine (0.300 g, 0.79 mmol) and methyl pyruvate (142μL, 1.58 mmol) were treated substantially as described in Part F of Example 113 to give 8-(2-chloro-4-difluoromethoxy- phenyl)-4-(l-cyclopropyl-butyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 117). 1H NMR (300 MHz, CDC1₃) δ 8.47-8.46 (2d, IH, =4.8 Hz), 7.37-7.28 (m, 2H), 7.20-7.10 (m, 2H), 6.85-6.37 (t, IH, J=72.8 Hz), 5.18-5.02, 4.60-4.51 (2m, IH), 2.49 (s, 3H), 2.40-2.32 (m, IH), 2.29-2.17 (m, 2H), 2.10-2.00 (m, IH), 0.92-0.88 (t, 3H, J=7.4 Hz), 0.87-0.77 (m, IH), 0.59-0.42 (m, 2H), 0.40-0.31 (m, 2H). MS (AP) m z 434.1 [(M+H)⁺, 100)].

Example 121a (R)-8-(2-chloro-4-difluoromethoxy-phenyl)-4-(2-methoxy-l-methyl-ethyl)-2-methyl-4H- pyrido [2,3-b]pyrazin-3-one

PARTS A and B

[00232] 4-(2-Chloro-4-difluoromethoxy-phenyl)-3-nitro-3H-pyridin-2-one was prepared substantially as described in Example 113.

PART C

[00233] Trifluoro-methanesulfonic acid 4-(2-chloro-4-difluroromethoxy-phenyl)-3- nitro-pyridin-2-yl ester (0.332 g, 0.74 mmol), prepared substantially as described in Part C of Example 115b, and 2-methoxy-l-methyl-ethylamine HCl (0.207 g, 1.5 mmol) were treated substantially as described in Part C of Example 115b to produce 0.231 g (78%) of [4-2- chloro-4-difluoromethoxy-phenyl)-3-nitro-pyridin-2-yl]-(2-methoxy-l-methyl-ethyl)-amine: MS (AP) m/z 387.9 [(M+H)⁺, 100].

PARTD

[00234] [4-2-Chloro-4-difluoromethoxy-phenyl)-3-nitro-pyridin-2-yl]-(2-methoxy-l- methyl-ethyl)-amine (0.231 g, 0.58 mmol), and Na₂SO₄ (0.809 g, 4.7 mmol), were treated substantially as described in Part E of Example 113 to give 0.149 g (72%) of 4-(2-chloro-4- difluoromethoxy-phenyl)- N²-(2-methoxy-l-methyl-ethyl)-pyridine-2,3-diamine: MS (AP) m/z 358.0 [(M+H)⁺, 100]. Crade intermediate was taken on to Part E

PARTE

[00235] 4-(2-Chloro-4-difluoromethoxy-phenyl)-N²-(2-methoxy- 1 -methyl-ethyl)- pyridine-2,3-diamine (0.149 g, 0.42 mmol) and methyl pyravate (75 μL, 0.83 mmol) were treated substantially as described in Part F of Example 113 to give 8-(2-chloro-4- difluoromethoxy-phenyl)-4-(2-methoxy- 1 -methyl-ethyl)-2-methyl-4H-pyrido [2,3-b]pyrazin- 3-one (Example 121a): 1H NMR (300 MHz, CDC1₃): δ 8.54-8.53 (d, IH, =4.8 Hz), 7.34- 7.32 (m, 2H), 7.21-7.13 (m, 2H), 6.85-6.36 (t, IH, =73.2 Hz), 4.41-4.37 (m, IH), 3.82-3.76 (m, 2H), 3.34 (s, 3H), 2.47 (s, 3H), 1.62 (d, 3H, J=6.9 Hz). MS (AP) m/z 410.0 [(M+H)⁺, 100].

Example 122a (i?)-8-(2-Chloro-4-difluoromethoxy-phenyl)-4-(l-methoxymethyl-propyl)-2-methyI-4H- pyrido [2,3-b]pyrazin-3-one

PARTS A and B

[00236] 4-(2-Chloro-4-difluoromethoxy-phenyl)-3-nitro-3H-pyridin-2-one was prepared substantially as described in Example 113. PART C

[00237] Trifluoro-methanesulfonic acid 4-(2-chloro-4-difluroromethoxy-phenyl)-3- nitro-pyridin-2-yl ester (0.405 g, 0.9 mmol), prepared substantially as described in Part C of Example 155b, and 2-methoxymethyl-propylamine HCl (0.252 g, 1.8 mmol) were treated in the same manner as in Part C of Example 115b to produce in crude yield 0.350 g (97%) of [4- 2-chloro-4-difluoromethoxy-phenyl)-3-nitro-pyridin-2-yl]-(l-methoxymethyl-propyl) amine. MS (AP) m/z 402.0 [(M+H)⁺, 100].

PARTD

[00238] [4-2-Chloro-4-difluoromethoxy-phenyl)-3-nitro-pyridin-2-yl]-(l- methoxymethyl-propyl) amine (0.350 g, 0.87 mmol), and Na₂SO₄ (1.23 g, 7.04 mmol), were treated substantially as described in Part E of Example 113 to give a crude yield of 0.268 g (83%) of 4-(2-chloro-4-difluoromethoxy-phenyl)-N²-(l-methoxymethyl-propyl)-pyridine- 2,3-diamine; MS (AP) m z 372.0 [(M+H)⁺, 100].

PARTE

[00239] 4-(2-Chloro-4-difluoromethoxy-phenyl)-N²-(l-methoxymethyl-propyl)- pyridine-2,3-diamine (0.268 g, 0.72 mmol) and methyl pyravate (130μL, 1.44 mmol) were treated substantially as described in Part F of Example 113 to give 8-(2-chloro-4- difluoromethoxy-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3- one (Example 122a): 1H NMR (300 MHz, CDC1₃) δ D 8.54-8.51 (m, IH), 7.33-7.32 (m,2H), 7.21-7.14 (m, 2H), 6.85-6.37 (t, IH, J=72.9 Hz), 6.21-6.19, 5.64-5.58 (2m, IH), 4.40-4.31 (m, IH), 3.92-.3.79 (m, IH), 3.33 (s, 3H), 2.48 (s, 3H), 2.30-2.20 (m, 1H),2.13-1.96 (m, IH), 0.90-0.85 (t, 3H, J=7.7 Hz). MS (AP) m/z 424.1 [(M+H)⁺, 100].

Example 122b (S)-8- (2- Chloro-4-difluoromethoxy-phenyl)-4- (1 -methoxymethyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PARTS A and B

[00240] 4-(2-Chloro-4-difluoromethoxy-phenyl)-3-nitro-3H-pyridin-2-one was prepared substantially as described in Example 113.

PART C

[00241] Trifluoro-methanesulfonic acid 4-(2-chloro-4-difluroromethoxy-phenyl)-3- nitro-pyridin-2-yl ester (0.473 g, 1.1 mmol), prepared substantially as described in Part C of Example 115b, and 2-methoxymethyl-propylamine HCl (0.295 g, 2.2 mmol) were treated in the same manner as in Part C of Example 115b to produce 0.380 g (86%) of [4-2-chloro-4- difluoromethoxy-phenyl)-3-nitro-pyridin-2-yl]-(l-methoxymethyl-propyl) amine: MS (AP) m z 402.0 [(M+H)⁺, 100].

PARTD

[00242] [4-2-Chloro-4-difluoromethoxy-phenyl)-3-nitro-pyridin-2-yl]-(l- methoxymethyl-propyl) amine (0.38 g, 0.95 mmol), and Na₂SO₄ (1.33 g, 7.6 mmol), were treated substantially as described in Part E of Example 113 to give a crude yield of 0.366 g of 4-(2-chloro-4-difluoromethoxy-phenyl)-N²-(l-methoxymethyl-propyl)-pyridine-2,3-di amine: MS (AP) m/z 372.0 [(M+H)⁺, 100].

PARTE

[00243] 4-(2-Chloro-4-difluoromethoxy-phenyl)-N²-(l-methoxymethyl-propyl)- pyridine-2,3-diamine (0.366 g, 0.99 mmol) and methyl pyruvate (178 μL, 1.97 mmol) were treated as in Part F of Example 133 to give 8-(2-chloro-4-difluoromethoxy-phenyl)-4-(l- methoxymethyl-propyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 122b): 1H NMR (300 MHz, CDC1₃) δ 8.56-8.51 (m, IH), 7.33-7.30 (m, 2H), 7.27-7.23 (m, 2H), 6.82-6.33 (t, IH, J=72.9 Hz), 6.20-6.18, 5.62-5.57 (2m, IH), 4.38-4.32 (m,lH), 3.93-3.80 (m, IH), 3.33 (s, 3H), 2.47 (s, 3H), 2.08-2.00 (m, 2H), 0.90-0.88 (t, 3H, =6.3 Hz). MS (AP) 424.1 [(M+H)⁺, 100].

Example 131a (S)-8-(2-chloro-4-trifluoromethyl-phenyl)-4-(l-cyclopropyl-propyl)-2-methyl-4H- py rido [2,3-b]pyrazin-3-one

PARTA

[00244] 2-Benzyloxy-4-chloro-3-nitro-pyridine (Wilde, et al. WO 99/01454, which is incoφorated herein by reference in its entirety) (2.0 g, 7.56 mmol) and 2-chloro-4- trifluoromethylphenylboronic acid (2.31 g, 11.3 mmol) were treated substantially as described in Part A of Example 19a to give 2.44 g (79 %) of 2-benzyloxy-4-(2-chloro-4- trifluoromethyl-phenyl)-3-nitro-pyridine: MS (AP) m/z 408.8 [(M+H)⁺, 72].

PARTB

[00245] 2-Benzyloxy-4-(2-chloro-4-trifluoromethyl-phenyl)-3-nitro-pyridine (2.44 g,

5.97 mmol) was treated as in Part B of Example 19a to give 2.01 g (100 %) of 4-(2-chloro-4- trifluoromethyl-phenyl)-3-nitro-lH-pyridin-2-one: MS (AP) m/e 318.6 [(2M-HV, 100]. PART C

[00246] Trifluoro-methanesulfonic acid 4-(2-chloro-4-trifluoromethyl-phenyl)-3-nitro- pyridin-2-yl-ester (0.62 g, 1.38 mmol), prepared substantially as described in Part C of Example 19a, and l-cyclopropyl-propylamine HCl (0.37 g, 2.75 mmol) were treated substantially as described in Part C of Example 19a to produce 0.55 g (100 %) of [4-(2- chloro-4-trifluoromethyl-phenyl)-3 -nitro-pyridin-2-yl] -(1 -cyclopropyl-propyl)-amine: MS (AP) m/z 399.8 [(M+H)⁺, 25].

PARTD

[00247] [4-(2-Chloro-4-trifluoromethyl-phenyl)-3 -nitro-pyridin-2-yl] -(1 -cyclopropyl- propyl)-amine (0.55 g, 1.38 mmol) and Na₂S₂O₄ (1.93 g, 11.1 mmol) were treated substantially as in Part E of Example 9 to yield 94 % of 4-(2-chloro-4-trifluoromethyl- phenyl)-N²-(l-cycloproρyl-propyl)-pyridine-2,3-diamine: MS (AP) m/z 369.8 [(M+H)⁺,

100].

PARTE

[00248] 4-(2-Chloro-4-trifluoromethyl-phenyl)-N²-(l-cyclopropyl-propyl)-pyridine-

2,3-diamine (0.31 g, 0.86 mmol) was treated substantially as described in Part F of Example 9 to give 8.2 mg (2 %) of 8-(2-chloro-4-trifluoromethyl-phenyl)-4-(l-cyclopropyl-propyl)-2- methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 131a): 1H NMR (300 MHz, CDC1₃): δ 8.5 (d, IH), 7.77 (s, IH), 7.6 (d, IH), 7.5 (d, IH), 7.17 (s, IH), 5.0 (q, IH), 4.45 (q, IH), 2.45 (s, 2H), 2.4-2.10 (m, IH), 1.3 (s, 3H), 0.90 (t, 3H), 0.70 (m, IH), 0.50-0.30 (m, 2H). MS (AP) m z 421.9 [(M+H)⁺, 100].

Example 137a (R)-8-(2-chloro-4-trifluoromethyl-phenyl)-4-(2-methoxy-l-methyl-ethyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one PARTA

[00249] 2-Benzyloxy-4-chloro-3-nitro-ρyridine (Wilde, et al. WO 99/01454, which is incoφorated herein by reference in its entirety) (2.0 g, 7.56 mmol) and 2-chloro-4- trifluoromethylphenylboronic acid (2.31 g, 11.3 mmol) were treated as in Part A of Example 19a to give 2.44 g (79%) of 2-benzyloxy-4-(2-chloro-4-trifluoromethyl-phenyl)-3-nitro- pyridine: MS (AP) m z 408.8 [(M+H)⁺, 72].

PARTB

[00250] 2-Benzyloxy-4-(2-chloro-4-trifluoromethyl-phenyl)-3-nitro-pyridine (2.44 g,

5.97 mmol) was treated as in Part B of Example 19a to give 2.01 g (100 %) of 4-(2-chloro-4- trifluoromethyl-phenyl)-3-nitro-lH-pyridin-2-one: MS (AP) m e 318.6 [(2M-H)^", 100].

PART C

[00251] Trifluoro-methanesulfonic acid 4-(2-chloro-4-trifluoromethyl-phenyl)-3-nitro- pyridin-2-yl-ester (0.50 g, 1.11 mmol), prepared substantially as described in Part C of Example 19a, and 2-methoxy-l-methyl-ethylamine HCl (0.28 g, 2.22 mmol) were treated in the same manner as in Part C of Example 19a to produce 0.45 g (100 %) of [4-(2-chloro-4- trifluoromethyl-phenyl)-3-nitro-pyridin-2-yl]-(2-methoxy-l-methyl-ethyl)-amine: MS (AP) m/z 389.8 [(M+H)⁺, 100].

PARTD

[00252] [4-(2-Chloro-4-trifluoromethyl-ρhenyl)-3-nitro-pyridin-2-yl]-(2-methoxy-l- methyl-ethyl)-amine (0.45 g, 1.15 mmol) and Na₂S₂O₄ (1.62 g, 9.32 mmol) were treated substantially as described in Part E of Example 9 to yield 0.3 lg (74 %) of 4-(2-chloro-4- trifluoromethyl-phenyl)-N²-(2-methoxy-l-methyl-ethyl)-pyridine-2,3-diamine: MS (AP) m/z 359.8 [(M+H)⁺, 97].

PARTE

[00253] 4-(2-Chloro-4-trifluoromethyl-ρhenyl)-N²-(2-methoxy- 1 -methyl-ethyl)- pyridine-2,3-diamine (0.31 g, 0.86 mmol) was treated substantially as described in Part F of Example 9 to give 8.2 mg (2 %) of 8-(2-chloro-4-trifluoromethyl-phenyl)-4-(2-methoxy-l- methyl-ethyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 137a): 1H NMR (300 MHz, CDC1₃): δ 8.5 (d, IH), 7.7 (s, IH), 7.6 (d, IH), 7.4 (d, IH), 7.20 (d, IH), 4.4 (t, IH), 3.8 (q, IH), 3.3 (s, 3H), 2.5 (bs, IH), 2.4 (s, 3H), 1.6 (d, 3H). MS (AP) m/z 411.8 [(M+H)⁺, 100].

Example 138a (R)-8-(2-chloro-4-trifluoromethyl-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PARTS A and B

[00254] 4-(2-Chloro-4-trifluoromethyl-phenyl)-3-nitro-lH-pyridin-2-one was prepared substantially as described in Example 137a.

PART C

[00255] Trifluoro-methanesulfonic acid 4-(2-chloro-4-trifluoromethyl-phenyl)-3-nitro- pyridin-2-yl-ester (0.50 g, 1.11 mmol), prepared substantially as described in Part C of

Example 19a, and 1-methoxymethyl-propylamine HCl (0.31 g, 2.22 mmol) were treated substantially as described in Part C of Example 19a to produce 0.40 g (89 %) of [4-(2- chloro-4-trifluoromethyl-phenyl)-3-nitro-pyridin-2-yl]-(l-methoxymethyl-propyl)-amine:

MS (AP) m/z 403.8 [(M+H)⁺, 98].

PARTD

[00256] [4-(2-Chloro-4-trifluoromethyl-phenyl)-3-nitro-ρyridin-2-yl]-(l- methoxymethyl-propyl)-amine (0.40 g, 1.0 mmol) and Na₂S₂O (1.39 g, 8.0 mmol) were treated substantially as described in Part E of Example 9 to yield 0.29 g (78 %) of 4-(2- chloro-4-trifluoromethyl-phenyl)-N²-(l-methoxymethyl-propyl)-pyridine-2,3-diamine: MS (AP) m/z 373.8 [(M+H)⁺, 100]. PARTE

[00257] 4-(2-Chloro-4-trifluoromethyl-phenyl)-N²-(l-methoxymethyl-propyl)- pyridine-2,3-diamine (0.29 g, 0.78 mmol) was treated substantially as described in Part F of Example 9 to give 6.5 mg (2 %) of 8-(2-chloro-4-trifluoromethyl-phenyl)-4-(l- methoxymethyl-propyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 138a): 1H NMR (300 MHz, CDC1₃): δ 8.5 (bs, IH), 7.7 (s, IH), 7.6 (d, IH), 7.45 (d, IH), 7.17 (d, IH), 6.10 (m, IH), 4.3 (m, IH), 3.8 (m, IH), 3.3 (s, 3H), 2.45 (s, 3H), 2.0 (m, IH), 1.2 (s, IH), 0.90 (t, 3H). MS (AP) m/z 425.8 [(M+H)⁺, 100].

Example 243a (5)-8-(2-Chloro-5-fluoro-4-methoxy-phenyl)-4-(l-cyclopropyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PART A and B

[00258] 4-(2-Chloro-5-fluoro-4-methoxy-phenyl)-3-nitro-lH-pyridin-2-one was prepared substantially as described in Example 250.

PART C

[00259] Trifluoro-methanesulfonic acid 4-(2-chloro-5-fluoro-4-methoxy-phenyl)-3- nitro-pyridin-2-yl ester (0.3 g, 0.70 mmol) and (S)- l-cyclopropyl-propylamine (0.28 g, 2.09 mmol) were treated substantially as described in Part C of Example 19a to produce 30 mg

(12%) of crade (S)-[4-(2-chloro-5-fluoro-4-methoxy-phenyl)-3-nitro-pyridin-2-yl]-(l- cyclopropyl-propyl)-amine. PARTD

[00260] (S)-[4-(2-Chloro-5-fluoro-4-methoxy-phenyl)-3-nitro-pyridin-2-yl]-(l- cyclopropyl-propyl)-amine (30 mg, 0.08 mmol) and SnCl₂ (44 mg, 0.23 mmol) were treated substantially as described in Part D of Example 74a to yield 25 mg (92%) of (S)-4-(2-chloro- 5-fluoro-4-methoxy-phenyl)-N -(l-cyclopropyl-propyl)-pyridine-2,3-diamine.

PARTE

[00261] (S)-4-(2-Chloro-5-fluoro-4-methoxy-phenyl)-N²-(l-cyclopropyl-propyl)- pyridine-2,3-diamine (25 mg, 0.07 mmol) was treated substantially as described in Part F of Example 9 to give 2.5mg (9%) of (S)-8-(2-chloro-5-fluoro-4-methoxy-phenyl)-4-(l- cyclopropyl-propyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 243a): 1H NMR (400 MHz, CDC1₃) δ ppm 8.47 (d, 7=4.89 Hz, 1 H), 7.18 (d, 7=4.89 Hz, 1 H), 7.12 (d, 7=8.07 Hz, 1 H), 7.09 (d, 7=4.40 Hz, 1 H), 4.81 (m, 1 H), 3.96 (s, 3 H), 2.49 (s, 3 H), 2.21 (m, 2 H), 0.86 (t, 7=7.46 Hz, 3 H), 0.83 (m, 1 H), 0.71 (m, 1 H), 0.47 (m, 1 H), 0.35 (m, 1 H), 0.15 (m, 1 H). MS (El) m/z 402.20 [(M+H)+, 100].

Example 250 8-(2-Chloro-5-fluoro-4-methoxy-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H- pyrido [2,3-b]pyrazin-3-one

PARTA

[00262] 2-Benzyloxy-4-chloro-3-nitro-pyridine (Wilde, et. al. WO 99/01454) (3.8 g,

14.3 mmol) and 2-chloro-5-fluoro-4-methoxyphenylboronic acid (Preparation 1) (3.8 g, 18.6 mmol) were treated substantially as described in Part A of Example 19a to give 3.5 g (63%) of 2-benzyloxy-4-(2-chloro-5-fluoro-4-methoxy-phenyl)-3-nitro-pyridine: 1H NMR (400 MHz, CDC1₃) δ ppm 8.30 (d, 7=5.4 Hz, 1 H), 7.45-7.42 (m, 2H), 7.40-7.29 (m, 3H), 7.04 (d, 7=7.6 Hz, 1 H), 7.00 (d, 7=10.8 Hz, 1 H), 6.91 (d, 7=5.4 Hz, 1 H), 5.54 (s, 2 H), 3.91 (s, 3 H).

PART B

[00263] 2-Benzyloxy-4-(2-chloro-5-fluoro-4-methoxy-phenyl)-3-nitro-pyridine (3.5 g,

9.0 mmol) was treated substantially as described in Part B of Example 19a to give 4-(2- chloro-5-fluoro-4-methoxy-phenyl)-3-nitro-lH-pyridin-2-one (2.3 g, 86%): 1H NMR (400 MHz, DMSO-d₆) δ ppm 12.97 (br s, IH), 7.79 (d, 7=6.3 Hz, 1 H), 7.44 (d, 7=7.8 Hz, 1 H), 7.38 (d, 7=11.3 Hz, 1 H), 6.30 (d, 7=6.3 Hz, 1 H), 3.91 (s, 3 H).

PART C

[00264] Trifluoro-methanesulfonic acid 4-(2-Chloro-5-fluoro-4-methoxy-phenyl)-3- nitro-lH-pyridin-2-one (0.3 g, 0.70 mmol), prepared substantially as described in Part C of

Example 19a, and 1-methoxymethyl-propylamine (0.28 g, 2.79 mmol) were treated substantially as described in Part C of Example 19a to produce 35 mg (13%) of crade [4-(2- chloro-5-fluoro-4-methoxy-phenyl)-3-nitro-pyridin-2-yl]-(l-methoxymethyl-propyl)-amine.

PARTD

[00265] [4-(2-Chloro-5-fluoro-4-methoxy-phenyl)-3-nitro-pyridin-2-yl]-(l- methoxymethyl-propyl)-amine (35 mg, 0.09 mmol) and SnCl₂ (51 mg, 0.27 mmol) were treated substantially as described in Part D of Example 74a to yield 30 mg (94%) of 4-(2-

Chloro-5-fluoro-4-methoxy-phenyl)-N²-(l-methoxymethyl-propyl)-pyridine-2,3-diamine:

MS (El) m/z 354.22 [(M+H)⁺, 100].

PARTE

[00266] 4-(2-Chloro-5-fluoro-4-methoxy-phenyl)-N²-(l-methoxymethyl-propyl)- pyridine-2,3-diamine (30 mg, 0.084 mmol) was treated substantially as described in Part F of Example 9 to give 3.3 mg (10%) of 8-(2-Chloro-5-fluoro-4-methoxy-phenyl)-4-(l- methoxymethyl-propyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 250): 1H NMR (400 MHz, CDC1₃) δ ppm 8.55 (d, 7=4.89 Hz, 1 H), 7.21 (d, 7=4.89 Hz, 1 H) 7.11 (d, 7=2.94 Hz, 1 H), 7.08 (d, 7=2.20 Hz, 1 H), 5.88 (m, 1 H), 4.33 (m, 1 H), 3.95 (s, 3 H), 3.81 (m, 1 H), 3.32 (s, 3 H), 2.48 (s, 3 H), 2.11 (d, 7=95.37 Hz, 2 H), 0.86 (t, 7=7.46 Hz, 3 H). MS (El) m/z 406.29 [(M+H)+, 100].

Example 449a

(R)-3-Chloro-4-[4-(l-methoxymethyl-propyl)-2-methyl-3-oxo-3,4-dihydro- pyrido[2,3-b]pyrazin-8-yl-benzonitrile

PARTA

[00267] To a solution of POCl₃ (100 mL) was added 2,4-hydroxy-3-nitropyridine (10.0 g, 64.1 mmol) and the reaction heated at reflux overnight. The reaction mixture was cooled and slowly added to an ice-water solution. The solution was extracted with EtOAc and the organic layer was dried (Na₂SO₄), filtered and concentrated in vacuo. The dark brown oil was purified by filtration through silica gel with 50% EtOAc/Hex to yield 4.31 g, 35% of 2,4- dichloro-3-nitropyridine as a dark yellow solid. Reaction was monitored by thin layer chromatography for completion.

PARTB

[00268] 2,4-Dichloro-3-nitropyridine (1.0 g, 5,18 mmol) was dissolved in EtOH (20 mL), followed by the addition of Et₃N (1.05 g, 10.4 mmol) and (R)- 1-methoxymethyl- propylamine (0.72 g, 5.18 mmol) and the reaction was heated at 60 °C for 3 h. The reaction was concentrated in vacuo to yield 2.09 g of (i?)-(4-chloro-3-nitro-pyridin-2-yl)-(l- methoxymethyl-propyl)-amine as a crade viscous oil: MS (AP) m/z 259.69 [(M+H)+, 97].

PART C

[00269] (i?)-(4-Chloro-3-nitropyridin-2-yl)-(l-methoxymethyl-propyl)-amine (2.09 g,

8.05 mmol) was dissolved in ether (30 mL) and cooled to 0 °C. Next, SnCl₂»2H₂0 (18.1 g, 80.5 mmol) in cone. HCl (10 mL) was added, dropwise at 0 °C and stined at room temperature for 4 h. The reaction mixture was poured over ice water containing 50% NaOH solution (20 mL) and extracted with EtOAc (2x). The aqueous layer was filtered through celite, then extracted with EtOAc (2x). The combined organic layers were dried (Na₂SO₄), filtered, and concentrated in vacuo. The crade product was purified by column chromatography (20% EtOAc/Hex) to yield 0.24 g, 13% of (R)-4-chloro-N²-(l- methoxymethyl-propyl)-ρyridine-2,3-diamine: MS (AP) m/z 229.71 [(M+H)+, 100].

PARTD

[00270] (R)-4-Chloro-N²-(l-methoxymethyl-propyl)-ρyridine-2,3-diamine (0.24 g,

1.04 mmol) was dissolved in n-BuOH, followed by methyl pyravate (1.07 g, 10.4 mmol) and the reaction was heated at 60 °C for 5 h, before heating at reflux overnight. The reaction was concentrated in vacuo and purified by column chromatography (20% EtOAc/hex) to yield 0.39 g, 100% ^* of (R)-8-chloro-4-(l-methoxymethylpropyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one: MS (AP) m/z 281.74 [(M+Η)+, 100].

PARTE

[00271] (R)-8-Chloro-4-(l-methoxymethyl-proρyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one (0.39 g, 1.38 mmol) was dissolved in EtOΗ/toluene (1:4), followed by Na₂CO₃ (2M, 1.73 mL, 3.46 mmol), 2-chloro-4-cyanophenyl boronic acid (0.38 g, 2.08 mmol) and Pd₂(PPh₃)₂Cl₂ (0.048 g, 0.069 mmol) and refluxed for 5 h. The reaction was cooled to room temperature, extracted with EtOAc, washed with Η O, brine, dried (MgSO₄), filtered and concentrated in vacuo. Purification by HPLC yielded 13.10 mg, 3% of (R)-3- chloro-4-[4-(l-methoxymethyl-propyl)-2-methyl-3-oxo-3,4-dihydro-pyrido[2,3-b]pyrazin-8- yl-benzonitrile (Ex. 449a): MS (ESI) 382.85 [(M+H)+, 100].

Example 452 8-(5-Chloro-4-methoxy-2-methyl-phenyl)-4-(l-cyclopropyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one PARTA

[00272] 2-Benzyloxy-4-chloro-3-nitro-pyridine (Wilde, et. al. WO 99/01454) (774 mg,

2.81 mmol) and 2-methyl-5-chloro-4-methoxyphenylboronic acid (prepared as described in Speicher, A.; Kolz, I.; Sambanje, R.P. Synthesis, 2002, 17, 2503) (620 mg, 3.09 mmol) were treated substantially as described in Part A of Example 19a to give 1.15 g (47%) of 2- benzyloxy-4-(5-chloro-4-methoxy-2-methyl-phenyl)-3-nitro-pyridine: 1H NMR (400 MHz, CDC1₃) δ ppm 8.26 (d, 7=5.1 Hz, 1 H), 7.45-7.42 (m, 2H), 7.39-7.30 (m, 3H), 7.13 (s, IH),

6.82 (d, 7=5.1 Hz, 1 H), 6.79 (s, 1 H), 5.54 (s, 2 H), 3.90 (s, 3H), 2.14 (s, 3H).

PART B

[00273] 2-Benzyloxy-4-(5-chloro-4-methoxy-2-methyl-phenyl)-3-nitro-pyridine (1.0g,

2.6 mmol) was treated substantially as described in Part B of Example 19a to give 4-(5- chloro-4-methoxy-2-methyl-phenyl)-3-nitro-lH-pyridin-2-one (0.75 g, 98%): MS (El) m/z 295.14 [(M+H)⁺, 100].

PART C

[00274] Trifluoro-methanesulfonic acid 4-(5-chloro-4-methoxy-2-methyl-phenyl)-3- nitro-pyridin-2-yl ester (0.33 g, 0.76 mmol), prepared substantially as described in Part C of Example 19a, and l-cyclopropyl-propylamine (0.25 g, 1.92 mmol) were treated substantially as described in Part C of Example 19a to produce 0.13 g (45%) of crade (1-cyclopropyl- propyl)-[4-(5-fluoro-4-methoxy-2-methyl-phenyl)-3-nitro-pyridin-2-yl]-amine: MS (El) m z 376.2 [(M+H)⁺, 100].

PARTD

[00275] (l-Cyclopropyl-propyl)-[4-(5-fluoro-4-methoxy-2-methyl-phenyl)-3-nitro- pyridin-2-yl]-amine (0.13 g, 0.34 mmol) and SnCl₂ (0.19 g, 1.0 mmol) were treated substantially as described in Part D of Example 74a to yield 0.12 g (96%) of 4-(5-chloro-4- methoxy-2-methyl-phenyl)-N²-(l-cyclopropyl-propyl)-pyridine-2,3-diamine.

PARTE

[00276] 4-(5-Chloro-4-methoxy-2-methyl-phenyl)-N²-(l-cyclopropyl-propyl)- pyridine-2,3-diamine (0.12 g, 0.33 mmol) was treated substantially as described in Part F of Example 9 to give 30 mg (23%) of 8-(5-chloro-4-methoxy-2-methyl-phenyl)-4-(l- cyclopropyl-propyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 452): 1H NMR (400 MHz, CDC1₃) δ ppm 8.48 (d, 7=4.89 Hz, 1 H), 7.24 (s, 1 H), 7.12 (d, 7=4.89 Hz, 1 H), 6.87 (s, 1 H), 4.79 (m, 1 H), 3.96 (s, 3 H), 2.51 (s, 3 H), 2.26 (m, 2 H), 2.10 (s, 3 H), 0.88 (m, 1 H), 0.87 (t, 7=6.72 Hz, 3 H), 0.70 (m, 1 H), 0.49 (m, 1 H), 0.34 (m, 1 H), 0.17 (m, 1 H). MS (El) m/z 400.21 [(M+H)+, 100].

Example 459 8-(5-Chloro-4-methoxy-2-methyl-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PART A and B

[00277] 4-(5-Chloro-4-methoxy-2-methyl-phenyl)-3-nitro-lH-pyridin-2-one was prepared substantially as described in Example 452.

PART C

[00278] Trifluoro-methanesulfonic acid 4-(5-chloro-4-methoxy-2-methyl-phenyl)-3- nitro-pyridin-2-yl ester (0.38 g, 0.89 mmol) and 1-methoxymethyl-propylamine (0.23 g, 2.23 mmol) were treated substantially as described in Part C of Example 19a to produce 0.13 g (40%) of crude [4-(5-chloro-4-methoxy-2-methyl-phenyl)-3-nitro-pyridin-2-yl]-(l- methoxymethyl-ρropyl)-amine: MS (El) m z 380.19 [(M+H)⁺, 100].

PARTD

[00279] [4-(5-Chloro-4-methoxy-2-methyl-phenyl)-3-nitro-pyridin-2-yl]-(l- methoxymethyl-propyl)-amine (0.13 g, 0.34 mmol) and SnCl₂ (0.19 g, 1.03 mmol) were treated substantially as described in Part D of Example 74a to yield 0.12 g (99%) of (S)-4-(2- chloro-5-fluoro-4-methoxy-phenyl)-N²-(l-cyclopropyl-propyl)-pyridine-2,3-diamine: MS (El) m/z 350.25 [(M+H)⁺, 100].

PARTE

[00280] 4-(5-Chloro-4-methoxy-2-methyl-phenyl)-N²-(l-methoxymethyl-propyl)- pyridine-2,3-diamine (0.11 g, 0.32 mmol) was treated substantially as described in Part F of Example 9 to give 48 mg (38%) of 8-(5-chloro-4-methoxy-2-methyl-phenyl)-4-(l- methoxymethyl-propyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 459): 1H NMR (400 MHz, CDC1₃) δ ppm 8.50 (d, 7=4.89 Hz, 1 H), 7.24 (s, 1 H), 7.12 (d, 7=4.89 Hz, 1 H), 6.86 (s, 1 H), 5.89 (m, 1 H), 4.38 (m, 1 H), 3.96 (s, 3 H), 3.81 (m, 1 H), 3.32 (s, 3 H), 2.47 (s, 3 H), 2.29 (m, 1 H), 2.09 (s, 3 H), 1.98 (m, 1 H), 0.85 (t, 7=7.46 Hz, 3 H). MS (El) m/z 402.20 [(M+H)+, 100].

Example 484 8-(2-Chloro-4-methoxy-5-methyl-phenyl)-4-(l-cyclopropyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PARTA

[00281] 2-Benzyloxy-4-chloro-3-nitro-pyridine (Wilde, et. al. WO 99/01454) (924 mg,

3.49mmol) and 2-chloro-5-methyl-4-methoxyphenylboronic acid (prepared substantially as described in Speicher, A.; Kolz, J.; Sambanje, R.P. Synthesis, 2002, 17, 2503) (770 mg, 3.84 mmol) were treated substantially as described in Part A of Example 19a to give 514 mg (39%) of 2-benzyloxy-4-(2-chloro-4-methoxy-5-methyl-phenyl)-3-nitro-pyridine: 1H NMR (400 MHz, CDC1₃) δ ppm 8.27 (d, 7=5.4 Hz, 1 H), 7.47-7.44 (m, 2H), 7.40-7.30 (m, 3H), 7.00 (s, IH), 6.94 (d, 7=5.4 Hz, 1 H), 6.90 (s, 1 H), 5.55 (s, 2 H), 3.84 (s, 3 H), 2.17 (s, 3 H). PARTB

[00282] 2-Benzyloxy-4-(2-chloro-4-methoxy-5-methyl-phenyl)-3-nitro-pyridine (0.5 g,

1.30 mmol) was treated substantially as described in Part B of Example 19a to give 4-(2- chloro-4-methoxy-5-methyl-phenyl)-3-nitro-lH-pyridin-2-one (0.38 g, 100%): MS (El) m z 295.11 [(M+H)⁺, 100].

PART C

[00283] Trifluoro-methanesulfonic acid 4-(2-chloro-4-methoxy-5-methyl-phenyl)-3- nitro-pyridin-2-yl ester (0.22 g, 0.51 mmol), prepared substantially as described in Part C of Example 19a, and l-cyclopropyl-propylamine (0.17 g, 1.29 mmol) were treated substantially as described in Part C of Example 19a to produce 90 mg (47%) of crude [4-(2-chloro-4- methoxy-5-methyl-phenyl)-3-nitro-pyridin-2-yl]-(l-cyclopropyl-propyl)-amine: MS (El) m/z 376.18 [(M+H)⁺, 100].

PARTD

[00284] [4-(2-Chloro-4-methoxy-5-methyl-ρhenyl)-3-nitro-ρyridin-2-yl]-(l- cyclopropyl-propyl)-amine (90 mg, 0.24 mmol) and SnCl₂ (0.13 g, 0.72 mmol) were treated substantially as described in Part D of Example 74a to yield 80 mg (98%) of 4-(2-chloro-4- methoxy-5-methyl-phenyl)-N -(l-cyclopropyl-propyl)-pyridine-2,3-diamine: MS (El) m z 346.22 [(M+H)⁺, 100].

PARTE

[00285] 4-(2-Chloro-4-methoxy-5-methyl-phenyl)-N²-(l-cyclopropyl-propyl)- pyridine-2,3-diamine (80 mg, 0.23 mmol) was treated substantially as described in Part F of Example 9 to give 7.4 mg (8%) of 8-(2-Chloro-4-methoxy-5-methyl-phenyl)-4-(l- cyclopropyl-propyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 484): 1H NMR (400 MHz, CDC1₃) δ ppm 8.42 (d, 7=4.89 Hz, 1 H), 7.17 (d, 7=4.89 Hz, 1 H), 7.11 (s, 1 H), 6.95 (s, 1 H), 4.74 (m, 1 H), 3.91 (m, 3 H), 2.51 (m, 3 H), 2.34 (m, 1 H), 2.22 (m, 3 H), 2.08 (m, 1 H), 0.89 (m, 1 H), 0.86 (s, 3 H), 0.70 (m, 1 H), 0.46 (m, 1 H), 0.32 (m, 1 H), 0.17 (m, 1 H). MS (El) m/z 398.23 [(M+H)+, 100].

Example 491 8-(2-Chloro-4-methoxy-5-methyl-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PART A and B

[00286] 4-(2-Chloro-4-methoxy-5-methyl-phenyl)-3-nitro- lH-pyridin-2-one was prepared substantially as described in Example 484.

PART C

[00287] Trifluoro-methanesuTfonic acid 4-(2-chloro-4-methoxy-5-methyl-phenyl)-3- nitro-pyridin-2-yl ester (0.22 g, 0.51 mmol) and 1-methoxymethyl-propylamine (0.13 g, 1.29 mmol) were treated substantially as described in Part C of Example 19a to produce 92 mg (47%) of crude [4-(5-chloro-4-methoxy-2-methyl-phenyl)-3-nitro-pyridin-2-yl]-(l- methoxymethyl-propyl)-amine: MS (El) m/z 380.24 [(M+H)⁺, 100].

PARTD

[00288] [4-(5-Chloro-4-methoxy-2-methyl-phenyl)-3-nitro-pyridin-2-yl]-(l- methoxymethyl-propyl)-amine (90 mg, 0.24 mmol) and SnCl₂ (0.13 g, 0.71 mmol) were treated substantially as described in Part D of Example 74a to yield 82 mg (99%) of 4-(2- Chloro-4-methoxy-5-methyl-phenyl)-N²-(l-methoxymethyl-propyl)-pyridine-2,3-di amine: MS (El) m/z 350.23 [(M+H)⁺, 100].

PARTE

[00289] 4-(2-Chloro-4-methoxy-5-methyl-phenyl)-N²-(l-methoxymethyl-propyl)- pyridine-2,3-diamine (82 mg, 0.22 mmol) was treated substantially as described in Part F of Example 9 to give 17.5 mg (19%) of 8-(2-chloro-4-methoxy-5-methyl-phenyl)-4-(l- methoxymethyl-propyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 491): 1H NMR (400 MHz, CDC1₃) δ ppm 8.51 (d, 7=4.89 Hz, 1 H), 7.20 (d, 7=4.89 Hz, 1 H), 7.09 (s, 1 H), 6.95 (s, 1 H), 5.89 (m, 1 H), 4.38 (m, 2 H), 3.88 (s, 3 H), 3.33 (m, 3 H), 2.48 (s, 3 H), 2.21 (s, 3 H), 2.09 (m, 2 H), 0.86 (t, 7=7.46 Hz, 3 H). MS (El) m/z 402.20 [(M+H)+, 100].

Example 500 8-(2-Chloro-4-dimethylamino-5-fluoro -phenyl)-4-(l-cyclopropyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PART A and B

[00290] 4-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-3-nitro-lH-pyridin-2-one was prepared substantially as described in Example 507.

PART C

[00291] Trifluoro-methanesulfonic acid 4-(2-chloro-4-dimethylamino-5-fluoro- phenyl)-3-nitro-pyridin-2-yl ester (548 mg, 1.76 mmol) and l-cyclopropyl-propylamine HCl (479 mg, 3.5 mmol) were treated substantially as described in Part C of Example 19a to produce 300 mg (43%) of crade [4-(2-chloro-4-dimethylamino-5-fluoro-phenyl)-3-nitro- pyridin-2-yl]-(l-cyclopropyl-propyl)-amine: MS (El) m/z 393.22 [(M+H)⁺, 100].

PARTD

[00292] [4-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-3-nitro-pyridin-2-yl]-(l- cyclopropyl-propyl)-amine (300 mg, 0.76 mmol) and SnCl₂*H₂O (1.2 g, 6.1 mmol) were treated substantially as described in Part D of Example 74a to yield 276 mg of crude 4-(2- chloro-4-dimethylamino-5-fluoro-phenyl)-N²-(l-cyclopropyl-propyl)-pyridine-2,3-di amine: MS (El) m/z 363.24 [(M+H)⁺, 100]. PARTE

[00293] 4-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-N²-(l-cyclopropyl-propyl)- pyridine-2,3-diamine (299 mg, 0.76 mmol) was treated substantially as described in Part F of Example 9 to give 20 mg (6 % for 4 steps) of 8-(2-chloro-4-dimethylamino-5-fluoro-phenyl)- 4-(l-cyclopropyl-propyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 500): 1H NMR (400 MHz, CDC1₃) δ ppm 8.52 (d, 7=4.65 Hz, 1 H), 7.60 (d, 7=7.09 Hz, 1 H), 7.27 (m, 1 H), 7.19 (d, 7=4.65 Hz, 1 H), 5.01 (m, 1 H), 3.26 (s, 6 H), 2.51 (s, 3 H), 2.25 (m, 2 H), 0.86 (t, 7=7.34 Hz, 3 H), 0.73 (m, 1 H), 0.48 (m, 1 H), 0.34 (m, 1 H), 0.21 (m, 1 H), 0.13 (m, 1 H). MS (El) m/z 415.26 [(M+H)+, 100].

Example 501a (R)-8-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-4-(l-cyclopropyl-ethyl)-2-methyl-

4H-pyrido[2,3-b]pyrazin-3-one

PART A and B

[00294] 4-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-3-nitro-lH-pyridin-2-one was prepared substantially as described in Example 507.

PART C

[00295] Trifluoro-methanesulfonic acid 4-(2-chloro-4-dimethylamino-5-fluoro- phenyl)-3-nitro-pyridin-2-yl ester TFA (1.06 g, 2.49 mmol) and (Z?)-l-cyclopropyl- ethylamine HCl (202 mg, 1.7 mmol) were treated substantially as described in Part C of

Example 19a to produce 314 mg of cmde (_Jrv)-[4-(2-chloro-4-dimethylamino-5-fluoro- phenyl)-3-nitro-pyridin-2-yl]-(l-cyclopropyl-ethyl)-amine. PARTD

[00296] (R)-[4-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-3-nitro-pyridin-2-yl]-(l- cyclopropyl-ethyl)-amine (314 mg, 0.83 mmol) and SnCl₂«H₂O (472 mg, 2.5 mmol) were treated substantially as described in Part D of Example 74a to yield 276 mg of cmde (R)-4-(2- chloro-4-dimethylamino-5-fluoro-phenyl)-N²-(l-cyclopropyl-ethyl)-pyridine-2,3-diamine:

MS (El) m/z 349.24 [(M+H)⁺, 100].

PARTE

[00297] (R)-4-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-N²-(l-cyclopropyl-ethyl)- pyridine-2,3-diamine (290 mg, 0.83 mmol) was treated substantially as described in Part F of Example 9 to give 22.5 mg (8% for 4 steps) of (R)-8-(2-chloro-4-dimethylamino-5-fluoro- phenyl)-4-(l-cyclopropyl-ethyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 501a): 1H NMR (400 MHz, CDC1₃) δ ppm 8.47 (d, 7=4.65 Hz, 1 H), 7.20 (d, 7=4.65 Hz, 1 H), 7.14 (d, 7=8.07 Hz, 1 H), 7.08 (d, 7=12.96 Hz, 1 H), 4.85 (m, 1 H), 3.02 (s, 6 H), 2.50 (s, 3 H), 1.25 (s, 3 H), 0.87 (m, 1 H), 0.67 (m, 1 H), 0.42 (m, 2 H), 0.22 (m, 1 H). MS (El) m/z 401.20 [(M+H)+, 100].

Example 503a (R)-8-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-4-(l-cyclobutyl-ethyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one

PART A and B

[00298] 4-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-3-nitro-lH-pyridin-2-one was prepared substantially as described in Example 507. PART C

[00299] Trifluoro-methanesulfonic acid 4-(2-chloro-4-dimethylamino-5-fmoro- phenyl)-3-nitro-pyridin-2-yl ester TFA (1.1 g, 2.49 mmol) and (i?)-l-cyclobutyl-ethylamine

HCl (225 mg, 1.7 mmol) were treated substantially as described in Part C of Example 19a to produce 326 mg of crade (i?)-[4-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-3-nitro- pyridin-2-yl]-(l-cyclobutyl-ethyl)-amine.

PARTD

[00300] (R)- [4-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-3-nitro-pyridin-2-yl] -( 1 - cyclobutyl-ethyl)-amine (326 mg, 0.83 mmol) and SnCl₂»H₂O (472 mg, 2.5 mmol) were treated substantially as described in Part D of Example 74a to yield 301 mg of crade (R)-4-(2- Chloro-4-dimethylamino-5-fluoro-phenyl)-N²-(l-cyclobutyl-ethyl)-pyridine-2,3-di amine: MS (El) m z 363.24 [(M+H)⁺, 100].

PARTE

[00301] (R)-4-(2-Chloro-4-dimethylamino-5-fluoro-ρhenyl)-N²-(l-cyclobutyl-ethyl)- pyridine-2,3-diamine (301 mg, 0.83 mmol) was treated substantially as described in Part F of Example 9 to give 8.5 mg (3% for 4 steps) of (R)-8-(2-Chloro-4-dimethylamino-5-fluoro- phenyl)-4-(l-cyclobutyl-ethyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 503a): 1H NMR (400 MHz, CDC1₃) δ ppm 8.52 (br s, 1 H), 7.17 (br s, 1 H), 7.04 (d, 7=13.20 Hz, 1 H), 6.99 (d, 7=8.07 Hz, 1 H), 5.70 (d, 1 H), 2.96 (s, 6 H), 2.49 (m, 3 H), 1.79 (m, 4 H), 1.51 (m, 2 H), 1.28 (m, 1 H), 1.25 (s, 3 H). MS (El) m/z 415.24 [(M+H)+, 100].

Example 506 8-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-4-(2-methoxy-l-methyl-ethyl)-2-methyl-

4H-pyrido[2,3-b]pyrazin-3-one PART A and B

[00302] 4-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-3-nitro- lH-pyridin-2-one was prepared substantially as described in Example 507.

PART C

[00303] Trifluoro-methanesulfonic acid 4-(2-chloro-4-dimethylamino-5-fluoro- phenyl)-3-nitro-pyridin-2-yl ester TFA (1.1 g, 2.49 mmol) and 2-methoxy-l-methyl- ethylamine HCl (208 mg, 1.7 mmol) were treated substantially as described in Part C of Example 19a to produce 318 mg of crude [4-(2-chloro-4-dimethylamino-5-fluoro-phenyl)-3- nitro-pyridin-2-yl]-(2-methoxy-l-methyl-ethyl)-amine.

PARTD

[00304] [4-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-3-nitro-pyridin-2-yl]-(2- methoxy-l-methyl-ethyl)-amine (318 mg, 0.83 mmol) and SnCl₂«H₂O (472 mg, 2.5 mmol) were treated substantially as described in Part D of Example 74a to yield 290 mg of crade 4-

(2-chloro-4-dimethylamino-5-fluoro-phenyl)-N²-(2-methoxy-l-methyl-ethyl)-pyridine-2,3- diamine: MS (El) m/z 353.23 [(M+H)⁺, 100].

PARTE

[00305] 4-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-N²-(2-methoxy-l-methyl- ethyl)-pyridine-2,3-diamine (290 mg, 0.83 mmol) was treated substantially as described in Part F of Example 9 to give 22.5 mg (8% for 4 steps) of 8-(2-chloro-4-dimethylamino-5- fluoro-phenyl)-4-(2-methoxy-l-methyl-ethyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 506): 1H NMR (400 MHz, CDC1₃) δ ppm 8.53 (d, 7=4.65 Hz, 1 H), 7.26 (d, 7=7.58 Hz, 1 H), 7.20 (d, 7=4.65 Hz, 1 H), 7.11 (d, 7=12.72 Hz, 1 H), 5.88 (m, 1 H), 4.39 ( , 1 H), 3.79 (m, 1 H), 3.34 (s, 3 H), 3.08 (s, 6 H), 2.49 (s, 3 H), 1.60 (d, 7=6.85 Hz, 3 H). MS (El) m/z 405.23 [(M+H)+, 100].

Example 507 8-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-

4H-pyrido[2,3-b]pyrazin-3-one

PARTA

[00306] 2-Benzyloxy-4-chloro-3-nitro-pyridine (Wilde, et. al. WO 99/01454) (800 mg,

3.02 mmol) and 2-chloro-4-dimethylamino-5-fluorophenylboronic acid (Example B) (854 mg, 3.93 mmol) were treated substantially as described in Part A of Example 19a to give 715 mg (59%) of 2-benzyloxy-4-(2-chloro-4-dimethylamino-5-fluoro-phenyl)-3-nitro-pyridine: 1H NMR (400 MHz, CDC1₃) δ ppm 8.27 (d, 7=5.4 Hz, 1 H), 7.45-7.43 (m, 2H), 7.40-7.29 (m, 3H), 6.93 (d, 7=5.4 Hz, 1 H), 6.89 (d, 7=13.2 Hz, 1 H), 6.85 (d, 7=8.0 Hz, 1 H), 5.53 (s, 2 H), 2.91 (d, 7=1.2 Hz, 6 H).

PARTB

[00307] 2-Benzyloxy-4-(2-chloro-4-dimethylamino-5-fluoro-phenyl)-3-nitro-pyridine

(2.8 g, 7.0 mmol) was treated substantially as described in Part B of Example 19a to give 4- (2-chloro-4-dimethylamino-5-fluoro-phenyl)-3-nitro-lH-pyridin-2-one TFA (3.0 g, 100%): : 1H NMR (400 MHz, CDC1₃) δ ppm 7.59 (d, 7=6.7 Hz, 1 H), 6.99 (d, 7=7.8 Hz, 1 H), 6.96 (d, 7=12.7 Hz, 1 H), 6.54 (d, 7=6.7 Hz, 1 H), 2.99 (d, 7=1.2 Hz, 6 H).

PART C

[00308] Trifluoro-methanesulfonic acid 4-(2-chloro-4-dimethylamino-5-fluoro- phenyl)-3-nitro-pyridin-2-yl ester TFA (39.6 mg, 0.093 mmol), prepared substantially as described in Part C of Example 19a, and 1-methoxymethyl-propylamine (191.0 mg, 1.85 mmol) were treated substantially as described in Part C of Example 19a to produce 30 mg (81 %) of crade [4-(2-chloro-4-dimethylamino-5-fluoro-phenyl)-3-nitro-pyridin-2-yl]-(l- methoxymethyl-propyl)-amine: MS (El) m/z 397.19 [(M+H)⁺, 100].

PARTD

[00309] [4-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-3-nitro-pyridin-2-yl]-(l- methoxymethyl-propyl)-amine (30.0 mg, 0.076 mmol) and SnCl₂»H₂O (43.2 mg, 0.23 mmol) were treated substantially as described in Part D of Example 74a to yield 30 mg (100 % crade) of 4- (2-Chloro-4-dimethylamino-5 -fluoro-phenyl)-N²-( 1 -methoxymethyl-propyl)- pyridine-2,3-diamine: MS (El) m z 367.23 [(M+H)⁺, 100].

PARTE

[00310] 4-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-N²-(l-methoxymethyl- propyl)-pyridine-2,3-diamine (27.9 mg, 0.076 mmol) was treated substantially as described in Part F of Example 9 to give 4 mg of 8-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-4-(l- methoxymethyl-propyl)-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one (Example 507): 1H NMR (400 MHz, CDC1₃) δ ppm 8.55 (d, 7=4.16 Hz, 1 H), 7.20 (d, 7=4.16 Hz, 1 H), 7.10 (d, 7=6.11 Hz, 1 H), 7.07 (d, 7=11.49 Hz, 1 H), 6.15 (m, 1 H), 4.38 (m, 1 H), 3.81 (m, 1 H), 3.32 (m, 3 H), 3.01 (m, 6 H), 2.49 (s, 3 H), 2.11 (m, 2 H), 0.86 (t, 7=7.46 Hz, 3 H). MS (El) m/z 419.25 [(M+H)+, 100].

Example 546 (R,5)-8-sec-Butyl-4-(2,4-dichloro-phenyl)-6-methyl-8H-pteridin-7-one

PART A

[00311] 4,6-Dichloro-5-nitropyrimidine (2.0 g, 0.012 mol) was diluted in EtOH (10 ml) and toluene (40 ml). A 2M Na₂CO₃ (15.0 ml) was added followed by Pd(PPh₃)₂Cl₂ (0.51 g, 0.0007 mol), and 2,4-dichlorophenylboronic acid (0.018 mol). The reaction was warmed to reflux under an inert atmosphere for 5 hours. The reaction was then allowed to cool to room temperature and poured over EtOAc/H₂O. The organic layer was separated and washed with sat'd sodium chloride, dried (MgSO₄), filtered and concentrated. The material was flushed through a plug of silica using 50%EtOAc/hexane as an eluting solvent. The crude material (2.9 g) was concentrated in vacuo and diluted in 20 ml butanol. Sec-butylamine was added to the solution and the mixture warmed to reflux for 18 hours. After concentrating the solution in vacuo and purification on silica gel using 80% EtOAc/hexane as the eluting solvent the desired intermediate N⁴-sec-butyl-6-(2,4-dichloro-phenyl)-pyrimidine-4,5- diamine was isolated (1.49 g, 40%). MS (AP) m/z 311.1 [(M+H)⁺, 100].

PARTB

[00312] N⁴-sec-butyl-6-(2,4-dichloro-phenyl)-pyrimidine-4,5-diamine (0.10 g, 0.00032 mol) was diluted in ethanol (20 ml) and ethyl pyruvate was added (0.68 ml, 0.006 mol). The mixture was stined for 18 hours at which time 10 ml of the solution was removed and concentrated. The residue was diluted in glacial acetic acid (10 ml) and warmed to 100 C for 1 hour. After concentrating the solution the product was purified by reverse phase HPLC to yield 9.8 mg of (R,S)-8-sec-butyl-4-(2,4-dichloro-phenyl)-6-methyl-8H-pteridin-7-one (Example 546). 1H NMR (300 MHz, CD₃OD) δ 9.02 (s, IH), 7.66-7.64 (d, IH), 7.49-7.48 (m, 2H), 5.68 (m, IH), 2.42 (s, 3H), 2.39-2.25 (m, IH), 2.01-2.15 (m, IH), 1.64-1.62 (d, 3H), 0.89-0.84 (t, 3H). MS (AP) 363.1 [(M+H)+, 100], 404.1 [(M+H+ACN)+, 20].

Example 563 4-(2-Chloro-4-methoxy-phenyl)-6-methyl-8-(l-propyl-butyl)-8H-pteridin-7-one

I

PARTA

[00313] 4,6-Dichloro-5-arninopyrimidine (5.8 g, 0.036 mol) was diluted in EtOH (25 ml) and toluene (100 ml). A 2M Na₂CO₃ (45.0 ml) was added followed by Pd(PPh₃)₂Cl₂ (1.5 g, 0.0021 mol), and 2-chloro-4-methoxyphenylboronic acid (0.035 mol). The reaction was warmed to reflux under an inert atmosphere for 5 hours. The reaction was then allowed to cool to room temperature and poured over EtOAc/H₂O. The organic layer was separated and washed with sat'd sodium chloride, dried (MgSO ), filtered and concentrated. The material was flushed through a plug of silica using 50% EtOAc/hexane as an eluting solvent. The crade material was concentrated in vacuo and diluted in 5 ml butanol. 4-Heptyamine was added to the solution and the mixture warmed to reflux for 18 hours. After concentrating the solution in vacuo and purification on silica gel using 80% EtOAc/hexane as the eluting solvent the desired intermediate 6-(2-chloro-4-methoxy-phenyl)-N4-(l-propyl-butyl)- pyrimidine-4,5-diamine was isolated (0.29 g, 73%). MS (AP) 349.3 [(M+H)+, 100].

PART B

[00314] 6-(2-Chloro-4-methoxy-phenyl)-N4-(l-propyl-butyl)-pyrimidine-4,5-diamine

(0.29 g, 0.83 mmol) was diluted in ethanol (8 ml) and ethyl pyravate was added (0.92 ml, 8.3 mmol). The mixture was stined for 18 hours at which time the solution was concentrated. The residue was diluted in glacial acetic acid (10 ml) and warmed to 100 °C for 1 hour. After concentrating the solution the product was purified by reverse phase HPLC to yield 13.5 mg of 4-(2-chloro-4-methoxy-phenyl)-6-methyl-8-(l-propyl-butyl)-8H-pteridin-7-one (Example 563). 1H NMR (300 MHz, CDC1₃) δ ppm 9.02 (s, 1 H), 7.41 (d, 7=8.42 Hz, 1 H), 7.05 (d, 7=2.56 Hz, 1 H), 6.93 (dd, 7=8.42, 2.56 Hz, 1 H), 3.86 (s, 3 H), 4.40 (m, IH), 2.48 (m, 2 H), 2.31 (m, 2 H), 1.89 (m, 2 H), 1.19 (m, 5 H), 0.88 (t, 7=7.32 Hz, 6 H). MS (AP) 321.2 [(M+H)+, 100]. MS (AP) 401.3 [(M+H)+, 100].

Example 565a (R)-4-(2-Chloro-4-methoxy-phenyl)-8-(l-cyclopropyl-ethyl)-6-methyl-8H-pteridin-7-one PARTA

[00315] 4-Chloro-6-(2-chloro-4-methoxy-phenyl)-pyrimidin-5-ylamine (prepared substantially as described in Example 466) (0.25 g, 0.93 mmol) was diluted in butanol (9 mL). (R)-l-Cyclopropyl-ethylamine (0.25g, 2.05 mmol) and triethylamine (0.52 mL, 3.6 mmol) were added to the solution and the mixture warmed to reflux for 18 hours. After concentrating the solution in vacuo and purification on silica gel using 100% EtOAc/hexane as the eluting solvent the desired intermediate (R)-6-(2-chloro-4-methoxy-phenyl)-N4-(l- cyclopropyl-ethyl)-pyrimidine-4,5-diamine was isolated (0.17 g, 57%).

PARTB

[00316] (R)-6-(2-Chloro-4-methoxy-phenyl)-N4-(l-cyclopropyl-ethyl)-pyrimidine-4,5- diamine (0.20 g, 0.52 mmol) was diluted in ethanol (5 ml) and ethyl pyruvate was added (0.58 ml, 5.2 mmol). The mixture was stirred for 18 hours at which time the solution was concentrated. The residue was diluted in glacial acetic acid (10 ml) and warmed to 100 °C for 1 hour. After concentrating the solution the product was purified by reverse phase HPLC to yield 2.0 mg of (i?)-4-(2-chloro-4-methoxy-phenyl)-8-(l-cyclopropyl-ethyl)-6-methyl-8H- pteridin-7-one (Example 565a). 1H NMR (300 MHz, CDC1₃) δ ppm 9.04 (s, 1 H), 7.45 (d, 7=8.42 Hz, 1 H), 7.09 (d, 7=2.56 Hz, 1 H), 6.98 (dd, 7=8.42, 2.56 Hz, 1 H), 4.26 (m, 1 H), 3.91 (s, 3 H), 2.54 (d, 7=7.32, 3 H), 2.18 (m, 3 H), 0.87 (m, 2 H), 0.45 (m, 2 H), 0.26 (m, 1 H). MS (AP) 371.3 [(M+H)+, 100].

Example 567a (5)-4-(2-Chloro-4-methoxy-phenyl)-8-(l-cyclobutyl-ethyl)-6-methyl-8H-pteridin-7-one PARTA

[00317] 4-Chloro-6-(2-chloro-4-methoxy-phenyl)-pyrimidin-5-ylamine (prepared substantially as described in Example 466) (0.23 g, 0.86 mmol) was diluted in butanol (9 mL). (S)-l-Cyclobutyl-ethylamine (0.25g, 1.9 mmol) and triethylamine (0.48 mL, 3.4 mmol) were added to the solution and the mixture warmed to reflux for 18 hours. After concentrating the solution in vacuo and purification on silica gel using 100% EtOAc/hexane as the eluting solvent the desired intermediate (S)-6-(2-chloro-4-methoxy-phenyl)-N4-(l- cyclobutyl-ethyl)-ρyrimidine-4,5-diamine was isolated (0.23 g, 81%). MS (AP) 333.3 [(M+H)+, 100].

PART B

[00318] (S)-6-(2-Chloro-4-methoxy-phenyl)-N4-(l-cyclobutyl-ethyl)-pyrimidine-4,5-

-diamine (0.23 g, 0.69 mmol) was diluted in ethanol (7 ml) and ethyl pyravate was added (0.78 ml, 6.9 mmol). The mixture was stined for 18 hours at which time the solution was concentrated. The residue was diluted in glacial acetic acid (10 ml) and warmed to 100 °C for 1 hour. After concentrating the solution the product was purified by reverse phase HPLC to yield 2.0 mg of (S)-4-(2-chloro-4-methoxy-phenyl)-8-(l-cyclobutyl-ethyl)-6-methyl-8H- pteridin-7-one (Example 567a). 1H NMR (300 MHz, CDC1₃) δ ppm 9.06 (s, 1 H), 7.46 (d, 7=8.79 Hz, 1 H), 7.09 (d, 7=2.56 Hz, 1 H), 6.97 (dd, 7=8.79, 2.56 Hz, 1 H), 5.82 (m, 1 H), 3.91 (s, 3 H), 2.51 (s, 3 H), 2.22 (m, 2 H), 1.87 (m, 4 H), 1.74 (s, 3 H), 1.55 (m, 1 H). MS (AP) 385.3 [(M+H)+, 100].

Example 570a

(R)-4-(2-Chloro-4-methoxy-phenyl)-8-(2-methoxy-l-methyl-ethyl)-6-methyl-8H- pteridin-7-one PARTA

[00319] 4-Chloro-6-(2-chloro-4-methoxy-phenyl)-pyrimidin-5-ylamine (prepared substantially as described in Example 466) (0.28 g, 1.0 mmol) was diluted in butanol (10 mL). (i?)-2-Methoxy-l-methyl-ethylamine (0.29 g, 3.3 mmol) and triethylamine (0.59 mL, 4.0 mmol) were added to the solution and the mixture warmed to reflux for 18 hours. After concentrating the solution in vacuo and purification on silica gel using 100% EtOAc/hexane as the eluting solvent the desired intermediate (i?)-6-(2-chloro-4-methoxy-phenyl)-N4-(2- methoxy-l-methyl-ethyl)-pyrimidine-4,5-diamine (0.26 g, 85%). MS (AP) 321.2 [(M+H)+, 100].

PARTB

[00320] (i?)-6-(2-Chloro-4-methoxy-ρhenyl)-N4-(2-methoxy-l-methyl-ethyl)- pyrimidine-4,5-diamine (0.26 g, 0.82 mmol) was diluted in ethanol (8 ml) and ethyl pyravate was added (0.92 ml, 8.2 mmol). The mixture was stined for 18 hours at which time the solution was concentrated. The residue was diluted in glacial acetic acid (10 ml) and warmed to 100 °C for 1 hour. After concentrating the solution the product was purified by reverse phase HPLC to yield 6.0 mg of (R)-4-(2-chloro-4-methoxy-phenyl)-8-(2-methoxy-l-methyl- ethyl)-6-methyl-8H-ρteridin-7-one (Example 570a). 1H NMR (300 MHz, CDC1₃) δ ppm 9.09 (s, 1 H), 7.43 (d, 7=8.79 Hz, 1 H), 7.09 (d, 7=2.56 Hz, 1 H), 6.97 (dd, 7=8.79, 2.56 Hz, 1 H), 4.39 (m, 3H), 3.91 (s, 3 H), 3.73 (dd, 7=10.07, 5.31 Hz, 2 H), 3.35 (s, 3H), 2.53 (s, 3 H), 1.62 (6, 7=6.96 Hz, 3 H). MS (AP) 375.2 [(M+H)+, 100].

Example 571a

(R)-4-(2-Chloro-4-methoxy-phenyl)-8-(l-methoxymethyl-propyl)-6-methyl-8H-pteridin-

7-one PARTA

[00321] 4-Chloro-6-(2-chloro-4-methoxy-phenyl)-pyrimidin-5-ylamine (prepared substantially as described in Example 466) (0.22 g, 0.81 mmol) was diluted in butanol (8 mL). (R)-2-Ethoxy-l-methyl-ethylamine (0.25 g, 1.8 mmol) and triethylamine (0.45 mL, 3.0 mmol) were added to the solution and the mixture warmed to reflux for 18 hours. After concentrating the solution in vacuo and purification on silica gel using 100% EtOAc/hexane as the eluting solvent the desired intermediate (R)-6-(2-chloro-4-methoxy-phenyl)-N4-(l- methoxymethyl-propyl)-pyrimidine-4,5-diamine (0.20 g, 74%). MS (AP) 337.2 [(M+H)+, 100].

PART B

[00322] (R)-6-(2-Chloro-4-methoxy-phenyl)-N4-(l-methoxymethyl-propyl)- pyrimidine-4,5-diamine (0.20 g, 0.60 mmol) was diluted in ethanol (6 ml) and ethyl pyruvate was added (0.68 ml, 6.0 mmol). The mixture was stined for 18 hours at which time the solution was concentrated. The residue was diluted in glacial acetic acid (10 ml) and warmed to 100 °C for 1 hour. After concentrating the solution the product was purified by reverse phase HPLC to yield 5.0 mg of (R)-4-(2-chloro-4-methoxy-phenyl)-8-(l-methoxymethyl- propyl)-6-methyl-8H-pteridin-7-one (Example 571a). 1H NMR (300 MHz, CDC1₃) δ ppm 9.02 (s, 1 H), 7.41 (d, 7=8.79 Hz, 1 H), 7.05 (d, 7=2.56 Hz, 1 H), 6.93 (dd, 7=8.79, 2.56 Hz, 1 H), 3.87 (s, 3 H), 3.73 (m, 2 H), 3.29 (s, 3 H), 2.63 (m, 2H), 2.49 (s, 3 H), 2.10 (m, 2H), 0.87 (t, 7=7.51 Hz, 3 H). MS (AP) 389.3 [(M+H)+, 100].

Example 612a

(R)-8-(l-Cyclopropyl-propyl)-4-(4-methoxy-2-methyI-phenyl)-6-methyl-8H-pteridin-7- one PARTA

[00323] 4,6-Dichloro-5-aminopyrimidine (2.0 g, 12.0 mmol) was diluted in EtOH (10 ml) and toluene (40 ml). A 2M Na₂CO₃ (15.0 ml) was added followed by Pd(PPh₃)₂Cl₂ (0.51 g, 0.72 mmol), and 4-methoxy-2-methylphenylboronic acid (2.0 g, 12.0 mmol). The reaction was warmed to reflux under an inert atmosphere for 5 hours. The reaction was then allowed to cool to room temperature and poured over EtOAc H₂O. The organic layer was separated and washed with sat'd sodium chloride, dried (MgSO ), filtered and concentrated. The material was flushed through a plug of silica using 50% EtOAc/hexane as an eluting solvent. The cmde material was concentrated in vacuo and diluted in 10 mL butanol. (R)-l- Cyclopropyl-propylamine (0.29 g, 2.11 mmol) and triethylamine (0.45 mL, 3.0 mmol) was added to the solution and the mixture warmed to reflux for 18 hours. After concentrating the solution in vacuo and purification on silica gel using 80% EtOAc/hexane as the eluting solvent the desired intermediate (R)-N4-(l-Cyclopropyl-propyl)-6-(4-methoxy-2-methyl- phenyl)-pyrimidine-4,5-diamine was isolated (0.20 g, 68%).

PART B

[00324] (R)-N4-(l-Cyclopropyl-propyl)-6-(4-methoxy-2-methyl-phenyl)-pyrimidine-

4,5-diamine (0.21 g, 0.67 mmol) was diluted in ethanol (7 ml) and ethyl pyravate was added (0.75 ml, 6.7 mmol). The mixture was stirred for 18 hours at which time the solution was concentrated. After concentrating the solution the product was purified by reverse phase HPLC to yield 2.0 mg of (R)-8-(l-Cyclopropyl-propyl)-4-(4-methoxy-2-methyl-phenyl)-6- methyl-8H-pteridin-7-one (Example 612a). 1H NMR (300 MHz, CDC1₃) δ ppm 8.86 (s, 1 H), 7.33 (d, 7=9.15 Hz, 1 H), 6.80 (d, 7=2.20 Hz, 1 H), 6.78 (d, 7=2.20 Hz, 1 H), 4.56 (m, 1 H), 3.80 (s, 3 H), 2.45 (s, 3 H), 2.30 (m, 1 H), 2.20 (s, 3 H), 2.12 (m, 1 H), 0.81 (t, 7=7.51 Hz, 3 H), 0.76 (m, 1 H), 0.68 (m, 1 H), 0.42 (m, 1 H), 0.29 (m, 1 H), 0.12 (m, 1 H). MS (El) 377.3 [(M- -H)-l-, 100].

Example 644a

(R)-8-(l-Cyclopropyl-propyl)-4-(6-methoxy-2-methyl-pyridin-3-yl)-6-methyl-8H- pteridin-7-one

PARTA

[00325] 4,6-Dichloro-5-aminopyrimidine (2.5 g, 15.0 mmol) was diluted in EtOH (10 ml) and toluene (40 ml). A 2M Na₂CO₃ (18.8 ml) was added followed by Pd(PPh₃)₂Cl₂ (0.63 g, 0.90 mmol), and 2-methoxy-6-methyl pyridine boronic acid (Wilde, et al. WO99/01454) (2.5 g, 15.0 mmol). The reaction was warmed to reflux under an inert atmosphere for 5 hours. The reaction was then allowed to cool to room temperature and poured over EtOAc/H₂O. The organic layer was separated and washed with sat'd sodium chloride, dried (MgSO₄), filtered and concentrated. The material was flushed through a plug of silica using 50% EtOAc/hexane as an eluting solvent. The crade material was concentrated in vacuo and diluted in 10 mL butanol. (R)-l-Cyclopropyl-propylamine (0.29 g, 2.11 mmol) and triethylamine (0.45 mL, 3.0 mmol) was added to the solution and the mixture warmed to reflux for 18 hours. After concentrating the solution in vacuo and purification on silica gel using 80% EtOAc/hexane as the eluting solvent the desired intermediate (R)-N4-(l- cyclopropyl-propyl)-6-(6-methoxy-2-methyl-pyridin-3-yl)-pyrimidine-4,5-diamine was isolated (0.20 g, 68%). MS (AP) 314.3 [(M+H)+, 100].

PARTB

[00326] (i?)-N4-(l-Cyclopropyl-propyl)-6-(6-methoxy-2-methyl-pyridin-3-yl)- pyrimidine-4,5-diamine (0.20 g, 0.64 mmol) was diluted in ethanol (7 ml) and ethyl pyruvate was added (0.73 ml, 6.4 mmol). The mixture was stined for 18 hours at which time the solution was concentrated. After concentrating the solution the product was purified by reverse phase HPLC to yield 2.0 mg of (R)-8-(l-cyclopropyl-propyl)-4-(6-methoxy-2- methyl-pyridin-3-yl)-6-methyl-8H-pteridin-7-one (Example 644a). 1H NMR (300 MHz, CDC1₃) δ ppm 8.92 (s, 1 H), 7.68 (d, 7=8.05 Hz, 1 H), 6.68 (d, 7=9.15 Hz, 1 H), 4.84 (m, 1 H), 3.99 (s, 3 H), ), 2.51 (s, 3 H), 2.39 (s, 3 H), 1.20 (m, 2 H), 0.86 (m, 8 H). MS (El) 366.3 [(M+H)+, 100].

Example 650a

(R)-8-(2-Methoxy-l-methyl-ethyl)-4-(6-methoxy-2-methyl-pyridin-3-yl)-6-methyl-8H- pteridin-7-one

PARTA

[00327] 6-(6-Methoxy-2-methyl-pyridin-3-yl)-pyrimidine-4,5-diamine (prepared substantially as described in Example 644a) (0.25 g, 1.0 mmol) was diluted in 10 mL butanol. (R)- 2-Methoxy-l-methyl-ethylamine (0.28 g, 2.2 mmol) and triethylamine (0.56 mL, 4.0 mmol) was added to the solution and the mixture warmed to reflux for 18 hours. After concentrating the solution in vacuo and purification on silica gel using 100% EtOAc/hexane as the eluting solvent the desired intermediate (R)-N4-(2-methoxy-l-methyl-ethyl)-6-(6~ methoxy-2-methyl-pyridin-3-yl)-pyrimidine-4,5-diamine was isolated (0.22 g, 74%).

PART B

[00328] (i?)-N4-(2-Methoxy-l-methyl-ethyl)-6-(6-methoxy-2-methyl-pyridin-3-yl)- pyrimidine-4,5-diamine (0.22 g, 0.74 mmol) was diluted in ethanol (8 ml) and ethyl pyruvate was added (0.82 ml, 7.4 mmol). The mixture was stined for 18 hours at which time the solution was concentrated. After concentrating the solution the product was purified by preparative TLC eluting with 35% ethyl acetate in hexanes to yield 5.0 mg of (R)-S-(2- methoxy-l-methyl-ethyl)-4-(6-methoxy-2-methyl-pyridin-3-yl)-6-methyl-8H-pteridin-7-one (Example 650a). 1H NMR (300 MHz, CDC1₃) δ ppm 8.99 (s, 1 H), 7.65 (d, 7=8.42 Hz, 1 H), 6.68 (d, 7=8.42 Hz, 1 H), 5.71 (m, IH), 3.99 (s, 3 H), 3.59 (m, 2 H), 3.31 (s, 3 H), 2.50 (s, 3H), 2.50 (s, 3H), 2.50 (s, 3H), 0.85 (d, 7=7.69 Hz, 3 H). MS (El) 356.3 [(M+H)+, 100].

Example 651a

(R)-8-(l-MethoxymethyI-propyl)-4-(6-methoxy-2-methyl-pyridin-3-yI)-6-methyl-8H- pteridin-7-one

PARTA

[00329] 6-(6-Methoxy-2-methyl-pyridin-3-yl)-pyrimidine-4,5-diamine (prepared substantially as described in Example 644a) (0.21 g, 0.84 mmol) was diluted in 10 mL butanol. (R)- 2-Methoxy-l-methyl-ethylamine (0.26 g, 1.8 mmol) and triethylamine (0.47 mL, 3.4 mmol) was added to the solution and the mixture warmed to reflux for 18 hours. After concentrating the solution in vacuo and purification on silica gel using 100% EtOAc/hexane as the eluting solvent the desired intermediate (R)-N4-(l-methoxymethyl- propyl)-6-(6-methoxy-2-methyl-pyridin-3-yl)-pyrimidine-4,5-diamine was isolated (0.20 g, 75%). MS (AP) 318.3 [(M+H)+, 100].

PART B

[00330] (R)-N4-(l-Methoxymethyl-propyl)-6-(6-methoxy-2-methyl-pyridin-3-yl)- pyrimidine-4,5-diamine (0.2 g, 0.63 mmol) was diluted in ethanol (7 ml) and ethyl pyravate was added (0.70 ml, 6.3 mmol). The mixture was stined for 18 hours at which time the solution was concentrated. After concentrating the solution the product was purified by reverse phase HPLC to yield 4.0 mg of (i?)-8-(l-methoxymethyl-propyl)-4-(6-methoxy-2- methyl-pyridin-3-yl)-6-methyl-8H-pteridin-7-one (Example 651a). 1H NMR (300 MHz, CDC1₃) δ ppm 8.93 (s, 1 H), 7.62 (d, 7=8.42 Hz, 1 H), 6.64 (d, 7=8.42 Hz, 1 H), 4.23 (m, IH), 3.94 (s, 3 H), 3.68 (m, 2 H), 3.25 (s, 3 H), 2.45 (s, 3H), 2.34 (s, 3 H), 1.22 (m, 2H), 0.82 (t, 7=7.51 Hz, 3 H). MS (El) 370.3 [(M+H)+, 100].

Example 1013a

(R)-4-(4-Methoxy-2,5-dimethyl-phenyl)-8-(l-methoxymethyl-propyl)-6-methyl-8H- pteridin-7-one

PARTA

[00331] 4,6-Dichloro-5-aminopyrimidine (0.91 g, 5.6 mmol) was diluted in EtOH (5

I ml) and toluene (20 ml). A 2M Na₂CO₃ (6.9 ml) was added followed by Pd(PPh₃)₂Cl₂ (0.23 g, 0.34 mmol), and 4-methoxy-2,5-dimethylphenylboronic acid (Wilde, et al. WO99/01454)(1.0 g, 5.6 mmol). The reaction was warmed to reflux under an inert atmosphere for 5 hours. The reaction was then allowed to cool to room temperature and poured over EtOAc/H₂O. The organic layer was separated and washed with sat'd sodium chloride, dried (MgSO₄), filtered and concentrated. The material was flushed through a plug of silica using 100% EtOAc/hexane as an eluting solvent. The crude material was concentrated in vacuo and diluted in 10 mL butanol. (R)-l-Cyclopropyl-propylamine (0.21 g, 0.82 mmol) and triethylamine (0.46 mL, 3.3 mmol) was added to the solution and the mixture warmed to reflux for 18 hours. After concentrating the solution in vacuo and purification on silica gel using 100% EtOAc/hexane as the eluting solvent the desired intermediate (R)-6-(4- methoxy-2,5-dimethyl-phenyl)-N4-(l-methoxymethyl-propyl)-pyrimidine-4,5-diamine was isolated (0.22 g, 82%).

PART B

[00332] (R)-6-(4-Methoxy-2,5-dimethyl-phenyl)-N4-(l-methoxymethyl-propyl)- pyrimidine-4,5-diamine (0.22 g, 0.68 mmol) was diluted in ethanol (7 ml) and ethyl pyruvate was added (0.76 ml, 6.8 mmol). The mixture was stined for 18 hours at which time the solution was concentrated. After concentrating the solution the product was purified by reverse phase HPLC to yield 8.0 mg of (i?)-4-(4-methoxy-2,5-dimethyl-phenyl)-8-(l- methoxymethyl-propyl)-6-methyl-8H-pteridin-7-one (Example 1013a). 1H NMR (300 MHz, CDC1₃) δ ppm 9.05 (s, 1 H), 7.21 (s, 1 H), 6.79 (s, 1 H), 4.86 (m, 1 H), 3.91 (s, 3 H), 2.55 (m, 3 H), 2.38 (m, 1 H), 2.22 (s, 3 H), ), 2.22 (s, 3 H), 2.04 (m, 1 H), 1.25 (m, 1 H), 0.89 (t, 7=7.51 Hz, 3 H), 0.77 (m, 1 H), 0.50 (m, 1 H), 0.39 (m, 1 H), 0.18 (m, 1 H). MS (El) 379.3 [(M+H)+, 100].

Example 1061a

(R)-4-(2-Chloro-4-trifluoromethoxy-phenyl)-8-(l-cyclopropyl-propyl)-6-methyl-8H- pteridin-7-one

PARTA

[00333] 4,6-Dichloro-5-aminopyrimidine (1.0 g, 6.3 mmol) was diluted in EtOH (10 ml) and toluene (40 ml). A 2M Na₂CO₃ (7.9 ml) was added followed by Pd(PPh₃)₂Cl₂ (0.26 g, 0.38 mmol), and 2-chloro-4-trimfluoromethoxyphenyl boronic acid ((prepared as described in Arvanitis, A.G.; Rescinito, I.T.; Arnold, C.R.; Wilde, R.G.; Cain, G.A.; Sun, J.H.; Yan, J.- S., Teleha, C.A.; Fitzgerald, L.W.; McElroy, J.; Zaczek, R. Bioorg. Med. Chem. Lett., 2003, 13, 129) (1.5 g, 6.3 mmol). The reaction was warmed to reflux under an inert atmosphere for 5 hours. The reaction was then allowed to cool to room temperature and poured over EtOAc/H₂O. The organic layer was separated and washed with sat'd sodium chloride, dried (MgSO₄), filtered and concentrated. The material was flushed through a plug of silica using 100% EtOAc/hexane as an eluting solvent. The crade material was concentrated in vacuo. A portion of 6-(2-Methyl-4-trifluoromethoxy-phenyl)-pyrimidine-4,5-diamine (0.33 g, 1.0 mmol) was diluted in 10 mL butanol. (R)-l-Cyclopropyl-propylamine (0.33 g, 2.2 mmol) and triethylamine (0.57 mL, 4.0 mmol) was added to the solution and the mixture warmed to reflux for 18 hours. After concentrating the solution in vacuo and purification on silica gel using 100% EtOAc/hexane as the eluting solvent the desired intermediate (R)-N4-(l- cyclopropyl-propyl)-6-(2-methyl-4-trifluoromethoxy-phenyl)-pyrimidine-4,5-diamine was isolated (0.31 g, 79%). MS (AP) 387.3 [(M+H)+, 100].

PART B

[00334] (R)-N4-(l-Cyclopropyl-propyl)-6-(2-methyl-4-trifluoromethoxy-phenyl)- pyrimidine-4,5-diamine (0.31 g, 0.80 mmol) was diluted in ethanol (8 ml) and ethyl pyruvate was added (0.89 ml, 8.0 mmol). The mixture was stined for 18 hours at which time the solution was concentrated. After concentrating the solution the product was purified by reverse phase HPLC to yield 6.0 mg of (R)-4-(2-Chloro-4-trifluoromethoxy-phenyl)-8-(l- cyclopropyl-ρropyl)-6-methyl-8H-pteridin-7-one (Example 1061a). 1H NMR (300 MHz, CDC1₃) δ ppm 8.91 (s, 1 H), 7.47 (d, 7=8.42 Hz, 1 H), 7.35 (d, 7=1.10 Hz, 1 H), 7.22 (ddd, 7=8.42, 2.29, 1.10 Hz, 1 H), 4.54 (m, 1 H), 2.45 (s, 3 H), 2.18 (m, 2 H), 1.32 (m, 1 H), 0.84 (m, 3 H), 0.68 (m, 1 H), 0.44 (m, 1 H), 0.30 (m, 1 H), 0.13 (m, 1 H).

Example 1062

4-(2-Chloro-4-trifluoromethoxy-phenyl)-8-(l-cyclopropyl-ethyl)-6-methyl-8H-pteridin-

7-one

PARTA

[00335] 6-(6-Methoxy-2-methyl-pyridin-3-yl)-pyrimidine-4,5-diamine (prepared substantially as described in Example 1061a) (0.23 g, 0.71 mmol) was diluted in 10 mL butanol. 1-Cyclopropyl-ethylamine (0.21 g, 1.6 mmol) and triethylamine (0.40 mL, 4.0 mmol) was added to the solution and the mixture warmed to reflux for 18 hours. After concentrating the solution in vacuo and purification on silica gel using 100% EtOAc/hexane as the eluting solvent the desired intermediate 6-(2-chloro-4-trifluoromethoxy-ρhenyl)-N4-(l- cyclopropyl-ethyl)-pyrimidine-4,5-diamine was isolated (0.20 g, 80%). PART'S

[00336] 6-(2-Chloro-4-trifluoromethoxy-phenyl)-N4-(l-cyclopropyl-ethyl)- pyrimidine-4,5-diamine (0.20 g, 0.52 mmol) was diluted in ethanol (6 ml) and ethyl pyruvate was added (0.58 ml, 5.2 mmol). The mixture was stined for 18 hours at which time the solution was concentrated. After concentrating the solution the product was purified by reverse phase HPLC to yield 4.5 mg of 4-(2-chloro-4-trifluoromethoxy-phenyl)-8-(l- cyclopropyl-ethyl)-6-methyl-8H-pteridin-7-one (Example 1062). 1H NMR (300 MHz, CDC1₃) δ ppm 8.99 (s, 1 H), 7.50 (d, 7=8.79 Hz, 1 H), 7.39 (d, 7=1.10 Hz, 1 H), 7.26 (dd, 7=8.79, 1.10 Hz, 1 H), 4.91 (m, 1 H), 2.49 (s, 3 H), 1.71 (d, 7=7.32, 3 H), 0.69 (m, 2 H), 0.41 (m, 2 H), 0.22 (m, 1 H). MS (El) 425.2 [(M+H)+, 100].

Example 1067a

(R)-4-(2-Chloro-4-trifluoromethoxy-phenyl)-8-(2-methoxy-l-methyl-ethyl)-6-methyl-

8H-pteridin-7-one

PARTA

[00337] 6-(6-Methoxy-2-methyl-pyridin-3-yl)-pyrimidine-4,5-diamineylamine

(prepared substantially as described in Example 1061a) (0.25 g, 0.77 mmol) was diluted in 10 mL butanol. (R)-l-cyclopropyl-ethylamine (0.25 g, 1.7 mmol) and triethylamine (0.43 mL, 3.1 mmol) was added to the solution and the mixture warmed to reflux for 18 hours. After concentrating the solution in vacuo and purification on silica gel using 100% EtOAc/hexane as the eluting solvent the desired intermediate (i?)-6-(2-chloro-4-trifluoromethoxy-phenyl)- N4-(2-methoxy-l-methyl-ethyl)-pyrimidine-4,5-diamine was isolated (0.20 g, 73%). PARTB

[00338] (i?)-6-(2-Chloro-4-trifluoromethoxy-phenyl)-N4-(2-methoxy- 1 -methyl-ethyl)- pyrimidine-4,5-diamine (0.20 g, 0.53 mmol) was diluted in ethanol (6 ml) and ethyl pyruvate was added (0.59 ml, 5.3 mmol). The mixture was stined for 18 hours at which time the solution was concentrated. After concentrating the solution the product was purified by reverse phase HPLC to yield 4.0 mg of (R)-4-(2-chloro-4-trifluoromethoxy-phenyl)-8-(2- methoxy-l-methyl-ethyl)-6-methyl-8H-pteridin-7-one (Example 1067a). 1H NMR (300 MHz, CDC1₃) δ ppm 9.02 (s, 1 H), 7.49 (d, 7=8.42 Hz, 1 H), 7.39 (d, 7=1.10 Hz, 1 H), 7.26 (dd, 7=8.42, 1.10 Hz, 1 H), 5.95 (s, 1 H), 4.36 (t, 7=9.52 Hz, 1 H), 3.68 (dd, 7=10.07, 5.31 Hz, 1 H), 3.30 (s, 3 H), 2.48 (s, 3 H), 1.58 (d, 7=6.96 Hz, 3 H).

Example A

Biological Assay [00339] The compounds of the present invention can have CRF receptor antagonist activity. A compound can be considered active if it has a K- value of less than about 10,000 nM for the inhibition of CRF. K- values can be determined by any suitable biological assay, such as, for example, the assay described below.

[00340] Provided herein is an example of a CRF- receptor binding assay that can be used for the evaluation of biological activity of compounds of the present invention. The example also includes isolation of cell membranes containing cloned human RFi receptors for use in the binding assay.

[00341] Messenger RNA is isolated from human hippocampus by standard techniques.

The mRNA is reverse transcribed using oligo (dt) 12-18 and the coding region is amplified by PCR from start to stop codons The resulting PCR fragment is cloned into the EcoRV site of pGEMV, from whence the insert is reclaimed using Xhol + Xbal and cloned into the Xhol + Xbal sites of vector pm3ar (which contains a CMV promoter, the SV40 't' splice and early poly A signals, an Epstein-Barr viral origin of replication, and a hygromycin selectable marker). The resulting expression vector, called phchCRFR is transfected in 293EBNA cells, and cells retaining the episome are selected in the presence of 400 μM hygromycin. Cells surviving 4 weeks of selection in hygromycin are pooled, adapted to growth in suspension, and used to generate membranes for the binding assay described below. Individual aliquots containing approximately 1 x 10^ of the suspended cells are then centrifuged to form a pellet and frozen.

[00342] For the binding assay, a frozen pellet described above containing 293EBNA cells transfected with hCRFRl receptors is homogenized in 10 mL of ice cold tissue buffer

(50 mM HEPES buffer pH 7.0, containing 10 mM MgCl2, 2 mM EGTA, 1 μg/1 aprotinin, 1 μg/ml leupeptin and 1 μg/ml pepstatin). The homogenate is centrifuged at 40,000 x g for 12 min and the resulting pellet rehomogenized in 10 mL of tissue buffer. After another centrifugation at 40,000 x g for 12 min, the pellet is resuspended to a protein concentration of 360 μg/ml to be used in the assay.

[00343] Binding assays are performed in 96 well plates; each well having a 300 μL capacity. To each well is added 50 μL of test drag dilutions (final concentration of drags range from 10^"10 to 10^"5 M), 100 μL of ¹²⁵I-ovine-CRF (¹²⁵I-o-CRF) (final concentration 150 pM) and 150 μL of the cell homogenate described above. Plates are then allowed to incubate at room temperature for 2 hours before filtering the incubate over GF/F filters (presoaked with 0.3% polyethyleneimine) using an appropriate cell harvester. Filters are rinsed 2 times with ice cold assay buffer before removing individual filters and assessing them for radioactivity on a gamma counter.

[00344] Curves of the inhibition of l-^^I-o-CRF binding to cell membranes at various dilutions of test drag are analyzed by the iterative curve fitting program LIGAND Munson, et al., Anal. Biochem., 1980, 107, 220, which is incoφorate herein by reference in its entirety, which provides K- values for inhibition which are then used to assess biological activity.

[00345] Other in vitro assays for the determination of CRFi receptor antagonist activity of the present compounds are described, for example, in Endocrinology, 1985, 116, 1653 and in Peptides, 1985, 10, 179, each of which is incoφorated by reference in its entirety. Receptor binding activity of compounds can also be evaluated according to the methods described in Grigoriadis, et al., Biochemical, Pharmacological, and Autoradio graphic Methods to Study Corticotropin-Releasing Factor Receptors. Methods in Neurosciences, Vol. 5, 1991, which is incoφorated herein by reference in its entirety. Example B Inhibition of CRF-Stimulated Adenylate Cyclase Activity [00346] Activity of the present compounds can be studied by the inhibition of CRF- stimulated adenylate cyclase activity which can be performed as described by Battaglia, et al, Synapse, 1987, 1, 572, which is incoφorated herein by reference in its entirety. Assays are carried out at 37° C for 10 min in 200 mL of buffer containing 100 mM Tris-HCl (pH 7.4 at 37° C), 10 mM MgCl2, 0.4 mM EGTA, 0.1% BSA, 1 mM isobutylmethylxanthine (LBMX), 250 units/ml phosphocreatine kinase, 5 mM creatine phosphate, 100 mM guanosine 5'-triphosphate, 100 nM oCRF, antagonist peptides (concentration range 10^"9 to 10^"6 M) and 0.8 mg original wet weight tissue (approximately 40-60 mg protein). Reactions are initiated by the addition of 1 mM ATP/3²P]ATP (approximately 2-4 mCi/tube) and terminated by the addition of 100 mL of 50 mM Tris-HCL, 45 mM ATP and 2% sodium dodecyl sulfate. In order to monitor the recovery of cAMP, 1 μL of [*1H]cAMP (approximately 40,000 dpm) is added to each tube prior to separation. The separation of [32p]cAMP from [3--P]ATP is performed by sequential elution over Dowex and alumina columns.

Example C In vivo Biological Assay [00347] The in vivo activity of the compounds of the present invention can be assessed using any one of the biological assays available and accepted within the art. Examples of in vivo biological assays for testing axiolytic activity of compounds include the "punished drinking test" (Vogel, et al., Psychopharmcologia, 1971, 21, 1, which is incoφorated herein by reference in its entirety); "elevated plus-maze test" (Pellow, et al, J. Neurosci. Methods, 1985, 14, 149, which is incoφorated herein by reference in its entirety); "stress-induced coritcal norepinephrine release" (Funk, et al, Brain Res., 1996, 741, 220, which is incoφorated herein by referenc ein its entirety); "light-dark test" (Misslin, et al, Behav. Process, 1989, 8, 119, which is incoφorated herein by reference in its entirety); "four-plate test" (Boissier, et al., Eur. J. Pharmacol, 1968, 4, 145, which is incoφorated herein by reference in its entirety); and "mouse defense test battery" (Griebel, et al, Aggress. Behav., 1997, 23, 19, which is incoφorated herein by reference in its entirety). Compounds may be tested in any species of rodent or small mammal.

[00348] Examples of in vivo biological assays for testing antidepressant-like activity of compounds include the "forced swimming test" (Porsolt, et al, Nature, 1977, 266, 730, which is incoφorated herein by reference in its entirety) and "CMS test" (Willner, et al., Clin. Neuropharmacol, 1992, 15 (supp. 1), 550A, which is incoφorated herein by reference in its entirety).

[00349] Other models useful for the testing of compounds for their anxiolytic or antidepressant activity are outlined in Berridge, et al, Brain Research Reviews, 1990, 15, 11, which is incoφorated herein by reference in its entirety. Models for testing activity of compounds for other indications are well known in the art.

[00350] As those skilled in the art will appreciate, numerous changes and modifications can be made to the preferred embodiments of the invention without departing from the spirit of the invention. It is intended that all such variations fall within the scope of the invention. Throughout this specification, various groupings are employed to conveniently describe constituent variables of compounds and groups of various related moieties. It is specifically intended that each occunence of such groups throughout this specification include every possible subcombination of the members of the groups, including the individual members thereof.

[00351] It is intended that each of the patents, applications, and printed publications mentioned in this patent document be hereby incoφorated by reference in its entirety.

Claims

What is claimed is:

1. A compound of Formula (I) :

(i) or a pharmaceutically acceptable salt form thereof, or prodrug thereof, or radiolabeled form thereof, wherein:

A and B are independently CR⁴ or N, with the proviso that at least one of A and B is N;

Ar is aryl or heteroaryl, wherein said aryl or heteroaryl is optionally substituted by one or more substituents independently selected from C1-C6 alkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C alkenyl, C2-C6 alkynyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, halogen, CN, NO₂, OR⁵, and SR⁵;

R¹ is H, CN, C1-C4 haloalkyl, NR^lcR^ld, NR^lcCOR^lb, COR^lb, CONR^lcR^ld, OR^lc,

SR^lc, C1-C4 alkyl substituted with 0 to 3 R^la, C2-C4 alkenyl substituted with 0 to 3 R^la,

C2-C4 alkynyl substituted with 0 to 3 R^la, C3-C6 cycloalkyl substituted with 0 to 3 Rl^a, or

C4-C8 cycloalkylalkyl substituted with 0 to 3 R^ia, with the proviso that R¹ is not CH₂X, wherein X is halogen; each R*^a is, independently at each occunence, halogen, CN, N₃, NO₂, C1-C2 haloalkyl, NR^lcR^ld, NR^lcCORlb, COR^lb, OR^lc, SR^lc, S(O)R⁸, or S(O)2R⁸; each Rib i_s, independently at each occunence, Cχ-C4 alkyl, Cχ-C4 haloalkyl, C3- C6 cycloalkyl, C2-C4 alkenyl, or C2-C4 alkynyl; each Rl^c is, independently at each occunence, selected from H, Cχ-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C2-C4 alkenyl, or C2-C4 alkynyl; each Rl^d is, independently at each occunence, selected from H, Cχ-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C2-C4 alkenyl, or C2-C4 alkynyl; R² is H, C1-C3 haloalkyl, CN, OH, COR^2b, SH, SR^2b, SO2NHR^2c, SO2NR^2cR^2d,

CONHR^2c, CONR^2cR^2d, OCOR^2b, OR²b, NR^2cR^2d, CO2R^2b,

C -C4 alkyl substituted with 0 to 3 R^2a, C2-C4 alkenyl substituted with 0 to 3 R^2a,

C2-C4 alkynyl substituted with 0 to 3 R^2a, or C3-C6 cycloalkyl substituted with 0 to 3 R^2a; with the proviso that R² is not CH₂X, wherein X is halogen; each R^2a is, independently at each occunence, halogen, CN, N₃, NO₂, CF3, OR^2c, NR^2c, NR^2cR^2d, NR^2cCO2R^2b, SR^2c, SOR⁸, SO2R⁸, CO2R^2b, CONR^2cR^2d, COR² , OCOR²b NR^2cCONR^2cR^2d, NR^2cCO2R^2b, OCONR^2cR^2d, piperidinyl, pynolidinyl, piperazinyl, N-methylpiperazinyl, moφholinyl, or thiomoφholinyl; each R²b is, independently at each occunence, Cχ-C4 alkyl, C1-C4 haloalkyl, C3- C cycloalkyl, C4-C12 cycloalkylalkyl, aryl, heteroaryl, aryl-C₁-C alkyl, or heteroaryl-C-- C₄ alkyl; each R ^c is, independently at each occunence, H, C1-C4 alkyl, Cχ-C4 haloalkyl, C3- C cycloalkyl, C4-CX2 cycloalkylalkyl aryl, heteroaryl, aryl-C₁-C₄ alkyl, or heteroaryl-C₁-C₄ alkyl; each R^2d is, independently at each occunence, H, Cχ-C4 alkyl, C1-C4 haloalkyl, C3- C cycloalkyl, C4-CX2 cycloalkylalkyl aryl, heteroaryl, aryl-C₁-C₄ alkyl, or heteroaryl-C₁-C₄ alkyl;

R³ is OR^3c, NR^3cR^3d, NHR ^c, SR^3c, SOR⁸, SO₂R⁸, SO2NHR³ , SO2NR^3cR^3d,

COR^3c, CONHR^3c, CONR^3cR^3d, aryl substituted with 0 to 3 R^3a, heteroaryl substituted with 0 to 3 R³ , heterocyclyl substituted with 0 to 3 R^3f, Ci-Cχo alkyl substituted with 0 to 3 R^3a, C3-Cχo alkenyl substituted with 0 to 3 R^3a, C3-C 0 alkynyl substituted with 0 to 3 R^3a, C3-C8 cycloalkyl substituted with 0 to 3 R^3a, C4-C12 cycloalkylalkyl substituted with 0 to 3 R^3a, C2-Cχo alkoxyalkyl substituted with 0 to 3 R^3a, C2-Cχo thioalkoxyalkyl substituted with 0 to 3 R^3a, C5.CX0 cycloalkenyl substituted with 0 to 3 R^3a, or C6-Cχo cycloalkenylalkyl substituted with 0 to 3 R^3a, wherein one carbon in any cycloalkyl moiety is optionally replaced with O, S or NR^; each R^3a is, independently at each occunence, Cχ-Cχo alkyl, C2-C o alkenyl,

C2-C10 alkynyl, C3-C6 cycloalkyl, halogen, C1-C4 haloalkyl, CN, OR^3c, SR^3c, S(O)R⁸, S(O)₂R⁸, COR ^b, NHR^3cSO2R^3b OC(O)NR ^cR^3d, N3, OC(O)OR³b, CO2R^3c, OC(O)R^3b NR^3cCOR^3b, N(COR ^b) , NR^3cCONR^3cR^3d NR^3cCO2R^3b, NR^3cR^3d, CONR^3cR³ , aryl, heteroaryl, or heterocyclyl; each R³b is, independently at each occurrence, Cχ-Cιo alkyl substituted with 0 to 3 R^3e, C2-C10 alkenyl substituted with 0 to 3 R^3e, C2-C10 alkynyl substituted with 0 to 3 R^3e, C3-C8 cycloalkyl substituted with 0 to 3 R^3e, C4-C12 cycloalkylalkyl substituted with 0 to 3 R^3e, C2-C10 alkoxyalkyl substituted with 0 to 3 R^3e, C5_Cχo cycloalkenyl substituted with 0 to 3 R^3e, or C6-Cχo cycloalkenylalkyl substituted with 0 to 3 R^3e, wherein one carbon in any cycloalkyl moiety is optionally replaced with O, S or NR5; each R^3c is, independently at each occunence, H, Cχ-Cχo alkyl substituted with 0 to 3 R^3e, C2-C10 alkenyl substituted with 0 to 3 R^3e, C2-C10 alkynyl substituted with 0 to 3 R^3e, C3-C8 cycloalkyl substituted with 0 to 3 R^3e, C4-CX2 cycloalkylalkyl substituted with 0 to 3 R^3e, C2-C10 alkoxyalkyl substituted with 0 to 3 R^3e, C5-C10 cycloalkenyl substituted with 0 to 3 R^3e, or C6-Cχo cycloalkenylalkyl substituted with 0 to 3 R^3e, wherein one carbon in any cycloalkyl moiety is optionally replaced with O, S or NR-^; each R^3d is, independently at each occurrence, H, Cχ-Cχo alkyl substituted with 0 to 3 R^3e, C2-C10 alkenyl substituted with 0 to 3 R^3e, C2-Cχo alkynyl substituted with 0 to 3 R^3e, C3-C8 cycloalkyl substituted with 0 to 3 R^3e, C4-C12 cycloalkylalkyl substituted with 0 to 3 R^3e, C2-C10 alkoxyalkyl substituted with 0 to 3 R^3e, C5-C10 cycloalkenyl substituted with 0 to 3 R^3e, or C6-Cχo cycloalkenylalkyl substituted with 0 to 3 R^3e, wherein one carbon in any cycloalkyl moiety is optionally replaced with O, S or NR^; each R^3e is, independently at each occunence, Cχ-C6 alkyl, C2-C6 alkenyl,

C2-C10 alkynyl, C3-C6 cycloalkyl, halogen, C1-C4 haloalkyl, CN, OR⁷ , SR^7a, S(O)_nR⁸, COR6, CO2R^7a, OC(O)R⁶, NR^7aCOR6, N(C0R6)₂, NR^7aCONR^7aR^7b, NR⁷ CO2R⁶, NR^7aR⁷ , NHR^7aSO2R⁶, OC(O)NR^7aR^7b, N3, OC(O)OR⁶, CONR^7aR^7b, aryl, heteroaryl, or heterocyclyl; each R^3f is, independently at each occurrence, oxo, sulfido, or R^3a;

R⁴ is H, halogen, CN, C1-C3 haloalkyl, COR⁴b, OR⁴ SR^4c, SO2NHR⁴c, SO2NR^4cR ^d, CONHR^4c, CONR^4cR^4d, OCOR^4b, NR^4cCONHR⁴ , NR ^cCONR^4cR^4d, NR^4cCO2R^4b, OCONR^4cR^4d, NR ^cR^4d, CO2R^4b, C1-C4 alkyl substituted with 0 to 1

R ^a, C2-C4 alkenyl substituted with 0 to 1 R^4a, C2-C4 alkynyl substituted with 0 to 1 R ^a,

C3-C6 cycloalkyl substituted with 0 to 1 R^4a, piperidinyl, pyrrolidinyl, piperazinyl, N- methylpiperazinyl, moφholinyl, or thiomoφholinyl; each R^4a is, independently at each occunence, halogen, CN, CF3, OR^4c, NHR ^c, _NR4c_R4d_j NR^4cCO2R^4b, SR^4c, SOR⁸, SO2R⁸, CO2R^4b, CONHR^4c, CONR^4cR ^d, COR^4b, OCOR^4b, NR^4cCONR^4cR^4d, NR^4cCO2R^4b, OCONR ^cR^4d, piperidinyl, pyrrolidinyl, piperazinyl, N-methylpiperazinyl, moφholinyl, or thiomoφholinyl; each R⁴b is, independently at each occunence, C1-C4 alkyl, C1-C4 haloalkyl, C3- C6 cycloalkyl, C4-C12 cycloalkylalkyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl, or heteroaryl-C-- C₄ alkyl; each R^4c is, independently at each occunence, H, C1-C4 alkyl, C1-C4 haloalkyl, C3- C cycloalkyl, C4-CX2 cycloalkylalkyl, aryl, heteroaryl, aryl-C--C₄ alkyl, or heteroaryl-C- - C₄ alkyl; each R ^d is, independently at each occunence, H, C1-C4 alkyl, C1-C4 haloalkyl, C3- C cycloalkyl, C4-C12 cycloalkylalkyl, aryl, heteroaryl, aryl-Ci-C₄ alkyl, or heteroaryl-C-- C₄ alkyl;

R⁵ is H, C1-C4 alkyl, C1-C4 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, or C2-C alkoxyalkyl;

R⁶ is, independently at each occunence, Cχ-C6 alkyl, Cχ-C6 haloalkyl, C2- C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, C2-C8 alkoxyalkyl, C₅-C₁₂ bis(alkoxy)alkyl, aryl, aryl-C₁-C₄ alkyl, heteroaryl, or heteroaryl- -C₄ alkyl; each R^7a is, independently at each occurrence, H, Cχ-C6 alkyl, Cχ-C6 haloalkyl, C2- C alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, C2-C8 alkoxyalkyl, C₅-C₁₂ bis(alkoxy)alkyl, aryl, aryl-C₁-C alkyl, heteroaryl, or heteroaryl- C1-C4 alkyl; each R^7b is, independently at each occurrence, H, Cχ-C6 alkyl, Cχ-C6 haloalkyl, C2- C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, C2-C8 alkoxyalkyl, C₅-C₁ bis(alkoxy)alkyl, aryl, aryl-C₁-C alkyl, heteroaryl, or heteroaryl- -C₄ alkyl; and

R⁸ is C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl, or heteroaryl-C₁-C₄ alkyl, or NR^7aR^7b.

2. The compound of claim 1 , of Formula (la):

da)

The compound of claim 2 wherein A is N.

4. The compound of claim 2 wherein A is CR⁴.

5. The compound of claim 2 wherein Ar is aryl.

6. The compound of 5 wherein said aryl is phenyl substituted with 0 to 5 substituents or naphthyl substituted with 0 to 7 substituents, wherein each of said substituents is independently selected from, at each occunence, Cχ-C6 alkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, halogen, CN, NO₂, OR⁵, and SR⁵.

7. The compound of claim 2 wherein Ar is heteroaryl.

8. The compound of claim 7 wherein said heteroaryl comprises a six-membered ring.

9. The compound of claim 8 wherein said heteroaryl is pyridyl or pyrimidinyl, wherein said heteroaryl is substituted with 0 to 4 substituents, wherein each of said substituents is independently selected from, at each occunence, Cχ-C6 alkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cχ-C4 haloalkyl, C1-C4 haloalkoxy, halogen, CN, NO₂, OR⁵, and SR⁵.

1

10. The compound of claim 7 wherein said heteroaryl comprises a five-membered ring.

11. The compound of claim 10 wherein said heteroaryl is oxazolyl, isoxazolyl, or thienyl, wherein said heteroaryl is substituted with 0 to 4 substituents, wherein each of said substituents is independently selected from, at each occunence, Cχ-C6 alkyl, C3-

C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cχ-C4 haloalkyl, Ci- C4 haloalkoxy, halogen, CN, NO₂, OR⁵, and SR⁵.

12. The compound of claim 2 wherein R¹ is H, CN, OH, C--C alkyl, or -C₂ haloalkyl.

13. The compound of claim 2 wherein R¹ is C--C₄ alkyl.

14. The compound of claim 2 wherein R² is H, CN, OH, SH, OR^2b, SR^2b, C--C₃ haloalkyl, or C--C₄ alkyl substituted with 0 to 3 R^2a.

15. The compound of claim 2 wherein R² is H.

16. The compound of claim 2 wherein R³ is S(O)R⁸, S(O)₂R⁸ , COR^3c, CONHR^3c, CONR^3cR^3d> Cχ-C8 alkyl substituted with 0 to 3 R^3a, C3-C8 alkenyl substituted with 0 to 3 R^3a, C3-C8 alkynyl substituted with 0 to 3 R^3a, C3-C6 cycloalkyl substituted with 0 to 3 R^3a, or C4-C10 cycloalkylalkyl substituted with 0 to 3 R^3a, wherein one carbon in any cycloalkyl moiety is optionally replaced with O, S or NR-\

17. The compound of claim 2 wherein R³ is Cχ-C6 alkyl substituted with 0 to 2 R^3a.

18. The compound of claim 2 wherein each R^3a is, independently at each occunence, methyl, ethyl, propyl, cyclopropyl, cyclobutyl, F, CI, Br, CF₃, CN, C--C₁₀ alkyl, C₂-C₁₀ alkenyl, OR^3c, SR^3c, COR³ , NHR^3cSO₂R^3b, OC(O)NR^3cR^3d, N₃, OC(O)OR^3b, CO₂R^3c, OC(O)R^3b, NR^3cCOR^3b, N(COR³ )₂, NR^3cCONR^3cR^3d, NR^3cCO₂R^3b, NR^3cR^3d, or CONR^3cR^3d.

19. The compound of claim 2 wherein R⁴ is H, CN, OH, C Q. alkyl, C C₃ haloalkyl, SR^4c, or OR^4c.

20. The compound of claim 2 wherein R⁴ is H.

21. A compound of claim 2 wherein:

R! is H, CN, OH, SH, C1-C4 haloalkyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, Cχ-C4 alkyl substituted with 0 to 3 Rl^a, C2-C4 alkenyl substituted with 0 to 3 Rl^a, or C2- C4 alkynyl substituted with 0 to 3 Rl^a;

R^la is F, CI, Br, CN, NO₂, OH, OCH3, CF3, CHF2, or OCF3;

R² is H, CN, OH, NR^2cR^2d C₁-C₃ alkyl substituted with 0 to 3 R^2a, C--C₃ alkoxy, C C₂ haloalkyl, or C_!-C₂ haloalkoxy;

R³ is SOR⁸, SO₂R⁸, SO2NR^3cR^3d, COR^3c, CONHR^3c, CONR^3cR ^d, aryl substituted with 0 to 3 R^3a, heteroaryl substituted with 0 to 3 R^3a, heterocyclyl substituted with 0 to 3 R^3f, Cχ-Cχo alkyl substituted with 0 to 3 R^3a, C3-C10 alkenyl substituted with 0 to 3 R^3a, C3-C10 alkynyl substituted with 0 to 3 R^3a, C3-C8 cycloalkyl substituted with 0 to 3 R^3a, C4-C12 cycloalkylalkyl substituted with 0 to 3 R^3a, C2-C10 alkoxyalkyl substituted with 0 to 3 R^3a, C2-C10 thioalkoxyalkyl substituted with 0 to 3 R^3a, C5-C10 cycloalkenyl substituted with 0 to 3 R³ , or C6-Cχo cycloalkenylalkyl substituted with 0 to 3 R^3a, wherein one carbon in any cycloalkyl moiety is optionally replaced with O, S or NP ;

R⁴ is H, halogen, CN, C1-C3 haloalkyl, OR^4c, SR^4c, NR^4cR^4d, CO2R^4b, Cχ-C4 alkyl substituted with 0 to 1 R^4a, or C3-C6 cycloalkyl substituted with 0 tol R ^a; each R^4a is, independently at each occunence, halogen, CN, CF3, OR^4c, NHR^4c, _NR4c_R4d_; NR^4cCO2R^4b, SR^4c, SOR⁸, SO2R⁸, CO2R^4b, CONHR^4c, CONR^4cR^4d, COR b, OCOR⁴b, NR^4cCONR^4CR^4d NR⁴cC02R^4b, OCONR^4cR^4d; R⁵ is H, Cχ-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, or C2-C6 alkoxyalkyl; each R⁷ is, independently at each occunence, H, Cχ-C6 alkyl, Cχ-C6 haloalkyl, C3- C cycloalkyl, C4-C12 cycloalkylalkyl, or C2-C8 alkoxyalkyl; and each R^7b is, independently at each occunence, H, Cχ-C6 alkyl, Cχ-C6 haloalkyl, C3- C cycloalkyl, C4-C12 cycloalkylalkyl, or C2-C8 alkoxyalkyl.

22. The compound of claim 21 wherein A is N.

23. The compound of claim 21 wherein A is CR 4

24. The compound of claim 21 wherein R¹ is H, CN, OH, C₁-C4 alkyl, or -C₂ haloalkyl.

25. The compound of claim 21 wherein R² is H, CN, OH, methyl, ethyl, methoxy, OCF₃, CF₃, CHF₂, CH₂CF₃, or CF₂CH₃.

26. The compound of claim 21 wherein R² is H.

27. The compound of claim 21 wherein R³ is -Ce alkyl substituted with 0 to 2 R³ .

28. The compound of claim 21 wherein R⁴ is H, CN, OH, d-C₄ alkyl, d-C₃ haloalkyl, SR^4c, or OR⁴⁰.

29. The compound of claim 21 wherein R⁴ is H.

30. The compound of claim 21 wherein Ar is aryl.

31. The compound of 30 wherein said aryl is phenyl substituted with 0 to 5 substituents or naphthyl substituted with 0 to 7 substituents, wherein each of said substituents is independently selected from, at each occunence, Cχ-C6 alkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C6 alkenyl, C2-C alkynyl, Cχ-C4 haloalkyl, C1-C4 haloalkoxy, halogen, CN, NO₂, OR⁵, and SR⁵.

32. The compound of claim 21 wherein Ar is heteroaryl.

33. The compound of claim 32 wherein said heteroaryl comprises a six-membered ring.

34. The compound of claim 33 wherein said heteroaryl is pyridyl or pyrimidinyl, wherein said heteroaryl is substituted with 0 to 4 substituents, wherein each of said substituents is independently selected from, at each occunence, Cχ-C6 alkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 haloalkyl, Cχ-C4 haloalkoxy, halogen, CN, NO₂, OR⁵, and SR⁵.

35. The compound of claim 32 wherein said heteroaryl comprises a five-membered ring.

36. The compound of claim 35 wherein said heteroaryl is oxazolyl, isoxazolyl, or thienyl, wherein said heteroaryl is substituted with 0 to 4 substituents, wherein each of said substituents is independently selected from, at each occurrence, Cχ-C6 alkyl, C3-

C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C alkenyl, C2-C6 alkynyl, C1-C4 haloalkyl, Ci- C4 haloalkoxy, halogen, CN, NO₂, OR⁵, and SR⁵.

37. A compound of claim 21 wherein:

Ar is phenyl, pyridyl, pyrimidinyl, oxazolyl, isoxazolyl, or thienyl, wherein said phenyl is substituted with 0 to 5 R^9a and said pyridyl, pyrimidinyl, oxazolyl, isoxazolyl, or thienyl is substituted with 0 to 4 R^9b;

R! is H, CN, methyl, ethyl, methoxy, OH, or Cχ-C2 haloalkyl; R² is H, CN, OH, CH3, OCH3, CF3, CHF₂, or OCF3;

R³ is S(O)R⁸, S(O)₂R⁸ , COR^3c, CONHR^3c, CONR^3cR^3d- Cχ-C8 alkyl substituted with 0 to 3 R^3a, C3-C8 alkenyl substituted with 0 to 3 R^3a, C3-C8 alkynyl substituted with 0 to 3 R^3a, C3-C6 cycloalkyl substituted with 0 to 3 R^3a, or C4-C10 cycloalkylalkyl substituted with 0 to 3 R³ , wherein one carbon in any cycloalkyl moiety is optionally replaced with O, S or NR⁵; each R^3a is, independently at each occunence, methyl, ethyl, methoxy, ethoxy, thiomethoxy, thioethoxy, cyclopropyl, cyclobutyl, F, CI, CF3 CHF₂, CH₃, or OCF3; R⁴ is H, CHF₂, CF₃, methyl, ethyl, CI, F, OH, SH, methoxy, thiomethoxy, CH₂CF₃,

CF₂CH₃; and eeaacchh R I ^9a and R^9b is, independently at each occurrence, F, CI, Br, CN, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, isopropoxy, d-C₂ haloalkyl, or d-C₂ haloalkoxy.

38. The compound of claim 37 wherein A is N.

39. The compound of claim 37 wherein A is CR

40. The compound of claim 37 wherein R² is H.

41. The compound of claim 37 wherein R is butyl, pentyl, hexyl, heptyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, methoxyhexyl, thiomethoxyethyl, thiomethoxypropyl, thiomethoxybutyl, thiomethoxypentyl, thiomethoxyhexyl, 1- cyclopropylpropyl, 1-cyclopropylbutyl, 1-cyclopropylpentyl, 1-cyclobutylpropyl, 1- cyclobutylbutyl, 1-cyclobutylpentyl, 1 -cyclopropyl- l-(CF₃)-methyl, 1 -cyclopropyl- 1-(CF )- ethyl, l-cyclopropyl-l-(CF )-propyl, 1 -cyclobutyl- l-(CF₃)-methyl, l-cyclobutyl-2-(CF₃)- ethyl, l-cyclobutyl-3-(CF₃)-propyl, or (cyclopropyl)₂CH.

42. The compound of claim 37 wherein R⁴ is H.

43. The compound of claim 37 wherein Ar is phenyl substituted with 0 to 5 R^9a.

44. The compound of claim 37 wherein Ar is pyridyl substituted with 0 to 4 R 9b or pyrimidinyl substituted with 0 to 4 R^9b.

45. A compound of claim 37 wherein:

Ar is phenyl substituted with 0 to 3 substituents each independently selected from F, CI, Br, CN, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, isopropoxy, CF₃, CHF₂, and OCF₃; or

Ar is pyridyl or pyrimidinyl substituted with 0 to 2 substituents each independently selected from F, CI, Br, CN, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, isopropoxy, CF₃, CHF₂, and OCF₃; R¹ is H, CN, OH, methyl, ethyl, methoxy, or C1-C2 haloalkyl;

R² is H;

R³ is Cχ-C6 alkyl substituted with 0 to 2 R^3a ; and

R⁴ is H.

46. The compound of claim 45 wherein Ar is phenyl substituted with 0 to 3 substituents each independently selected from F, CI, Br, CN, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, isopropoxy, CF₃, CHF₂, and OCF₃.

47. The compound of claim 45 wherein Ar is pyridyl or pyrimidinyl substituted with 0 to 2 substituents each independently selected from F, CI, Br, CN, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, isopropoxy, CF₃, CHF₂, and OCF₃.

48. The compound of claim 47 wherein said pyridyl is pyrid-3-yl.

49. The compound of claim 45 wherein A is N.

50. The compound of claim 45 wherein A is CR⁴.

51. The compound of claim 45 wherein R³ is butyl, pentyl, hexyl, heptyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, methoxyhexyl, thiomethoxyethyl, thiomethoxypropyl, thiomethoxybutyl, thiomethoxypentyl, thiomethoxyhexyl, 1- cyclopropylpropyl, 1 -cyclopropylbutyl, 1-cyclopropylpentyl, 1-cyclobutylpropyl, 1- cyclobutylbutyl, 1-cyclobutylpentyl, l-cyclopropyl-l-(CF₃)-methyl, 1 -cyclopropyl- 1-(CF₃)- ethyl, l-cyclopropyl-l-(CF₃)-propyl, l-cyclobutyl-l-(CF₃)-methyl, l-cyclobutyl-2-(CF₃)- ethyl, l-cyclobutyl-3-(CF₃)-propyl, or (cyclopropyl)₂CH.

52. A compound of claim 2 selected from: (i?)-8-(2,4-dichloro-phenyl)-4-isobutyl-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one; (S)-8-(2,4-dichloro-phenyl)-4-isobutyl-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one; (i?)-8-(2,4-dichloro-phenyl)-2-methyl-4-(l-methyl-butyl)-4H-pyrido[2,3-b]pyrazin-3- one; (S)-8-(2,4-dichloro-phenyl)-2-methyl-4-(l-methyl-butyl)-4H-pyrido[2,3-b]pyrazin-3- one;

(S)-4-(l-cyclopropyl-propyl)-8-(2,4-dichloro-phenyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one;

(i )-4-(l-cyclopropyl-propyl)-8-(2,4-dichloro-phenyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one;

(R)-8-(2,4-dichloro-phenyl)-4-(l,2-dimethyl-propyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one;

(S)-8-(2,4-dichloro-phenyl)-4-(l,2-dimethyl-propyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one;

( ?)-4-(l-cyclopropyl-butyl)-8-(2,4-dichloro-phenyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one;

(S)-4-(l-cyclopropyl-butyl)-8-(2,4-dichloro-phenyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one;

(i?)-8-(2,4-dichloro-pheny)-4-(2-methoxy-l-methyl-ethyl)-2-methyl-4H - pyrido[2,3-b]pyrazin-3-one;

(S)-8-(2,4-dichloro-pheny)-4-(2-methoxy- 1 -methyl-ethyl)-2-methyl-4H - pyrido[2,3-b]pyrazin-3-one;

(S)-8-(2,4-dichloro-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H-pyrido[2,3- b]pyrazin-3-one;

(i?)-8-(2,4-dichloro-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(R)-8-(2-chloro-4-methoxy-phenyl)-4-(l-cyclopropyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(R)-8-(2-chloro-4-methoxy-phenyl)-4-(l-cyclobutyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(S)-8-(2-chloro-4-methoxy-phenyl)-4-(l-cyclobutyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(S)-8-(2-chloro-4-methoxy-phenyl)-4-(2-methoxy-l-methyl-ethyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one; (R)-8-(2-chloro-4-methoxy-phenyl)-4-(2-methoxy-l-methyl-ethyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

( ?)-4-(l-cylcopropropyl-propyl)-8-(4-methoxy-2-methyl-phenyl)-2-methyl-4H- pyrido [2,3 -b]pyrazin-3 -one ;

(R)-4-(l-cyclopropyl-butyl)-8-(4-methoxy-2-methyl-phenyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(7?)-4-(2-methoxy-l-methyl-ethyl)-8-(4-methoxy-2-methyl-phenyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(S)-4-(l-ethyl-pentyl)-8-(6-methoxy-2-methyl-pyridin-3-yl)-2-methyl-4H- pyrido [2,3 -b]pyrazin-3 -one ;

(R)-4-(l-cyclopropyl-propyl)-8-(6-methoxy-2-methyl-pyridin-3-yl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(R)-4-(l-cyclopropyl-butyl)-8-(6-methoxy-2-methyl-pyridin-3-yl)-2-methyl-4H- pyrido [2,3 -b]pyrazin-3-one ;

(R)-4-(2-methoxy-l-methyl-ethyl)-8-(6-methoxy-2-methyl-pyridyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(i?)-4-sec-butyl-8-(2-chloro-4-difluoromethoxy-phenyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(S)-8-(2-chloro-4-difluoromethoxy-phenyl)-4-(l-cyclopropyl-propyl)2-methyl-4H- ' pyrido[2,3-b]pyrazin-3-one;

(R)-8-(2-chloro-4-difluoromethoxy-phenyl)-4-(l-cyclopropyl-butyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one; (S)-8-(2-chloro-4-difluoromethoxy-phenyl)-4-(l-cyclopropyl-butyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

(i?)-8-(2-chloro-4-difluoromethoxy-phenyl)-4-(2-methoxy-l-methyl-ethyl)-2-methyl- 4H-pyrido[2,3-b]pyrazin-3-one;

(R)-8-(2-chloro-4-difluoromethoxy-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl- 4H-pyrido[2,3-b]pyrazin-3-one;

(R)-8-sec-butyl-4-(2,4-dichloro-phenyl)-6-methyl-8H-pteridin-7-one; and

(S)-8-sec-butyl-4-(2,4-dichloro-phenyl)-6-methyl-8H-pteridin-7-one.

53. A compound of claim 2 selected from:

(R,5)- 8-(4-Methoxy-2-methyl-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4Η- pyrido[2,3-b]pyrazin-3-one;

(R)-4-(l-Cyclopropyl-propyl)-8-(5-fluoro-4-methoxy-2-methyl-phenyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one; (R)-8-(5-Fluoro-4-methoxy-2-methyl-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-

4H-pyrido[2,3-b]pyrazin-3-one;

(S)-8-(2-Chloro-5-fluoro-4-methoxy-phenyl)-4-(l-cyclopropyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

8-(2-Chloro-5-fluoro-4-methoxy-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

8-(5-Chloro-4-methoxy-2-methyl-phenyl)-4-(l-cyclopropyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

8-(5-Chloro-4-methoxy-2-methyl-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one; 8-(2-Chloro-4-methoxy-5-methyl-phenyl)-4-(l-cyclopropyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one;

8-(2-Chloro-4-methoxy-5-methyl-phenyl)-4-(l-methoxymethyl-propyl)-2-methyl-4H- pyrido[2,3-b]pyrazin-3-one; 8-(2-Chloro-4-dimethylamino-5-fluoro -phenyl)-4-( 1 -cyclopropyl-propyl)-2-methyl-

4H-pyrido[2,3-b]pyrazin-3-one;

(i?)-8-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-4-(l-cyclopropyl-ethyl)-2- methyl-4H-pyrido[2,3-b]pyrazin-3-one;

(/?)-8-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-4-(l-cyclobutyl-ethyl)-2-methyl- 4H-pyrido[2,3-b]pyrazin-3-one;

8-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-4-(2-methoxy-l-methyl-ethyl)-2- methyl-4H-pyrido[2,3-b]pyrazin-3-one;

8-(2-Chloro-4-dimethylamino-5-fluoro-phenyl)-4-(l-methoxymethyl-propyl)-2- methyl-4H-pyrido[2,3-b]pyrazin-3-one; 4-(2-Chloro-4-methoxy-phenyl)-6-methyl-8-(l-propyl-butyl)-8H-pteridin-7-one;

(R)-4-(2-Chloro-4-methoxy-phenyl)-8-(l-cyclopropyl-ethyl)-6-methyl-8H-pteridin-7- one;

(S)-4-(2-Chloro-4-methoxy-phenyl)-8-(l-cyclobutyl-ethyl)-6-methyl-8H-pteridin-7- one; (R)-4-(2-Chloro-4-methoxy-phenyl)-8-(2-methoxy-l-methyl-ethyl)-6-methyl-8H- pteridin-7-one;

(i?)-4-(2-Chloro-4-methoxy-phenyl)-8-(l-methoxymethyl-propyl)-6-methyl-8H- pteridin-7-one;

(2?)-8-(l-Cyclopropyl-propyl)-4-(4-methoxy-2-methyl-phenyl)-6-methyl-8H-pteridin- 7-one;

(i?)-8-(l-Cyclopropyl-propyl)-4-(6-methoxy-2-methyl-pyridin-3-yl)-6-methyl-8H- pteridin-7-one;

(i?)-8-(2-Methoxy-l-methyl-ethyl)-4-(6-methoxy-2-methyl-pyridin-3-yl)-6-methyl- 8H-pteridin-7-one; (i?)-8-(l-Methoxymethyl-propyl)-4-(6-methoxy-2-methyl-pyridin-3-yl)-6-methyl-8H- pteridin-7-one;

(i?)-4-(4-Methoxy-2,5-dimethyl-phenyl)-8-(l-methoxymethyl-propyl)-6-methyl-8H- pteridin-7-one; (i?)-4-(2-Chloro-4-trifluoromethoxy-phenyl)-8-(l-cyclopropyl-propyl)-6-methyl-8H- pteridin-7-one;

4-(2-Chloro-4-trifluoromethoxy-phenyl)-8-(l-cyclopropyl-ethyl)-6-methyl-8H- pteridin-7-one; and (i?)-4-(2-Chloro-4-trifluoromethoxy-phenyl)-8-(2-methoxy- 1 -methyl-ethyl)-6-methyl-

8H-pteridin-7-one.

54. A compound of claim 1 selected from the group consisting of:

(R)-5-(2,4-Dichloro-phenyl)-l-isobutyl-3-methyl-lH-pyrido[3,4-b]pyrazin-2-one;

(S)-5-(2,4-Dichloro-phenyl)-l-isobutyl-3-methyl-lH-pyrido[3,4-b]pyrazin-2-one;

(i?)-l-(l-Cyclopropyl-propyl)-5-(2,4-dichloro-phenyl)-3-methyl-lH-pyrido[3,4- b]pyrazin-2-one;

(S)-l -( 1 -CyclopiOpyl-propyl)-5-(2,4-dichloro-phenyl)-3-methyl- lH-pyrido [3 ,4- b]pyrazin-2-one;

(i?)-5-(2,4-Dichloro-phenyl)-l-(2-methoxy-l-methyl-ethyl)-3-methyl-lH-pyrido[3,4- b]pyrazin-2-one;

(i?)-l-(l-Cyclopropyl-2-methoxy-ethyl)-5-(2,4-dichloro-phenyl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one;

(i?)-l-(l-Cyclobutyl-propyl)-5-(2,4-dichloro-phenyl)-3-methyl-lH-pyrido[3,4- b]pyrazin-2-one;

(S)-l-(l-Cyclobutyl-propyl)-5-(2,4-dichloro-phenyl)-3-methyl-lH-pyrido[3,4- b]pyrazin-2-one; (i?)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-cyclopropyl-ethyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(5)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-cyclopropyl-ethyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(i?)-5-(2-Chloro-5-f luoro-4-methoxy-phenyl)- 1 -( 1 -cyclopropyl-propyl)-3-methyl- 1H- pyrido [3 ,4-b] pyrazin-2-one ;

(S)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-cyclopropyl-propyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;,

(i?)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)- 1 -(2-methoxy- 1 -methyl-ethyl)-3- methyl-lH-pyrido[3,4-b]pyrazin-2-one;

(S)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(2-methoxy-l-methyl-ethyl)-3- methyl- 1 H-pyrido [3 ,4-b]pyrazin-2-one ;

(i?)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-methoxymethyl-propyl)-3-methyl- lH-pyrido [3 ,4-b]pyrazin-2-one ;

(7?)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-cyclopropyl-2-methoxy-ethyl)-3- methyl-lH-pyrido[3,4-b]pyrazin-2-one;

(_Jrv)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-cyclobutyl-ethyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-cyclobutyl-ethyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(_Jrv)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-cyclobutyl-propyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-5-(2-Chloro-5-fluoro-4-methoxy-phenyl)-l-(l-cyclobutyl-propyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-l-(l-Cyclopropyl-ethyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(i?)-l-(l-Cyclopropyl-propyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one; (-S)-l-(l -Cyclopropyl-propyl)-5 -(6-methoxy-2-methyl-pyridin-3 -yl)-3 -methyl- 1 H- pyrido[3,4-b]pyrazin-2-one;

(R)-l-(2-Methoxy-l-methyl-ethyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3-methyl- lH-pyrido[3,4-b]pyrazin-2-one;

(S)-l-(2-Methoxy-l-methyl-ethyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3-methyl- lH-pyrido [3 ,4-b]pyrazin-2-one;

(R)-l-(l-Methoxymethyl-propyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-l-(l-Methoxymethyl-propyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(R)-l-(l-Cyclopropyl-2-methoxy-ethyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3- methyl-lH-pyrido[3,4-b]pyrazin-2-one;

(S)-l-(l-Cyclopropyl-2-methoxy-ethyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3- methy 1- 1 H-pyrido [3 ,4-b]pyrazin-2-one;

(i?)-l-(l-Cyclobutyl-ethyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-l-(l-Cyclobutyl-ethyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one;

(i?)-l-(l-Cyclobutyl-propyl)-5-(6-methoxy-2-methyl-pyridin-3-yl)-3-methyl-lH- pyrido [3 ,4-b] pyrazin-2-one;

(i?)-l-(l-Cyclopropyl-ethyl)-5-(6-methoxy-2,5-dimethyl-pyridin-3-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(i?)-l-(l-Cyclopropyl-propyl)-5-(6-methoxy-2,5-dimethyl-pyridin-3-yl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one;

(S)-l-(l-Cyclopropyl-propyl)-5-(6-methoxy-2,5-dimethyl-pyridin-3-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(i?)-5-(6-Methoxy-2,5-dimethyl-pyridin-3-yl)-l-(2-methoxy-l-methyl-ethyl)-3- methyl-lH-pyrido[3,4-b]pyrazin-2-one;

(S)-5-(6-Methoxy-2,5-dimethyl-pyridin-3-yl)-l-(2-methoxy-l-methyl-ethyl)-3- methyl-lH-pyrido[3,4-b]pyrazin-2-one; (i?)-5-(6-Methoxy-2,5-dimethyl-pyridin-3-yl)-l-(l-methoxymethyl-propyl)-3-methyl- lH-pyrido [3 ,4-b]pyrazin-2-one;

(S)-5-(6-Methoxy-2,5-dimethyl-pyridin-3-yl)-l-(l-methoxymethyl-propyl)-3-methyl- lH-pyrido[3,4-b]pyrazin-2-one;

(R)-l-(l-Cyclopropyl-2-methoxy-ethyl)-5-(6-methoxy-2,5-dimethyl-pyridin-3-yl)-3- methyl- lH-pyrido [3 ,4-b]pyrazin-2-one;

(S)-l-(l-Cyclobutyl-ethyl)-5-(6-methoxy-2,5-dimethyl-pyridin-3-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-l-(l-Cyclobutyl-propyl)-5-(6-methoxy-2,5-dimethyl-pyridin-3-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(R)-l-(l-Cyclopropyl-ethyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one ;

(S)-l-(l-Cyclopropyl-ethyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(R)-l-(l -Cyclopropyl-propyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3-methyl- 1H- pyrido[3,4-b]pyrazin-2-one;

(S)-l-(l-Cyclopropyl-propyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(R)-5-(4-Methoxy-2,5-dimethyl-phenyl)-l-(2-methoxy-l-methyl-ethyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-5-(4-Methoxy-2,5-dimethyl-phenyl)-l-(2-methoxy-l-methyl-ethyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(i?)-5-(4-Methoxy-2,5-dimethyl-phenyl)-l-(l-methoxymethyl-propyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-5-(4-Methoxy-2,5-dimethyl-phenyl)-l-(l-methoxymethyl-propyl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one;

(R)-l-(l-Cyclopropyl-2-methoxy-ethyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3- methyl-lH-pyrido[3,4-b]pyrazin-2-one; (S)-l-(l-Cyclopropyl-2-methoxy-ethyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3- methyl- 1 H-pyrido [3 ,4-b]pyrazin-2-one ;

(R)-l-(l-Cyclobutyl-ethyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-l-(l-Cyclobutyl-ethyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one ;

(R)-l-(l-Cyclobutyl-propyl)-5-(4-methoxy-2,5-dimethyl-phenyl)-3-methyl-lH- pyrido [3 ,4-b] pyrazin-2-one;

(i?)-l-(l-Cyclopropyl-ethyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)- 1 -( 1 -CyclopiOpyl-ethyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl- 1H- pyrido[3,4-b]pyrazin-2-one;

(7?)-l-(l-Cyclopropyl-propyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl-lH- pyrido[3 ,4-b]pyrazin-2-one;

(R)-5-(2,4-Dimethoxy-pyrimidin-5-yl)- 1 -(2-methoxy- 1 -methyl-ethyl)-3 -methyl- 1H- pyrido[3,4-b]pyrazin-2-one;

(R)-5-(2,4-Dimethoxy-pyrimidin-5-yl)-l-(l-methoxymethyl-propyl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-5-(2,4-Dimethoxy-pyrimidin-5-yl)-l-(l-methoxymethyl-propyl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one;

(R)-l-(l-Cyclopropyl-2-methoxy-ethyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl- lH-pyrido[3,4-b]pyrazin-2-one;

(S)-l-(l-CyclopiOpyl-2-methoxy-ethyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl- lH-pyrido [3 ,4-b]pyrazin-2-one ;

(i?)-l-(l-Cyclobutyl-ethyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one;

(S)-l-(l-Cyclobutyl-ethyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl-lH- pyrido[3,4-b]pyrazin-2-one; (R)-l-(l-Cyclobutyl-propyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl-lH- pyrido[3 ,4-b]pyrazin-2-one;

(S)-l-(l-Cyclobutyl-propyl)-5-(2,4-dimethoxy-pyrimidin-5-yl)-3-methyl-lH- pyrido [3 ,4-b]pyrazin-2-one .

55. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

56. A composition comprising a compound of claim 2 and a pharmaceutically acceptable canier.

57. A method of reducing symptoms caused by elevated levels of corticotropin releasing factor in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1.

58. A method of reducing symptoms caused by elevated levels of corticotropin releasing factor in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 2.

59. A method of treating stress-related symptoms in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1.

60. A method of treating stress-related symptoms in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 2.

61. A method of treating a disorder characterized by abnormal levels of corticotropin releasing factor in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1.

62. The method of claim 61 wherein said disorder is characterized by elevated levels of corticotropin releasing factor.

63. A method of treating a disorder characterized by abnormal levels of corticotropin releasing factor in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 2.

64. The method of claim 63 wherein said disorder is characterized by elevated levels of corticotropin releasing factor.

65. A method of treating anxiety or depression in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1.

66. A method of treating anxiety or depression in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 2.

67. A method of treating irritable bowel syndrome in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1.

68. A method of treating irritable bowel syndrome in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 2.